descriptor_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	section_name	section_description	path	root_field	parent_path	parent_name	parent_description	preferred_term	term_id	term_label	description	raw_json	postcomp_located_in	postcomp_located_in_ids	postcomp_modifier	postcomp_therapeutic_agent	postcomp_therapeutic_agent_ids	qualifier_clinical_course	qualifier_clinical_course_ids	qualifier_clinical_course_predicate_ids	qualifier_has_participant	qualifier_has_participant_ids	qualifier_has_participant_predicate_ids	qualifier_immunologic_factor	qualifier_immunologic_factor_ids	qualifier_immunologic_factor_predicate_ids	qualifier_monoclonal_antibody_predicate_ids	qualifier_route_of_administration	qualifier_route_of_administration_ids	qualifier_route_of_administration_predicate_ids	qualifier_surgical_procedure	qualifier_surgical_procedure_ids	qualifier_surgical_procedure_predicate_ids	qualifier_therapeutic_agent	qualifier_therapeutic_agent_ids	qualifier_therapeutic_agent_predicate_ids	qualifier_therapeutic_procedure	qualifier_therapeutic_procedure_ids	qualifier_therapeutic_procedure_predicate_ids
26	16	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	0	Cardiac surgery	"Surgical repair of conotruncal defects is often required in infancy. Timing and approach depend on the specific cardiac malformation.
"	treatment_term	treatment_term	$	Cardiac surgery	"Surgical repair of conotruncal defects is often required in infancy. Timing and approach depend on the specific cardiac malformation.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
27	17	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	1	Calcium and vitamin D supplementation	"Management of hypocalcemia with calcium and active vitamin D (calcitriol) supplementation.
"	treatment_term	treatment_term	$	Calcium and vitamin D supplementation	"Management of hypocalcemia with calcium and active vitamin D (calcitriol) supplementation.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
28	18	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	2	Thymus transplantation	"For complete DiGeorge syndrome (thymic aplasia), thymus tissue transplantation can reconstitute T-cell immunity.
"	treatment_term	treatment_term	$	Thymus transplantation	"For complete DiGeorge syndrome (thymic aplasia), thymus tissue transplantation can reconstitute T-cell immunity.
"	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
29	19	1	22q11.2 Deletion Syndrome	22q11.2_Deletion_Syndrome.yaml	treatments	3	Speech therapy	"Management of velopharyngeal insufficiency and hypernasal speech.
"	treatment_term	treatment_term	$	Speech therapy	"Management of velopharyngeal insufficiency and hypernasal speech.
"	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
42	35	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	0	Alectinib	Second-generation ALK TKI with excellent CNS penetration. First-line standard of care based on ALEX trial showing superior PFS and OS vs crizotinib. Active against many crizotinib-resistant mutations.	treatment_term	treatment_term	$	Alectinib	Second-generation ALK TKI with excellent CNS penetration. First-line standard of care based on ALEX trial showing superior PFS and OS vs crizotinib. Active against many crizotinib-resistant mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
43	36	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	1	Lorlatinib	Third-generation ALK TKI designed to overcome resistance mutations including G1202R. Excellent CNS activity. Can be used first-line (CROWN trial) or after progression on prior ALK TKIs.	treatment_term	treatment_term	$	Lorlatinib	Third-generation ALK TKI designed to overcome resistance mutations including G1202R. Excellent CNS activity. Can be used first-line (CROWN trial) or after progression on prior ALK TKIs.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
44	37	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	2	Brigatinib	Second-generation ALK TKI with broad activity against resistance mutations and good CNS penetration. Alternative to alectinib in first-line or subsequent settings.	treatment_term	treatment_term	$	Brigatinib	Second-generation ALK TKI with broad activity against resistance mutations and good CNS penetration. Alternative to alectinib in first-line or subsequent settings.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
45	38	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	3	Crizotinib	First-generation ALK TKI that established proof-of-concept for ALK inhibition in lung cancer. Now largely replaced by more potent second/third generation agents due to lower CNS efficacy and resistance.	treatment_term	treatment_term	$	Crizotinib	First-generation ALK TKI that established proof-of-concept for ALK inhibition in lung cancer. Now largely replaced by more potent second/third generation agents due to lower CNS efficacy and resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
46	39	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ALK TKIs. ALK-positive tumors often respond to pemetrexed.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ALK TKIs. ALK-positive tumors often respond to pemetrexed.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
62	56	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	0	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	treatment_term	treatment_term	$	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""all-trans-retinoic acid"", ""term"": {""id"": ""CHEBI:15367"", ""label"": ""all-trans-retinoic acid""}}]}"				all-trans-retinoic acid	CHEBI:15367																						
63	56	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	0	All-Trans Retinoic Acid (ATRA)	Pharmacological doses of ATRA (45 mg/m2/day) overcome PML-RARA-mediated transcriptional repression, inducing differentiation of leukemic promyelocytes into mature granulocytes. Must be started immediately upon clinical suspicion, even before molecular confirmation. Foundation of APL treatment.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			all-trans-retinoic acid	CHEBI:15367	all-trans-retinoic acid		"{""preferred_term"": ""all-trans-retinoic acid"", ""term"": {""id"": ""CHEBI:15367"", ""label"": ""all-trans-retinoic acid""}}"																											
64	57	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	1	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	treatment_term	treatment_term	$	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""arsenic trioxide"", ""term"": {""id"": ""CHEBI:30621"", ""label"": ""diarsenic trioxide""}}]}"				diarsenic trioxide	CHEBI:30621																						
65	57	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	1	Arsenic Trioxide (ATO)	ATO induces degradation of PML-RARA fusion protein through SUMOylation and ubiquitination, restoring PML nuclear bodies and eliminating the leukemic clone. Synergizes with ATRA for curative therapy. Also induces apoptosis at higher concentrations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			arsenic trioxide	CHEBI:30621	diarsenic trioxide		"{""preferred_term"": ""arsenic trioxide"", ""term"": {""id"": ""CHEBI:30621"", ""label"": ""diarsenic trioxide""}}"																											
66	58	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	2	ATRA plus Arsenic Trioxide Combination	The combination of ATRA and ATO without chemotherapy achieves greater than 90% cure rates in standard-risk APL. This regimen avoids chemotherapy-related toxicities including secondary malignancies and cardiomyopathy. Represents the standard of care for non-high-risk APL.	treatment_term	treatment_term	$	ATRA plus Arsenic Trioxide Combination	The combination of ATRA and ATO without chemotherapy achieves greater than 90% cure rates in standard-risk APL. This regimen avoids chemotherapy-related toxicities including secondary malignancies and cardiomyopathy. Represents the standard of care for non-high-risk APL.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
67	59	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	3	Chemotherapy-Based Regimens	ATRA combined with anthracycline-based chemotherapy remains an option, particularly for high-risk APL (WBC greater than 10,000/uL) where early death risk is higher. Idarubicin is commonly used. ATO is increasingly incorporated into chemotherapy regimens.	treatment_term	treatment_term	$	Chemotherapy-Based Regimens	ATRA combined with anthracycline-based chemotherapy remains an option, particularly for high-risk APL (WBC greater than 10,000/uL) where early death risk is higher. Idarubicin is commonly used. ATO is increasingly incorporated into chemotherapy regimens.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
68	60	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	treatments	4	Supportive Care for Coagulopathy	Aggressive blood product support is essential during induction, including platelet transfusions to maintain count above 30-50,000/uL and cryoprecipitate or fibrinogen concentrate to maintain fibrinogen above 150 mg/dL.	treatment_term	treatment_term	$	Supportive Care for Coagulopathy	Aggressive blood product support is essential during induction, including platelet transfusions to maintain count above 30-50,000/uL and cryoprecipitate or fibrinogen concentrate to maintain fibrinogen above 150 mg/dL.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
101	93	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	0	Tafamidis	Helps stabilize transthyretin and prevent amyloid fibril formation.	treatment_term	treatment_term	$	Tafamidis	Helps stabilize transthyretin and prevent amyloid fibril formation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
102	94	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	1	Patisiran	Reduces production of transthyretin protein to decrease amyloid formation.	treatment_term	treatment_term	$	Patisiran	Reduces production of transthyretin protein to decrease amyloid formation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
103	95	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	2	Inotersen	Reduces TTR protein production to limit amyloid accumulation.	treatment_term	treatment_term	$	Inotersen	Reduces TTR protein production to limit amyloid accumulation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
104	96	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	3	Liver Transplant	Considered for hereditary cases to reduce production of mutant TTR.	treatment_term	treatment_term	$	Liver Transplant	Considered for hereditary cases to reduce production of mutant TTR.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
105	97	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	4	Heart Transplant	May be necessary for those with severe cardiomyopathy.	treatment_term	treatment_term	$	Heart Transplant	May be necessary for those with severe cardiomyopathy.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
106	98	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	treatments	5	Supportive Care	Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues.	treatment_term	treatment_term	$	Supportive Care	Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
140	127	6	Achondroplasia	Achondroplasia.yaml	treatments	0	Vosoritide (Voxzogo)	"C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved in 2021 for children aged 5 years and older with open growth plates. Clinical trials demonstrated increased annualized growth velocity.
"	treatment_term	treatment_term	$	Vosoritide (Voxzogo)	"C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR-B receptor, promoting endochondral bone growth. FDA approved in 2021 for children aged 5 years and older with open growth plates. Clinical trials demonstrated increased annualized growth velocity.
"	Vosoritide therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Vosoritide therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
141	128	6	Achondroplasia	Achondroplasia.yaml	treatments	1	Surgical limb lengthening	"Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.
"	treatment_term	treatment_term	$	Surgical limb lengthening	"Distraction osteogenesis techniques (Ilizarov, PRECICE) can increase limb length but are controversial due to complications, prolonged treatment duration, and quality of life considerations.
"	Limb lengthening surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Limb lengthening surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
142	129	6	Achondroplasia	Achondroplasia.yaml	treatments	2	Foramen magnum decompression	"Surgical decompression may be required for symptomatic foramen magnum stenosis with cervicomedullary compression, which can cause central apnea, hypotonia, or sudden death in infants.
"	treatment_term	treatment_term	$	Foramen magnum decompression	"Surgical decompression may be required for symptomatic foramen magnum stenosis with cervicomedullary compression, which can cause central apnea, hypotonia, or sudden death in infants.
"	Foramen magnum decompression	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Foramen magnum decompression"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
143	130	6	Achondroplasia	Achondroplasia.yaml	treatments	3	Management of spinal stenosis	"Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.
"	treatment_term	treatment_term	$	Management of spinal stenosis	"Progressive lumbar spinal stenosis is common in adults and may require laminectomy for symptomatic relief of neurogenic claudication.
"	Spinal surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Spinal surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
163	150	7	Achoo Syndrome	Achoo_Syndrome.yaml	treatments	0	Sunglasses	Wearing sunglasses before exposure to bright light may prevent triggering of the reflex.	treatment_term	treatment_term	$	Sunglasses	Wearing sunglasses before exposure to bright light may prevent triggering of the reflex.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
195	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term	treatment_term	$	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	retinoid agent therapy	MAXO:0000237	retinoid agent therapy		"{""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""retinoid"", ""term"": {""id"": ""NCIT:C68299"", ""label"": ""Retinoid""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}"																						Retinoid	NCIT:C68299	NCIT:C2259			
196	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
197	186	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	0	Topical retinoids	"First-line treatment that normalizes follicular keratinization, reduces comedone formation, and has anti-inflammatory effects. Examples include tretinoin, adapalene, and tazarotene.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			retinoid	NCIT:C68299	Retinoid		"{""preferred_term"": ""retinoid"", ""term"": {""id"": ""NCIT:C68299"", ""label"": ""Retinoid""}}"																											
198	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term	treatment_term	$	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	retinoid agent therapy	MAXO:0000237	retinoid agent therapy		"{""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""trifarotene"", ""term"": {""id"": ""NCIT:C118577"", ""label"": ""Trifarotene""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}"																						Trifarotene	NCIT:C118577	NCIT:C2259			
199	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
200	187	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	1	Trifarotene	"Topical retinoid selective for retinoic acid receptor gamma with evidence for reducing comedonal and inflammatory lesions, including truncal acne.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			trifarotene	NCIT:C118577	Trifarotene		"{""preferred_term"": ""trifarotene"", ""term"": {""id"": ""NCIT:C118577"", ""label"": ""Trifarotene""}}"																											
201	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term	treatment_term	$	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	antimicrobial agent therapy	MAXO:0001021	antimicrobial agent therapy		"{""preferred_term"": ""antimicrobial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}], ""term"": {""id"": ""MAXO:0001021"", ""label"": ""antimicrobial agent therapy""}}"																						Benzoyl Peroxide	NCIT:C47411	NCIT:C2259			
202	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
203	188	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	2	Benzoyl peroxide	"Antimicrobial agent that kills C. acnes through oxidative damage without promoting antibiotic resistance. Also has mild comedolytic activity.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}"																											
204	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term	treatment_term	$	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy		"{""preferred_term"": ""antibacterial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""antibiotic"", ""term"": {""id"": ""NCIT:C258"", ""label"": ""Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}"																						Antibiotic	NCIT:C258	NCIT:C2259			
205	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
206	189	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	3	Topical antibiotics	"Clindamycin and erythromycin reduce C. acnes populations and have anti-inflammatory effects. Should be combined with benzoyl peroxide to prevent resistance.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			antibiotic	NCIT:C258	Antibiotic		"{""preferred_term"": ""antibiotic"", ""term"": {""id"": ""NCIT:C258"", ""label"": ""Antibiotic""}}"																											
207	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term	treatment_term	$	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""clindamycin phosphate"", ""term"": {""id"": ""NCIT:C47978"", ""label"": ""Clindamycin Phosphate""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adapalene"", ""term"": {""id"": ""NCIT:C28989"", ""label"": ""Adapalene""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Clindamycin Phosphate; Adapalene; Benzoyl Peroxide	NCIT:C47978; NCIT:C28989; NCIT:C47411	NCIT:C2259			
208	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
209	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			clindamycin phosphate	NCIT:C47978	Clindamycin Phosphate		"{""preferred_term"": ""clindamycin phosphate"", ""term"": {""id"": ""NCIT:C47978"", ""label"": ""Clindamycin Phosphate""}}"																											
210	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
211	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			adapalene	NCIT:C28989	Adapalene		"{""preferred_term"": ""adapalene"", ""term"": {""id"": ""NCIT:C28989"", ""label"": ""Adapalene""}}"																											
212	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[2].predicate	treatment_term	treatment_term.qualifiers[2]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
213	190	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	4	Clindamycin/adapalene/benzoyl peroxide gel	"Triple-combination topical therapy for moderate to severe acne, combining clindamycin phosphate, adapalene, and benzoyl peroxide for long-term use.
"	treatment_term.qualifiers[2].value	treatment_term	treatment_term.qualifiers[2]			benzoyl peroxide	NCIT:C47411	Benzoyl Peroxide		"{""preferred_term"": ""benzoyl peroxide"", ""term"": {""id"": ""NCIT:C47411"", ""label"": ""Benzoyl Peroxide""}}"																											
214	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term	treatment_term	$	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy		"{""preferred_term"": ""antibacterial agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tetracycline antibiotic"", ""term"": {""id"": ""NCIT:C1595"", ""label"": ""Tetracycline Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}"																						Tetracycline Antibiotic	NCIT:C1595	NCIT:C2259			
215	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
216	191	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	5	Oral antibiotics	"Tetracyclines (doxycycline, minocycline) are used for moderate-to-severe inflammatory acne. Have both antimicrobial and anti-inflammatory effects, but prolonged use contributes to antimicrobial resistance and requires stewardship.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			tetracycline antibiotic	NCIT:C1595	Tetracycline Antibiotic		"{""preferred_term"": ""tetracycline antibiotic"", ""term"": {""id"": ""NCIT:C1595"", ""label"": ""Tetracycline Antibiotic""}}"																											
217	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term	treatment_term	$	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	retinoid agent therapy	MAXO:0000237	retinoid agent therapy		"{""preferred_term"": ""retinoid agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""isotretinoin"", ""term"": {""id"": ""NCIT:C603"", ""label"": ""Isotretinoin""}}}], ""term"": {""id"": ""MAXO:0000237"", ""label"": ""retinoid agent therapy""}}"																						Isotretinoin	NCIT:C603	NCIT:C2259			
218	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
219	192	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	6	Oral isotretinoin	"Systemic retinoid reserved for severe, recalcitrant acne. Addresses all four pathogenic factors but requires careful monitoring due to teratogenicity and other adverse effects.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			isotretinoin	NCIT:C603	Isotretinoin		"{""preferred_term"": ""isotretinoin"", ""term"": {""id"": ""NCIT:C603"", ""label"": ""Isotretinoin""}}"																											
220	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term	treatment_term	$	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""oral contraceptive"", ""term"": {""id"": ""NCIT:C389"", ""label"": ""Oral Contraceptive""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}], ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																						Oral Contraceptive; Spironolactone	NCIT:C389; NCIT:C840	NCIT:C2259			
221	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
222	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			oral contraceptive	NCIT:C389	Oral Contraceptive		"{""preferred_term"": ""oral contraceptive"", ""term"": {""id"": ""NCIT:C389"", ""label"": ""Oral Contraceptive""}}"																											
223	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
224	193	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	7	Hormonal therapy	"Combined oral contraceptives and spironolactone reduce androgen effects on sebaceous glands. Used in female patients with hormonal acne patterns.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			spironolactone	NCIT:C840	Spironolactone		"{""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}"																											
225	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term	treatment_term	$	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																									Chemical Peel	NCIT:C93203	NCIT:C49236
226	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
227	194	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	8	Chemical peels	"Organic acid-based peels are used to exfoliate acne-prone skin and reduce lesion counts, with agent selection tailored to patient tolerability.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			chemical peel	NCIT:C93203	Chemical Peel		"{""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}"																											
228	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term	treatment_term	$	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azelaic acid"", ""term"": {""id"": ""NCIT:C47407"", ""label"": ""Azelaic Acid""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																						Azelaic Acid	NCIT:C47407	NCIT:C2259	Chemical Peel	NCIT:C93203	NCIT:C49236
229	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
230	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			chemical peel	NCIT:C93203	Chemical Peel		"{""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}"																											
231	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
232	195	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	9	Azelaic acid peel	"Azelaic acid peels reduce sebum and lesion burden as a nonpharmacologic option for facial acne.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			azelaic acid	NCIT:C47407	Azelaic Acid		"{""preferred_term"": ""azelaic acid"", ""term"": {""id"": ""NCIT:C47407"", ""label"": ""Azelaic Acid""}}"																											
233	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term	treatment_term	$	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""glycolic acid"", ""term"": {""id"": ""NCIT:C83737"", ""label"": ""Glycolic Acid""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical trichloroacetic acid"", ""term"": {""id"": ""NCIT:C125002"", ""label"": ""Topical Trichloroacetic Acid""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																						Glycolic Acid; Topical Trichloroacetic Acid	NCIT:C83737; NCIT:C125002	NCIT:C2259	Chemical Peel	NCIT:C93203	NCIT:C49236
234	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
235	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			chemical peel	NCIT:C93203	Chemical Peel		"{""preferred_term"": ""chemical peel"", ""term"": {""id"": ""NCIT:C93203"", ""label"": ""Chemical Peel""}}"																											
236	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
237	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			glycolic acid	NCIT:C83737	Glycolic Acid		"{""preferred_term"": ""glycolic acid"", ""term"": {""id"": ""NCIT:C83737"", ""label"": ""Glycolic Acid""}}"																											
238	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[2].predicate	treatment_term	treatment_term.qualifiers[2]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
239	196	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	10	Chemical peels for acne scarring	"Medium-depth peels such as glycolic acid and trichloroacetic acid are used to improve atrophic acne scars.
"	treatment_term.qualifiers[2].value	treatment_term	treatment_term.qualifiers[2]			topical trichloroacetic acid	NCIT:C125002	Topical Trichloroacetic Acid		"{""preferred_term"": ""topical trichloroacetic acid"", ""term"": {""id"": ""NCIT:C125002"", ""label"": ""Topical Trichloroacetic Acid""}}"																											
240	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term	treatment_term	$	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																									Laser Therapy	NCIT:C15466	NCIT:C49236
241	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
242	197	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	11	Ablative fractional CO2 laser	"Ablative fractional CO2 laser is used for atrophic acne scars but can cause erythema, dyspigmentation, and prolonged recovery.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser therapy	NCIT:C15466	Laser Therapy		"{""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}"																											
243	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term	treatment_term	$	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vitamin C"", ""term"": {""id"": ""NCIT:C68507"", ""label"": ""Vitamin C""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""topical vitamin E"", ""term"": {""id"": ""NCIT:C67081"", ""label"": ""Topical Vitamin E""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Vitamin C; Topical Vitamin E	NCIT:C68507; NCIT:C67081	NCIT:C2259			
244	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
245	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			vitamin C	NCIT:C68507	Vitamin C		"{""preferred_term"": ""vitamin C"", ""term"": {""id"": ""NCIT:C68507"", ""label"": ""Vitamin C""}}"																											
246	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
247	198	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	12	Post-laser antioxidant serum	"Topical antioxidant serum with vitamins C and E (with ferulic acid) is used after ablative laser procedures to support skin recovery.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			topical vitamin E	NCIT:C67081	Topical Vitamin E		"{""preferred_term"": ""topical vitamin E"", ""term"": {""id"": ""NCIT:C67081"", ""label"": ""Topical Vitamin E""}}"																											
248	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term	treatment_term	$	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																									Phototherapy	NCIT:C15301	NCIT:C49236
249	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
250	199	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	13	Blue light therapy	"Blue light phototherapy is used as an alternative for inflammatory acne, with evidence of clinical improvement.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			phototherapy	NCIT:C15301	Phototherapy		"{""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}"																											
251	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term	treatment_term	$	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																									Phototherapy	NCIT:C15301	NCIT:C49236
252	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
253	200	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	14	Visible light therapy	"Visible light devices, including blue light, can reduce acne lesion counts in patients seeking nonpharmacologic treatments.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			phototherapy	NCIT:C15301	Phototherapy		"{""preferred_term"": ""phototherapy"", ""term"": {""id"": ""NCIT:C15301"", ""label"": ""Phototherapy""}}"																											
254	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term	treatment_term	$	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""photodynamic therapy"", ""term"": {""id"": ""NCIT:C15300"", ""label"": ""Photodynamic Therapy""}}}], ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																									Photodynamic Therapy	NCIT:C15300	NCIT:C49236
255	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
256	201	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	15	Photodynamic therapy	"Photodynamic therapy is used off-label for inflammatory acne with evidence supporting efficacy in dermatologic indications.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			photodynamic therapy	NCIT:C15300	Photodynamic Therapy		"{""preferred_term"": ""photodynamic therapy"", ""term"": {""id"": ""NCIT:C15300"", ""label"": ""Photodynamic Therapy""}}"																											
257	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term	treatment_term	$	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	therapeutic procedure of skin of body	MAXO:0001417	therapeutic procedure of skin of body		"{""preferred_term"": ""therapeutic procedure of skin of body"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""platelet-rich plasma"", ""term"": {""id"": ""NCIT:C106557"", ""label"": ""Platelet-rich Plasma""}}}], ""term"": {""id"": ""MAXO:0001417"", ""label"": ""therapeutic procedure of skin of body""}}"																						Platelet-rich Plasma	NCIT:C106557	NCIT:C2259	Laser Therapy	NCIT:C15466	NCIT:C49236
258	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
259	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser therapy	NCIT:C15466	Laser Therapy		"{""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}"																											
260	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
261	202	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	16	Nd:YAG laser and intralesional PRP	"Nd:YAG laser and intralesional platelet-rich plasma injections are used for inflammatory acne in split-face comparative protocols.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			platelet-rich plasma	NCIT:C106557	Platelet-rich Plasma		"{""preferred_term"": ""platelet-rich plasma"", ""term"": {""id"": ""NCIT:C106557"", ""label"": ""Platelet-rich Plasma""}}"																											
262	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term	treatment_term	$	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""infrared laser therapy"", ""term"": {""id"": ""NCIT:C66918"", ""label"": ""Infrared Laser Therapy""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																									Laser Therapy; Infrared Laser Therapy	NCIT:C15466; NCIT:C66918	NCIT:C49236
263	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
264	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser therapy	NCIT:C15466	Laser Therapy		"{""preferred_term"": ""laser therapy"", ""term"": {""id"": ""NCIT:C15466"", ""label"": ""Laser Therapy""}}"																											
265	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
266	203	8	Acne Vulgaris	Acne_Vulgaris.yaml	treatments	17	1726 nm laser therapy	"Targeted laser therapy that selectively affects sebaceous glands and is being evaluated for moderate to severe acne.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			infrared laser therapy	NCIT:C66918	Infrared Laser Therapy		"{""preferred_term"": ""infrared laser therapy"", ""term"": {""id"": ""NCIT:C66918"", ""label"": ""Infrared Laser Therapy""}}"																											
297	235	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	0	Antiretroviral Therapy	Combination of drugs that suppress HIV replication and preserve immune function.	treatment_term	treatment_term	$	Antiretroviral Therapy	Combination of drugs that suppress HIV replication and preserve immune function.	antiretroviral therapy	MAXO:0000573	antiretroviral therapy		"{""preferred_term"": ""antiretroviral therapy"", ""term"": {""id"": ""MAXO:0000573"", ""label"": ""antiretroviral therapy""}}"																											
298	236	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	1	Prophylaxis for Opportunistic Infections	Preventive treatments to reduce risk of common opportunistic infections.	treatment_term	treatment_term	$	Prophylaxis for Opportunistic Infections	Preventive treatments to reduce risk of common opportunistic infections.	preventative therapy	MAXO:0000017	preventative therapy		"{""preferred_term"": ""preventative therapy"", ""term"": {""id"": ""MAXO:0000017"", ""label"": ""preventative therapy""}}"																											
299	237	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	treatments	2	Treatment of Opportunistic Infections	Specific therapies targeting diagnosed opportunistic infections.	treatment_term	treatment_term	$	Treatment of Opportunistic Infections	Specific therapies targeting diagnosed opportunistic infections.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
342	272	10	Addison's Disease	Addisons_Disease.yaml	treatments	0	Glucocorticoid Replacement	Hydrocortisone or prednisone to replace cortisol.	treatment_term	treatment_term	$	Glucocorticoid Replacement	Hydrocortisone or prednisone to replace cortisol.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
343	273	10	Addison's Disease	Addisons_Disease.yaml	treatments	1	Mineralocorticoid Replacement	Fludrocortisone to replace aldosterone and manage electrolyte balance.	treatment_term	treatment_term	$	Mineralocorticoid Replacement	Fludrocortisone to replace aldosterone and manage electrolyte balance.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
344	274	10	Addison's Disease	Addisons_Disease.yaml	treatments	2	Salt Supplementation	Increased salt intake to manage hyponatremia.	treatment_term	treatment_term	$	Salt Supplementation	Increased salt intake to manage hyponatremia.	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																											
345	275	10	Addison's Disease	Addisons_Disease.yaml	treatments	3	Emergency Medical ID	Patients should carry an ID indicating their condition for emergency situations.	treatment_term	treatment_term	$	Emergency Medical ID	Patients should carry an ID indicating their condition for emergency situations.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
346	276	10	Addison's Disease	Addisons_Disease.yaml	treatments	4	Stress Dose Adjustments	Increased dose of corticosteroids during illness or stress.	treatment_term	treatment_term	$	Stress Dose Adjustments	Increased dose of corticosteroids during illness or stress.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
363	302	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	0	Chemotherapy	Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease.	treatment_term	treatment_term	$	Chemotherapy	Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
364	303	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	1	Mogamulizumab	Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression.	treatment_term	treatment_term	$	Mogamulizumab	Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
365	304	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
366	305	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	treatments	3	Interferon-alpha and Zidovudine	Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects.	treatment_term	treatment_term	$	Interferon-alpha and Zidovudine	Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
384	327	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	0	Surgical Resection	Hepatic resection is potentially curative for early-stage HCC with preserved liver function. Limited by underlying cirrhosis and multifocal disease in many aflatoxin-exposed populations.	treatment_term	treatment_term	$	Surgical Resection	Hepatic resection is potentially curative for early-stage HCC with preserved liver function. Limited by underlying cirrhosis and multifocal disease in many aflatoxin-exposed populations.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
385	328	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	1	Liver Transplantation	Curative option for early HCC within Milan criteria (single tumor <=5cm or up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease. Limited by organ availability.	treatment_term	treatment_term	$	Liver Transplantation	Curative option for early HCC within Milan criteria (single tumor <=5cm or up to 3 tumors each <=3cm). Treats both tumor and underlying liver disease. Limited by organ availability.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
386	329	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	2	Locoregional Therapy	Transarterial chemoembolization (TACE), radiofrequency ablation, or microwave ablation for unresectable tumors. Provides local control but not curative for advanced disease.	treatment_term	treatment_term	$	Locoregional Therapy	Transarterial chemoembolization (TACE), radiofrequency ablation, or microwave ablation for unresectable tumors. Provides local control but not curative for advanced disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
387	330	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	3	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	treatment_term	treatment_term	$	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sorafenib"", ""term"": {""id"": ""CHEBI:50924"", ""label"": ""sorafenib""}}]}"				sorafenib	CHEBI:50924																						
388	330	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	3	Systemic Therapy	Sorafenib, lenvatinib, or atezolizumab-bevacizumab for advanced HCC. Checkpoint inhibitors (nivolumab, pembrolizumab) show activity as second-line therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			sorafenib	CHEBI:50924	sorafenib		"{""preferred_term"": ""sorafenib"", ""term"": {""id"": ""CHEBI:50924"", ""label"": ""sorafenib""}}"																											
389	331	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	treatments	4	Aflatoxin Exposure Prevention	Public health interventions including proper grain storage, crop rotation, and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically reduces HCC incidence by eliminating the synergistic interaction.	treatment_term	treatment_term	$	Aflatoxin Exposure Prevention	Public health interventions including proper grain storage, crop rotation, and use of aflatoxin-resistant crop varieties. HBV vaccination dramatically reduces HCC incidence by eliminating the synergistic interaction.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
409	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term	treatment_term	$	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																			Excision	NCIT:C15232	NCIT:C15329						
410	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
411	376	14	Ainhum	Ainhum.yaml	treatments	0	Surgical excision of constriction band with disarticulation	Surgical management includes excision of the constricting band with disarticulation at the metatarsophalangeal joint and skin closure.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			excision	NCIT:C15232	Excision		"{""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}"																											
437	399	15	Akinetopsia	Akinetopsia.yaml	treatments	0	Treat underlying condition	Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant.	treatment_term	treatment_term	$	Treat underlying condition	Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant.	medical action	MAXO:0000001	medical action		"{""preferred_term"": ""medical action"", ""term"": {""id"": ""MAXO:0000001"", ""label"": ""medical action""}}"																											
438	400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	treatment_term	treatment_term	$	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""carbamazepine"", ""term"": {""id"": ""CHEBI:3387"", ""label"": ""carbamazepine""}}]}"				carbamazepine	CHEBI:3387																						
439	400	15	Akinetopsia	Akinetopsia.yaml	treatments	1	Carbamazepine for seizure-related akinetopsia	Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			carbamazepine	CHEBI:3387	carbamazepine		"{""preferred_term"": ""carbamazepine"", ""term"": {""id"": ""CHEBI:3387"", ""label"": ""carbamazepine""}}"																											
519	434	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	0	Cholinesterase Inhibitors	Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).	treatment_term	treatment_term	$	Cholinesterase Inhibitors	Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
520	435	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	1	NMDA Receptor Antagonist	Medication that regulates glutamate activity to improve symptoms (e.g., memantine).	treatment_term	treatment_term	$	NMDA Receptor Antagonist	Medication that regulates glutamate activity to improve symptoms (e.g., memantine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
521	436	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	2	Cognitive Therapy	Non-pharmacological interventions to maintain cognitive function.	treatment_term	treatment_term	$	Cognitive Therapy	Non-pharmacological interventions to maintain cognitive function.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
522	437	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	3	Supportive Care	Includes occupational therapy, speech therapy, and caregiver support.	treatment_term	treatment_term	$	Supportive Care	Includes occupational therapy, speech therapy, and caregiver support.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
523	438	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	treatments	4	Lifestyle Modifications	Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.	treatment_term	treatment_term	$	Lifestyle Modifications	Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
551	472	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	0	Alpha-1 Antitrypsin Augmentation Therapy	"Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.
"	treatment_term	treatment_term	$	Alpha-1 Antitrypsin Augmentation Therapy	"Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
552	474	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	2	Bronchodilators	"Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.
"	treatment_term	treatment_term	$	Bronchodilators	"Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
553	475	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	3	Lung Transplantation	"For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.
"	treatment_term	treatment_term	$	Lung Transplantation	"For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.
"	transplantation procedure	MAXO:0000068	transplantation procedure		"{""preferred_term"": ""transplantation procedure"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}"																											
554	476	19	Alpha-1 Antitrypsin Deficiency	Alpha_1_Antitrypsin_Deficiency.yaml	treatments	4	Liver Transplantation	"For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.
"	treatment_term	treatment_term	$	Liver Transplantation	"For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.
"	transplantation procedure	MAXO:0000068	transplantation procedure		"{""preferred_term"": ""transplantation procedure"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}"																											
565	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}"				vincristine; actinomycin D; cyclophosphamide	CHEBI:28445; CHEBI:27666; CHEBI:4026																						
566	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
567	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"																											
568	493	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) forms the backbone of treatment. Ifosfamide and etoposide are added for high-risk disease.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
569	494	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	1	Surgical Resection	Complete surgical resection with negative margins when feasible without excessive morbidity. Surgery may be delayed until after chemotherapy to facilitate resection.	treatment_term	treatment_term	$	Surgical Resection	Complete surgical resection with negative margins when feasible without excessive morbidity. Surgery may be delayed until after chemotherapy to facilitate resection.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
570	495	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	treatments	2	Radiation Therapy	Radiation therapy is used for local control, particularly when complete surgical resection is not possible or margins are positive.	treatment_term	treatment_term	$	Radiation Therapy	Radiation therapy is used for local control, particularly when complete surgical resection is not possible or margins are positive.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
581	508	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	0	Cholinesterase Inhibitors	Medications such as donepezil, rivastigmine, and galantamine that inhibit acetylcholinesterase to increase acetylcholine availability in the brain, providing modest symptomatic improvement in cognitive function.	treatment_term	treatment_term	$	Cholinesterase Inhibitors	Medications such as donepezil, rivastigmine, and galantamine that inhibit acetylcholinesterase to increase acetylcholine availability in the brain, providing modest symptomatic improvement in cognitive function.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
582	509	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	1	NMDA Receptor Antagonist	Memantine blocks NMDA receptors to reduce glutamate excitotoxicity and may provide modest cognitive and functional benefits, particularly in moderate to severe Alzheimer's disease.	treatment_term	treatment_term	$	NMDA Receptor Antagonist	Memantine blocks NMDA receptors to reduce glutamate excitotoxicity and may provide modest cognitive and functional benefits, particularly in moderate to severe Alzheimer's disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
583	510	21	Alzheimer's Disease	Alzheimers_Disease.yaml	treatments	2	Cognitive Stimulation and Rehabilitation	Non-pharmacological interventions including cognitive training, reality orientation, and memory rehabilitation to maintain cognitive function and quality of life.	treatment_term	treatment_term	$	Cognitive Stimulation and Rehabilitation	Non-pharmacological interventions including cognitive training, reality orientation, and memory rehabilitation to maintain cognitive function and quality of life.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
626	549	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	0	Riluzole	"Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
"	treatment_term	treatment_term	$	Riluzole	"Glutamate antagonist that modestly extends survival by 2-3 months. It is the first FDA-approved treatment for ALS and works by reducing excitotoxic neuronal damage.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
627	550	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	1	Edaravone	"Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.
"	treatment_term	treatment_term	$	Edaravone	"Antioxidant that may slow functional decline in a subset of ALS patients. It reduces oxidative stress and has shown benefit in early-stage patients.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
628	551	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	2	Tofersen	"Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.
"	treatment_term	treatment_term	$	Tofersen	"Antisense oligonucleotide therapy approved for SOD1-ALS that reduces SOD1 protein production, targeting the underlying genetic cause in this subset of patients.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
629	552	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	3	Non-invasive Ventilation	"Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.
"	treatment_term	treatment_term	$	Non-invasive Ventilation	"Respiratory support using BiPAP or similar devices to assist breathing as respiratory muscles weaken. This improves quality of life and extends survival.
"	noninvasive ventilation	MAXO:0000506	noninvasive ventilation		"{""preferred_term"": ""noninvasive ventilation"", ""term"": {""id"": ""MAXO:0000506"", ""label"": ""noninvasive ventilation""}}"																											
630	553	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	4	Physical Therapy	"Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.
"	treatment_term	treatment_term	$	Physical Therapy	"Range of motion exercises and adaptive strategies to maintain function and prevent complications such as contractures.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
631	554	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	5	Speech Therapy	"Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.
"	treatment_term	treatment_term	$	Speech Therapy	"Techniques to optimize communication and swallowing safety, including augmentative and alternative communication devices.
"	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
632	555	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	6	Percutaneous Endoscopic Gastrostomy	"Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.
"	treatment_term	treatment_term	$	Percutaneous Endoscopic Gastrostomy	"Feeding tube placement to maintain nutrition when swallowing becomes unsafe or inadequate due to bulbar involvement.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
633	556	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	treatments	7	Multidisciplinary Care	"Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.
"	treatment_term	treatment_term	$	Multidisciplinary Care	"Coordinated care from neurologists, pulmonologists, physical therapists, occupational therapists, speech therapists, nutritionists, and palliative care specialists extends survival and improves quality of life.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
672	616	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	0	Cranial Vault Remodeling	"Surgical release and reshaping of the skull to relieve intracranial pressure and improve cranial shape. Often performed in infancy with additional procedures as needed during growth.
"	treatment_term	treatment_term	$	Cranial Vault Remodeling	"Surgical release and reshaping of the skull to relieve intracranial pressure and improve cranial shape. Often performed in infancy with additional procedures as needed during growth.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
673	617	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	1	Midface Advancement	"Le Fort III or monobloc osteotomy to advance the midface, improving appearance, airway, and occlusion. Often performed in childhood or adolescence.
"	treatment_term	treatment_term	$	Midface Advancement	"Le Fort III or monobloc osteotomy to advance the midface, improving appearance, airway, and occlusion. Often performed in childhood or adolescence.
"	Midface surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
674	618	25	Apert Syndrome	Apert_Syndrome.yaml	treatments	2	Syndactyly Release	"Staged surgical separation of fused digits to improve hand function. Multiple procedures typically required.
"	treatment_term	treatment_term	$	Syndactyly Release	"Staged surgical separation of fused digits to improve hand function. Multiple procedures typically required.
"	Hand surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Hand surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
706	642	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	0	Estrogen Replacement Therapy	Corrects estrogen deficiency and supports normal sexual development and bone health.	treatment_term	treatment_term	$	Estrogen Replacement Therapy	Corrects estrogen deficiency and supports normal sexual development and bone health.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy	Therapeutic administration of estrogen to replace deficient endogenous hormone production.	"{""description"": ""Therapeutic administration of estrogen to replace deficient endogenous hormone production."", ""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
707	643	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	1	Antiandrogen Therapy	Adjunctive treatment to mitigate virilization from androgen excess using agents like spironolactone or flutamide.	treatment_term	treatment_term	$	Antiandrogen Therapy	Adjunctive treatment to mitigate virilization from androgen excess using agents like spironolactone or flutamide.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Drug therapy using antiandrogens to block androgen effects and reduce virilization.	"{""description"": ""Drug therapy using antiandrogens to block androgen effects and reduce virilization."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
708	644	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	treatments	2	Surgical Management	May be considered for ambiguous genitalia or other anatomical abnormalities.	treatment_term	treatment_term	$	Surgical Management	May be considered for ambiguous genitalia or other anatomical abnormalities.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention for anatomical abnormalities such as ambiguous genitalia.	"{""description"": ""Operative intervention for anatomical abnormalities such as ambiguous genitalia."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
726	666	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	1	Surgical Excision	Surgical removal of skin cancers and premalignant keratoses. May require multiple procedures given multiplicity of lesions. Mohs surgery for invasive carcinomas in cosmetically sensitive areas.	treatment_term	treatment_term	$	Surgical Excision	Surgical removal of skin cancers and premalignant keratoses. May require multiple procedures given multiplicity of lesions. Mohs surgery for invasive carcinomas in cosmetically sensitive areas.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
727	667	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	2	Topical Therapy	Topical 5-fluorouracil or imiquimod for superficial lesions and field therapy of areas with multiple keratoses. Photodynamic therapy is also effective for widespread lesions.	treatment_term	treatment_term	$	Topical Therapy	Topical 5-fluorouracil or imiquimod for superficial lesions and field therapy of areas with multiple keratoses. Photodynamic therapy is also effective for widespread lesions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
728	668	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	treatments	3	Systemic Cancer Treatment	Standard treatment protocols for lung cancer (surgery, chemotherapy, immunotherapy, radiation) and bladder cancer (TURBT, intravesical therapy, cystectomy, systemic chemotherapy) based on stage and tumor characteristics.	treatment_term	treatment_term	$	Systemic Cancer Treatment	Standard treatment protocols for lung cancer (surgery, chemotherapy, immunotherapy, radiation) and bladder cancer (TURBT, intravesical therapy, cystectomy, systemic chemotherapy) based on stage and tumor characteristics.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
781	711	28	Asthma	Asthma.yaml	treatments	0	Inhaled Corticosteroid	Reduce inflammation and prevent flare-ups.	treatment_term	treatment_term	$	Inhaled Corticosteroid	Reduce inflammation and prevent flare-ups.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
782	712	28	Asthma	Asthma.yaml	treatments	1	Long-acting Beta Agonist	Relax the muscles around the airways.	treatment_term	treatment_term	$	Long-acting Beta Agonist	Relax the muscles around the airways.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
783	713	28	Asthma	Asthma.yaml	treatments	2	Leukotriene Modifier	Reduce inflammation, decrease mucus secretion, and prevent airway constriction.	treatment_term	treatment_term	$	Leukotriene Modifier	Reduce inflammation, decrease mucus secretion, and prevent airway constriction.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
784	714	28	Asthma	Asthma.yaml	treatments	3	Anti-IgE Therapy	Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response.	treatment_term	treatment_term	$	Anti-IgE Therapy	Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
785	715	28	Asthma	Asthma.yaml	treatments	4	Short-acting Beta Agonist	Provides rapid relief from acute asthma symptoms.	treatment_term	treatment_term	$	Short-acting Beta Agonist	Provides rapid relief from acute asthma symptoms.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
795	741	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	0	Anticoagulation	Warfarin or DOACs to prevent stroke based on CHA2DS2-VASc score.	treatment_term	treatment_term	$	Anticoagulation	Warfarin or DOACs to prevent stroke based on CHA2DS2-VASc score.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
796	742	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	1	Rate Control	Beta blockers, calcium channel blockers, or digoxin.	treatment_term	treatment_term	$	Rate Control	Beta blockers, calcium channel blockers, or digoxin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
797	743	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	2	Rhythm Control	Antiarrhythmic drugs (amiodarone, flecainide, sotalol).	treatment_term	treatment_term	$	Rhythm Control	Antiarrhythmic drugs (amiodarone, flecainide, sotalol).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
798	744	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	treatments	3	Catheter Ablation	Pulmonary vein isolation for rhythm control.	treatment_term	treatment_term	$	Catheter Ablation	Pulmonary vein isolation for rhythm control.	radiofrequency ablation therapy	MAXO:0001395	radiofrequency ablation therapy		"{""preferred_term"": ""radiofrequency ablation therapy"", ""term"": {""id"": ""MAXO:0001395"", ""label"": ""radiofrequency ablation therapy""}}"																											
814	762	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	0	Antifungal Therapy	"Antifungal medications such as fluconazole (100 mg/day for 3 weeks) are first-line therapy for fungal ABS. Nystatin and micafungin are alternatives for refractory cases.
"	treatment_term	treatment_term	$	Antifungal Therapy	"Antifungal medications such as fluconazole (100 mg/day for 3 weeks) are first-line therapy for fungal ABS. Nystatin and micafungin are alternatives for refractory cases.
"	Pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
815	763	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	1	Low Carbohydrate Diet	"Dietary modification to restrict carbohydrate intake reduces substrate available for microbial fermentation. High-protein diets are recommended with initial complete carbohydrate elimination for approximately 6 weeks.
"	treatment_term	treatment_term	$	Low Carbohydrate Diet	"Dietary modification to restrict carbohydrate intake reduces substrate available for microbial fermentation. High-protein diets are recommended with initial complete carbohydrate elimination for approximately 6 weeks.
"	Dietary Intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""Dietary Intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
816	765	30	Auto-Brewery Syndrome	Auto-Brewery_Syndrome.yaml	treatments	3	Fecal Microbiota Transplantation	"FMT has emerged as a promising option for refractory cases by restoring normal gut microbiome composition and diversity.
"	treatment_term	treatment_term	$	Fecal Microbiota Transplantation	"FMT has emerged as a promising option for refractory cases by restoring normal gut microbiome composition and diversity.
"	Fecal Microbiota Transplantation	MAXO:0000748	fecal microbiota transplantation		"{""preferred_term"": ""Fecal Microbiota Transplantation"", ""term"": {""id"": ""MAXO:0000748"", ""label"": ""fecal microbiota transplantation""}}"																											
853	824	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	0	Glaucoma Pharmacotherapy	Topical medications to reduce intraocular pressure, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. First-line treatment for glaucoma management.	treatment_term	treatment_term	$	Glaucoma Pharmacotherapy	Topical medications to reduce intraocular pressure, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. First-line treatment for glaucoma management.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
854	825	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	1	Glaucoma Surgery	Surgical interventions including trabeculectomy, tube shunt procedures, and angle surgery to control intraocular pressure when medical therapy is insufficient. Surgery is frequently required in ARS-associated glaucoma, particularly in FOXC1-related cases with early onset.	treatment_term	treatment_term	$	Glaucoma Surgery	Surgical interventions including trabeculectomy, tube shunt procedures, and angle surgery to control intraocular pressure when medical therapy is insufficient. Surgery is frequently required in ARS-associated glaucoma, particularly in FOXC1-related cases with early onset.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
855	826	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	treatments	2	Dental Management	Orthodontic and dental treatments to address dental anomalies including hypodontia, microdontia, and enamel hypoplasia. May include prosthetic reconstruction, dental implants, and orthodontic correction.	treatment_term	treatment_term	$	Dental Management	Orthodontic and dental treatments to address dental anomalies including hypodontia, microdontia, and enamel hypoplasia. May include prosthetic reconstruction, dental implants, and orthodontic correction.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
866	841	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with or without lymph node dissection is the primary treatment for papillary thyroid cancer regardless of BRAF status. Extent of surgery guided by tumor size and nodal involvement.	treatment_term	treatment_term	$	Thyroidectomy	Total thyroidectomy with or without lymph node dissection is the primary treatment for papillary thyroid cancer regardless of BRAF status. Extent of surgery guided by tumor size and nodal involvement.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
867	842	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	1	Radioiodine Therapy	Adjuvant radioactive iodine (I-131) therapy is used for intermediate and high-risk disease. BRAF-mutant tumors may have reduced radioiodine avidity due to dedifferentiation and NIS suppression.	treatment_term	treatment_term	$	Radioiodine Therapy	Adjuvant radioactive iodine (I-131) therapy is used for intermediate and high-risk disease. BRAF-mutant tumors may have reduced radioiodine avidity due to dedifferentiation and NIS suppression.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
868	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term	treatment_term	$	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dabrafenib"", ""term"": {""id"": ""CHEBI:75045"", ""label"": ""dabrafenib""}}, {""preferred_term"": ""trametinib"", ""term"": {""id"": ""CHEBI:75998"", ""label"": ""trametinib""}}]}"				dabrafenib; trametinib	CHEBI:75045; CHEBI:75998																						
869	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			dabrafenib	CHEBI:75045	dabrafenib		"{""preferred_term"": ""dabrafenib"", ""term"": {""id"": ""CHEBI:75045"", ""label"": ""dabrafenib""}}"																											
870	843	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	2	Dabrafenib Plus Trametinib	Combined BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E-mutant anaplastic thyroid cancer and shows activity in radioiodine-refractory differentiated thyroid cancer.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			trametinib	CHEBI:75998	trametinib		"{""preferred_term"": ""trametinib"", ""term"": {""id"": ""CHEBI:75998"", ""label"": ""trametinib""}}"																											
871	844	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	3	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	treatment_term	treatment_term	$	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}"				lenvatinib	CHEBI:85994																						
872	844	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	treatments	3	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer regardless of BRAF status. May be used when BRAF-targeted therapy is not available or has failed.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"																											
885	862	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	0	Encorafenib plus Cetuximab	FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON CRC trial demonstrated significant improvement in overall survival and response rate compared to standard chemotherapy.	treatment_term	treatment_term	$	Encorafenib plus Cetuximab	FDA-approved combination for BRAF V600E metastatic CRC after prior therapy. Encorafenib inhibits mutant BRAF while cetuximab blocks EGFR to prevent feedback reactivation. BEACON CRC trial demonstrated significant improvement in overall survival and response rate compared to standard chemotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
886	863	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	1	Encorafenib plus Cetuximab plus Binimetinib	Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab. Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity.	treatment_term	treatment_term	$	Encorafenib plus Cetuximab plus Binimetinib	Triple combination adding the MEK inhibitor binimetinib to encorafenib and cetuximab. Provides more complete MAPK pathway suppression. Originally studied in BEACON CRC but doublet (encorafenib/cetuximab) is preferred due to similar efficacy with less toxicity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
887	864	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	2	FOLFOXIRI plus Bevacizumab	Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive therapy. TRIBE2 showed benefit in this subgroup.	treatment_term	treatment_term	$	FOLFOXIRI plus Bevacizumab	Intensive triplet chemotherapy (5-FU, leucovorin, oxaliplatin, irinotecan) with bevacizumab may provide benefit for fit patients with BRAF V600E mCRC who can tolerate aggressive therapy. TRIBE2 showed benefit in this subgroup.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
888	865	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	treatments	3	Surgical Resection	Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have attenuated benefit.	treatment_term	treatment_term	$	Surgical Resection	Surgery for localized disease or oligometastatic disease in selected patients. Adjuvant chemotherapy is standard for stage III disease, though BRAF-mutant tumors may have attenuated benefit.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
899	879	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	0	Dabrafenib plus Trametinib	Combination of BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E NSCLC. Combination prevents paradoxical MAPK activation and delays resistance compared to BRAF inhibitor alone. Approved based on BRF113928 trial.	treatment_term	treatment_term	$	Dabrafenib plus Trametinib	Combination of BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) is approved for BRAF V600E NSCLC. Combination prevents paradoxical MAPK activation and delays resistance compared to BRAF inhibitor alone. Approved based on BRF113928 trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
900	880	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	1	Dabrafenib Monotherapy	BRAF inhibitor with activity against V600E mutant. Generally used in combination with trametinib for improved efficacy and reduced paradoxical activation.	treatment_term	treatment_term	$	Dabrafenib Monotherapy	BRAF inhibitor with activity against V600E mutant. Generally used in combination with trametinib for improved efficacy and reduced paradoxical activation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
901	881	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	2	Encorafenib plus Binimetinib	Alternative BRAF/MEK inhibitor combination approved for other V600E tumors (melanoma, colorectal). May be considered for BRAF V600E NSCLC based on mechanism of action.	treatment_term	treatment_term	$	Encorafenib plus Binimetinib	Alternative BRAF/MEK inhibitor combination approved for other V600E tumors (melanoma, colorectal). May be considered for BRAF V600E NSCLC based on mechanism of action.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
902	882	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for BRAF V600E NSCLC, though targeted therapy with dabrafenib/trametinib is generally preferred given high response rates.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors may be used for BRAF V600E NSCLC, though targeted therapy with dabrafenib/trametinib is generally preferred given high response rates.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
903	883	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy used at progression on targeted therapy or when targeted therapy is contraindicated.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy used at progression on targeted therapy or when targeted therapy is contraindicated.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
915	893	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	0	Dabrafenib plus Trametinib	First-line targeted therapy combining BRAF inhibitor dabrafenib with MEK inhibitor trametinib. Combination therapy achieves higher response rates (approximately 70%) and longer duration of response compared to BRAF inhibitor monotherapy, while reducing paradoxical MAPK activation and cutaneous squamous cell carcinomas.	treatment_term	treatment_term	$	Dabrafenib plus Trametinib	First-line targeted therapy combining BRAF inhibitor dabrafenib with MEK inhibitor trametinib. Combination therapy achieves higher response rates (approximately 70%) and longer duration of response compared to BRAF inhibitor monotherapy, while reducing paradoxical MAPK activation and cutaneous squamous cell carcinomas.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
916	894	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	1	Vemurafenib plus Cobimetinib	Alternative BRAF plus MEK inhibitor combination. Vemurafenib was the first BRAF inhibitor approved for melanoma. Combined with the MEK inhibitor cobimetinib to improve efficacy and reduce paradoxical activation side effects.	treatment_term	treatment_term	$	Vemurafenib plus Cobimetinib	Alternative BRAF plus MEK inhibitor combination. Vemurafenib was the first BRAF inhibitor approved for melanoma. Combined with the MEK inhibitor cobimetinib to improve efficacy and reduce paradoxical activation side effects.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
917	895	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	2	Encorafenib plus Binimetinib	Third-generation BRAF plus MEK inhibitor combination offering improved tolerability profile. Encorafenib has a longer half-life than other BRAF inhibitors, potentially reducing dosing frequency.	treatment_term	treatment_term	$	Encorafenib plus Binimetinib	Third-generation BRAF plus MEK inhibitor combination offering improved tolerability profile. Encorafenib has a longer half-life than other BRAF inhibitors, potentially reducing dosing frequency.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
918	896	37	BRAF V600 Mutant Melanoma	BRAF_V600_Mutant_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are also effective in BRAF-mutant melanoma. The optimal sequencing of targeted therapy versus immunotherapy remains an active area of investigation.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are also effective in BRAF-mutant melanoma. The optimal sequencing of targeted therapy versus immunotherapy remains an active area of investigation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
928	909	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	0	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	treatment_term	treatment_term	$	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}]}"				olaparib	CHEBI:83766																						
929	909	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	0	Olaparib	PARP inhibitor approved for mCRPC with BRCA1/2 mutations (or other HRR gene alterations) after progression on enzalutamide or abiraterone. Exploits synthetic lethality in HRR-deficient tumors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"																											
930	910	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	1	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	treatment_term	treatment_term	$	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""rucaparib"", ""term"": {""id"": ""CHEBI:134689"", ""label"": ""rucaparib""}}]}"				rucaparib	CHEBI:134689																						
931	910	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	1	Rucaparib	PARP inhibitor approved for BRCA1/2-mutated mCRPC after progression on androgen receptor-directed therapy and taxane-based chemotherapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			rucaparib	CHEBI:134689	rucaparib		"{""preferred_term"": ""rucaparib"", ""term"": {""id"": ""CHEBI:134689"", ""label"": ""rucaparib""}}"																											
932	911	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	2	Platinum Chemotherapy	HRR-deficient tumors show increased sensitivity to platinum agents due to inability to repair platinum-induced DNA crosslinks. Carboplatin-based regimens may be considered.	treatment_term	treatment_term	$	Platinum Chemotherapy	HRR-deficient tumors show increased sensitivity to platinum agents due to inability to repair platinum-induced DNA crosslinks. Carboplatin-based regimens may be considered.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
933	912	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	treatments	3	Androgen Deprivation Therapy	Standard treatment for advanced prostate cancer regardless of HRR status. May be combined with novel hormonal agents like enzalutamide or abiraterone.	treatment_term	treatment_term	$	Androgen Deprivation Therapy	Standard treatment for advanced prostate cancer regardless of HRR status. May be combined with novel hormonal agents like enzalutamide or abiraterone.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
991	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term	treatment_term	$	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Broad Spectrum Antibiotic	NCIT:C2883	NCIT:C2259			
992	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
993	958	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	0	Empiric Antibiotic Therapy	Broad-spectrum antibiotics (e.g., ceftriaxone, vancomycin) started immediately after lumbar puncture.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}"																											
994	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term	treatment_term	$	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anti-infective agent"", ""term"": {""id"": ""NCIT:C28254"", ""label"": ""Anti-Infective Agent""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Anti-Infective Agent	NCIT:C28254	NCIT:C2259			
995	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
996	959	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	1	Targeted Antibiotic Therapy	Antibiotics tailored to the specific pathogen once identified.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			anti-infective agent	NCIT:C28254	Anti-Infective Agent		"{""preferred_term"": ""anti-infective agent"", ""term"": {""id"": ""NCIT:C28254"", ""label"": ""Anti-Infective Agent""}}"																											
997	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term	treatment_term	$	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dexamethasone"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Dexamethasone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Dexamethasone	NCIT:C620	NCIT:C2259			
998	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
999	960	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	2	Dexamethasone	Corticosteroid used to reduce inflammation and complications, particularly in pneumococcal meningitis.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			dexamethasone	NCIT:C620	Dexamethasone		"{""preferred_term"": ""dexamethasone"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Dexamethasone""}}"																											
1000	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term	treatment_term	$	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""fluid therapy"", ""term"": {""id"": ""NCIT:C15693"", ""label"": ""Fluid Replacement Therapy""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""anticonvulsant agent"", ""term"": {""id"": ""NCIT:C614"", ""label"": ""Anticonvulsant Agent""}}}], ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																						Anticonvulsant Agent	NCIT:C614	NCIT:C2259	Fluid Replacement Therapy	NCIT:C15693	NCIT:C49236
1001	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
1002	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			fluid therapy	NCIT:C15693	Fluid Replacement Therapy		"{""preferred_term"": ""fluid therapy"", ""term"": {""id"": ""NCIT:C15693"", ""label"": ""Fluid Replacement Therapy""}}"																											
1003	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1004	961	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	3	Supportive Care	Fluids, electrolyte management, seizure control, and monitoring of intracranial pressure.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			anticonvulsant agent	NCIT:C614	Anticonvulsant Agent		"{""preferred_term"": ""anticonvulsant agent"", ""term"": {""id"": ""NCIT:C614"", ""label"": ""Anticonvulsant Agent""}}"																											
1005	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term	treatment_term	$	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""immunologic factor"", ""term"": {""id"": ""NCIT:C307"", ""label"": ""Immunologic Factor""}}, ""value"": {""preferred_term"": ""vaccine"", ""term"": {""id"": ""NCIT:C15260"", ""label"": ""Vaccine""}}}], ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"												Vaccine	NCIT:C15260	NCIT:C307													
1006	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			immunologic factor	NCIT:C307	Immunologic Factor		"{""preferred_term"": ""immunologic factor"", ""term"": {""id"": ""NCIT:C307"", ""label"": ""Immunologic Factor""}}"																											
1007	962	39	Bacterial meningitis	Bacterial_meningitis.yaml	treatments	4	Vaccination	Vaccines available for prevention of meningococcal, pneumococcal, and Hib meningitis.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			vaccine	NCIT:C15260	Vaccine		"{""preferred_term"": ""vaccine"", ""term"": {""id"": ""NCIT:C15260"", ""label"": ""Vaccine""}}"																											
1040	996	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	0	Supportive Therapy	Addressing specific symptoms like vision support, weight management, and physical therapy.	treatment_term	treatment_term	$	Supportive Therapy	Addressing specific symptoms like vision support, weight management, and physical therapy.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1041	997	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	1	Genetic Counseling	For affected individuals and families to understand inheritance patterns, risks, and implications.	treatment_term	treatment_term	$	Genetic Counseling	For affected individuals and families to understand inheritance patterns, risks, and implications.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
1042	998	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	2	Surgical Interventions	For polydactyly or other structural anomalies as needed.	treatment_term	treatment_term	$	Surgical Interventions	For polydactyly or other structural anomalies as needed.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1043	999	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	3	Dietary and Lifestyle Modifications	To manage obesity and associated metabolic conditions.	treatment_term	treatment_term	$	Dietary and Lifestyle Modifications	To manage obesity and associated metabolic conditions.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
1044	1000	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	4	Gene Therapy	Experimental gene augmentation therapy to preserve retinal function in BBS-related retinal degeneration.	treatment_term	treatment_term	$	Gene Therapy	Experimental gene augmentation therapy to preserve retinal function in BBS-related retinal degeneration.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
1045	1001	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	treatments	5	Setmelanotide	An MC4R (melanocortin-4 receptor) agonist that activates the melanocortin pathway downstream of impaired leptin receptor signaling. Reduces hyperphagia and promotes weight loss in patients with BBS-associated obesity by bypassing the defective ciliary GPCR trafficking.	treatment_term	treatment_term	$	Setmelanotide	An MC4R (melanocortin-4 receptor) agonist that activates the melanocortin pathway downstream of impaired leptin receptor signaling. Reduces hyperphagia and promotes weight loss in patients with BBS-associated obesity by bypassing the defective ciliary GPCR trafficking.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1059	1018	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	0	Surgical Excision	Standard treatment for most BCCs with excellent cure rates (95% or higher). Mohs micrographic surgery provides highest cure rates for high-risk tumors through complete margin assessment while preserving tissue.	treatment_term	treatment_term	$	Surgical Excision	Standard treatment for most BCCs with excellent cure rates (95% or higher). Mohs micrographic surgery provides highest cure rates for high-risk tumors through complete margin assessment while preserving tissue.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1060	1019	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	treatment_term	treatment_term	$	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}]}"				vismodegib	CHEBI:66903																						
1061	1019	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor that binds and inhibits Smoothened. FDA-approved for locally advanced or metastatic BCC. Response rates of 30-60% in advanced disease. Side effects include muscle spasms, alopecia, and dysgeusia.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"																											
1062	1020	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	2	Sonidegib	Second SMO inhibitor approved for locally advanced BCC. Similar mechanism of action to vismodegib with comparable efficacy profile. May provide alternative for patients intolerant of vismodegib.	treatment_term	treatment_term	$	Sonidegib	Second SMO inhibitor approved for locally advanced BCC. Similar mechanism of action to vismodegib with comparable efficacy profile. May provide alternative for patients intolerant of vismodegib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1063	1021	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	3	Radiation Therapy	Alternative treatment for patients who are not surgical candidates or refuse surgery. Also used for adjuvant treatment of high-risk tumors with perineural invasion or positive margins.	treatment_term	treatment_term	$	Radiation Therapy	Alternative treatment for patients who are not surgical candidates or refuse surgery. Also used for adjuvant treatment of high-risk tumors with perineural invasion or positive margins.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1064	1022	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	4	Topical Therapy	Topical imiquimod (immune response modifier) or 5-fluorouracil may be used for superficial BCC. Not appropriate for nodular or aggressive subtypes.	treatment_term	treatment_term	$	Topical Therapy	Topical imiquimod (immune response modifier) or 5-fluorouracil may be used for superficial BCC. Not appropriate for nodular or aggressive subtypes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1065	1023	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	treatments	5	Immune Checkpoint Inhibitors	Cemiplimab (anti-PD-1) has shown activity in locally advanced and metastatic BCC refractory to Hedgehog inhibitors, representing a treatment option for this previously difficult population.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Cemiplimab (anti-PD-1) has shown activity in locally advanced and metastatic BCC refractory to Hedgehog inhibitors, representing a treatment option for this previously difficult population.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1078	1044	43	Bejel	Bejel.yaml	treatments	0	Penicillin therapy	Penicillin therapy is effective for endemic treponematoses.	treatment_term	treatment_term	$	Penicillin therapy	Penicillin therapy is effective for endemic treponematoses.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1104	1088	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	treatments	0	Supportive care	"Symptom management including speech therapy, physical therapy, educational support, and management of hearing impairment with hearing aids or cochlear implants.
"	treatment_term	treatment_term	$	Supportive care	"Symptom management including speech therapy, physical therapy, educational support, and management of hearing impairment with hearing aids or cochlear implants.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1180	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term	treatment_term	$	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}, {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}]}"				prednisone; azathioprine	CHEBI:8382; CHEBI:2948																						
1181	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"																											
1182	1167	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	0	Prednisone and Azathioprine	Glucocorticoid therapy with prednisone, sometimes combined with azathioprine, has been used in chronic hypersensitivity pneumonitis.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"																											
1183	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term	treatment_term	$	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""CHEBI:8764"", ""label"": ""mycophenolate mofetil""}}, {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}]}"				mycophenolate mofetil; azathioprine	CHEBI:8764; CHEBI:2948																						
1184	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			mycophenolate mofetil	CHEBI:8764	mycophenolate mofetil		"{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""CHEBI:8764"", ""label"": ""mycophenolate mofetil""}}"																											
1185	1168	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	1	Mycophenolate Mofetil or Azathioprine	Immunosuppressive pharmacotherapy with mycophenolate mofetil or azathioprine has been used in chronic hypersensitivity pneumonitis and associated with improved DLCO.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			azathioprine	CHEBI:2948	azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""CHEBI:2948"", ""label"": ""azathioprine""}}"																											
1186	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	treatment_term	treatment_term	$	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""pirfenidone"", ""term"": {""id"": ""CHEBI:32016"", ""label"": ""pirfenidone""}}]}"				pirfenidone	CHEBI:32016																						
1187	1169	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	2	Pirfenidone	Antifibrotic pharmacotherapy evaluated for fibrotic hypersensitivity pneumonitis.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			pirfenidone	CHEBI:32016	pirfenidone		"{""preferred_term"": ""pirfenidone"", ""term"": {""id"": ""CHEBI:32016"", ""label"": ""pirfenidone""}}"																											
1188	1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	treatment_term	treatment_term	$	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""nintedanib"", ""term"": {""id"": ""CHEBI:85164"", ""label"": ""nintedanib""}}]}"				nintedanib	CHEBI:85164																						
1189	1170	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	treatments	3	Nintedanib	Antifibrotic therapy shown to reduce the rate of FVC decline in progressive fibrosing ILD, including hypersensitivity pneumonitis subgroups.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			nintedanib	CHEBI:85164	nintedanib		"{""preferred_term"": ""nintedanib"", ""term"": {""id"": ""CHEBI:85164"", ""label"": ""nintedanib""}}"																											
1191	1174	48	Botulism	Botulism.yaml	treatments	0	Botulinum Antitoxin	Administration of botulinum antitoxin to neutralize circulating toxin.	treatment_term	treatment_term	$	Botulinum Antitoxin	Administration of botulinum antitoxin to neutralize circulating toxin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1193	1178	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	0	Surgical Excision	Surgical removal of symptomatic fibroadenomas.	treatment_term	treatment_term	$	Surgical Excision	Surgical removal of symptomatic fibroadenomas.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1194	1179	49	Breast Fibroadenoma	Breast_Fibroadenoma.yaml	treatments	1	Conservative Management	Observation with clinical and imaging follow-up when triple-test evaluation is consistent with fibroadenoma.	treatment_term	treatment_term	$	Conservative Management	Observation with clinical and imaging follow-up when triple-test evaluation is consistent with fibroadenoma.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1226	1209	50	Bronchiectasis	Bronchiectasis.yaml	treatments	0	Airway Clearance Techniques	Physical therapies to enhance mucus clearance, such as chest physiotherapy.	treatment_term	treatment_term	$	Airway Clearance Techniques	Physical therapies to enhance mucus clearance, such as chest physiotherapy.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1227	1210	50	Bronchiectasis	Bronchiectasis.yaml	treatments	1	Antibiotic Therapy	Used to treat and prevent bacterial infections in the airways.	treatment_term	treatment_term	$	Antibiotic Therapy	Used to treat and prevent bacterial infections in the airways.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1228	1211	50	Bronchiectasis	Bronchiectasis.yaml	treatments	2	Bronchodilators	Medications to open airways and improve breathing.	treatment_term	treatment_term	$	Bronchodilators	Medications to open airways and improve breathing.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1229	1212	50	Bronchiectasis	Bronchiectasis.yaml	treatments	3	Inhaled Corticosteroids	Reduce inflammation in the airways.	treatment_term	treatment_term	$	Inhaled Corticosteroids	Reduce inflammation in the airways.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
1230	1213	50	Bronchiectasis	Bronchiectasis.yaml	treatments	4	Surgery	Rarely performed; may include removal of severely affected lung areas if localized and recurrent infections persist.	treatment_term	treatment_term	$	Surgery	Rarely performed; may include removal of severely affected lung areas if localized and recurrent infections persist.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1231	1214	50	Bronchiectasis	Bronchiectasis.yaml	treatments	5	Vaccinations	Prevent respiratory infections and exacerbations.	treatment_term	treatment_term	$	Vaccinations	Prevent respiratory infections and exacerbations.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
1247	1237	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	0	Intensive Chemotherapy	Intensive, short-duration chemotherapy regimens achieve high cure rates (>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC, hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high risk of CNS involvement.	treatment_term	treatment_term	$	Intensive Chemotherapy	Intensive, short-duration chemotherapy regimens achieve high cure rates (>90% in children, 60-80% in adults). Regimens include CODOX-M/IVAC, hyper-CVAD, and DA-EPOCH-R. CNS prophylaxis is essential given high risk of CNS involvement.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
1248	1238	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	1	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	treatment_term	treatment_term	$	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""rituximab"", ""term"": {""id"": ""CHEBI:64357"", ""label"": ""rituximab""}}]}"				rituximab	CHEBI:64357																						
1249	1238	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	1	Rituximab	Anti-CD20 monoclonal antibody added to chemotherapy improves outcomes, particularly in adults. Standard component of modern treatment regimens.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			rituximab	CHEBI:64357	rituximab		"{""preferred_term"": ""rituximab"", ""term"": {""id"": ""CHEBI:64357"", ""label"": ""rituximab""}}"																											
1250	1239	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	treatments	2	Tumor Lysis Syndrome Prophylaxis	Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are essential given the extremely high risk of tumor lysis syndrome from rapid tumor cell death.	treatment_term	treatment_term	$	Tumor Lysis Syndrome Prophylaxis	Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are essential given the extremely high risk of tumor lysis syndrome from rapid tumor cell death.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1253	1243	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	0	Antimycobacterial therapy	Antimycobacterial therapy is effective for early lesions.	treatment_term	treatment_term	$	Antimycobacterial therapy	Antimycobacterial therapy is effective for early lesions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1254	1244	52	Buruli ulcer	Buruli_Ulcer.yaml	treatments	1	Surgical management	Surgery may be required for advanced ulcerated lesions.	treatment_term	treatment_term	$	Surgical management	Surgery may be required for advanced ulcerated lesions.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1269	1259	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	0	Supportive Care	Multidisciplinary care addressing individual symptoms and complications.	treatment_term	treatment_term	$	Supportive Care	Multidisciplinary care addressing individual symptoms and complications.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1270	1260	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	1	Cardiac Surgery	Surgical correction of congenital heart defects when indicated.	treatment_term	treatment_term	$	Cardiac Surgery	Surgical correction of congenital heart defects when indicated.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1271	1261	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	2	Seizure Management	Antiepileptic medications for seizure control.	treatment_term	treatment_term	$	Seizure Management	Antiepileptic medications for seizure control.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1272	1262	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	3	Dermatologic Care	Topical and systemic treatments for ichthyosiform dermatosis management, including topical therapies and IL-17 antagonists for severe cases.	treatment_term	treatment_term	$	Dermatologic Care	Topical and systemic treatments for ichthyosiform dermatosis management, including topical therapies and IL-17 antagonists for severe cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1273	1263	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	4	Hearing Aids	Assistive devices for conductive hearing loss.	treatment_term	treatment_term	$	Hearing Aids	Assistive devices for conductive hearing loss.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1274	1264	53	CHIME_syndrome	CHIME_syndrome.yaml	treatments	5	Educational Support	Special educational services tailored to intellectual disability.	treatment_term	treatment_term	$	Educational Support	Special educational services tailored to intellectual disability.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
1300	1285	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	0	Supportive Developmental Therapies	"Early intervention services including speech therapy, occupational therapy, and physical therapy to address developmental delays.
"	treatment_term	treatment_term	$	Supportive Developmental Therapies	"Early intervention services including speech therapy, occupational therapy, and physical therapy to address developmental delays.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1301	1288	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	3	Behavioral Management	"Management of behavioral abnormalities including ADHD-like features, autistic behaviors, and aggression through behavioral therapy and potentially pharmacological interventions.
"	treatment_term	treatment_term	$	Behavioral Management	"Management of behavioral abnormalities including ADHD-like features, autistic behaviors, and aggression through behavioral therapy and potentially pharmacological interventions.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1302	1289	54	CTCF-related Neurodevelopmental Disorder	CTCF-related_Neurodevelopmental_Disorder.yaml	treatments	4	Genetic Counseling	"Genetic counseling for families regarding recurrence risk, inheritance patterns, and implications of diagnosis. Most cases are de novo with low recurrence risk, but rare familial cases have been reported.
"	treatment_term	treatment_term	$	Genetic Counseling	"Genetic counseling for families regarding recurrence risk, inheritance patterns, and implications of diagnosis. Most cases are de novo with low recurrence risk, but rare familial cases have been reported.
"	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
1318	1309	55	Camptodactyly	Camptodactyly.yaml	treatments	0	Physical Therapy	Exercises and splinting to improve range of motion and prevent further contracture. First-line conservative management for mild to moderate cases.	treatment_term	treatment_term	$	Physical Therapy	Exercises and splinting to improve range of motion and prevent further contracture. First-line conservative management for mild to moderate cases.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1319	1310	55	Camptodactyly	Camptodactyly.yaml	treatments	1	Serial Splinting	Progressive splinting to gradually extend the affected joints over time.	treatment_term	treatment_term	$	Serial Splinting	Progressive splinting to gradually extend the affected joints over time.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
1320	1311	55	Camptodactyly	Camptodactyly.yaml	treatments	2	Surgical Release	Surgical intervention may be necessary for severe cases to release the tendons and improve finger extension. Options include tendon lengthening or volar plate release.	treatment_term	treatment_term	$	Surgical Release	Surgical intervention may be necessary for severe cases to release the tendons and improve finger extension. Options include tendon lengthening or volar plate release.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1321	1312	55	Camptodactyly	Camptodactyly.yaml	treatments	3	Orthotic Interventions	Use of orthotic devices to support and properly align affected fingers.	treatment_term	treatment_term	$	Orthotic Interventions	Use of orthotic devices to support and properly align affected fingers.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
1322	1313	55	Camptodactyly	Camptodactyly.yaml	treatments	4	Genetic Counseling	Recommended for syndromic forms to assess inheritance patterns and recurrence risks.	treatment_term	treatment_term	$	Genetic Counseling	Recommended for syndromic forms to assess inheritance patterns and recurrence risks.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
1339	1330	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	0	Cardiac Management	"Management of congenital heart defects, including surgical correction of pulmonary stenosis when indicated.
"	treatment_term	treatment_term	$	Cardiac Management	"Management of congenital heart defects, including surgical correction of pulmonary stenosis when indicated.
"	Cardiac surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cardiac surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1340	1331	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	1	Nutritional Support	"Nutritional interventions for failure to thrive, including tube feeding when necessary.
"	treatment_term	treatment_term	$	Nutritional Support	"Nutritional interventions for failure to thrive, including tube feeding when necessary.
"	Nutritional support	MAXO:0000088	dietary intervention		"{""preferred_term"": ""Nutritional support"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
1341	1332	56	Cardiofaciocutaneous Syndrome	Cardiofaciocutaneous_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	"MEK inhibitors are under investigation for treatment of RASopathies, with potential to ameliorate some features. Zebrafish model studies suggest MEK inhibitors could treat progressive phenotypes.
"	treatment_term	treatment_term	$	MEK Inhibitor Therapy	"MEK inhibitors are under investigation for treatment of RASopathies, with potential to ameliorate some features. Zebrafish model studies suggest MEK inhibitors could treat progressive phenotypes.
"	Pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1368	1379	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	0	HPV Vaccination	Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut.	treatment_term	treatment_term	$	HPV Vaccination	Prophylactic vaccination against HPV-16, 18, and other high-risk types prevents infection and subsequent development of cervical cancer and precancerous lesions. Most effective when administered before sexual debut.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
1369	1380	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	1	Cone Biopsy/LEEP	Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease.	treatment_term	treatment_term	$	Cone Biopsy/LEEP	Loop electrosurgical excision procedure (LEEP) or cold knife cone biopsy for treatment of high-grade cervical intraepithelial neoplasia (CIN2/3). Allows fertility preservation while treating preinvasive disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1370	1381	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	2	Radical Hysterectomy	Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases.	treatment_term	treatment_term	$	Radical Hysterectomy	Surgical treatment for early-stage invasive cervical cancer (IA2-IB2) includes removal of the uterus, parametria, and upper vagina, with pelvic lymphadenectomy. Fertility-sparing radical trachelectomy may be considered in select cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1371	1382	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	3	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	treatment_term	treatment_term	$	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
1372	1382	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	3	Chemoradiation	Concurrent cisplatin-based chemotherapy with external beam radiation and brachytherapy is the standard treatment for locally advanced cervical cancer (stages IB3-IVA). Improves survival compared to radiation alone.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
1373	1383	58	Cervical Cancer	Cervical_Cancer.yaml	treatments	4	Pembrolizumab	PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors.	treatment_term	treatment_term	$	Pembrolizumab	PD-1 inhibitor approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS score of at least 1) in combination with chemotherapy, or as monotherapy in previously treated PD-L1 positive tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1377	1389	59	Chagas disease	Chagas_Disease.yaml	treatments	0	Benznidazole or nifurtimox therapy	Antitrypanosomal therapy for Chagas disease.	treatment_term	treatment_term	$	Benznidazole or nifurtimox therapy	Antitrypanosomal therapy for Chagas disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1382	1395	60	Chikungunya	Chikungunya.yaml	treatments	0	Symptomatic management	Supportive care for acute chikungunya.	treatment_term	treatment_term	$	Symptomatic management	Supportive care for acute chikungunya.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1426	1460	61	Cholera	Cholera.yaml	treatments	0	Oral Rehydration Solution (ORS)	Mixture of clean water, salt, and sugar to replace lost fluids and electrolytes.	treatment_term	treatment_term	$	Oral Rehydration Solution (ORS)	Mixture of clean water, salt, and sugar to replace lost fluids and electrolytes.	hydrotherapy	MAXO:0000458	hydrotherapy		"{""preferred_term"": ""hydrotherapy"", ""term"": {""id"": ""MAXO:0000458"", ""label"": ""hydrotherapy""}}"																											
1427	1461	61	Cholera	Cholera.yaml	treatments	1	Intravenous Rehydration	Used for severe dehydration when rapid fluid replacement is necessary.	treatment_term	treatment_term	$	Intravenous Rehydration	Used for severe dehydration when rapid fluid replacement is necessary.	hydrotherapy	MAXO:0000458	hydrotherapy		"{""preferred_term"": ""hydrotherapy"", ""term"": {""id"": ""MAXO:0000458"", ""label"": ""hydrotherapy""}}"																											
1428	1462	61	Cholera	Cholera.yaml	treatments	2	Antibiotics	Shorten the course of the illness and reduce the severity, examples include doxycycline, azithromycin.	treatment_term	treatment_term	$	Antibiotics	Shorten the course of the illness and reduce the severity, examples include doxycycline, azithromycin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1429	1463	61	Cholera	Cholera.yaml	treatments	3	Zinc Supplementation	Recommended for children to reduce the duration and severity of diarrhea.	treatment_term	treatment_term	$	Zinc Supplementation	Recommended for children to reduce the duration and severity of diarrhea.	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																											
1430	1464	61	Cholera	Cholera.yaml	treatments	4	Vaccination	Oral cholera vaccines can provide protection in endemic areas or during outbreaks.	treatment_term	treatment_term	$	Vaccination	Oral cholera vaccines can provide protection in endemic areas or during outbreaks.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
1475	1541	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	0	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	treatment_term	treatment_term	$	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}]}"				ibrutinib	CHEBI:76612																						
1476	1541	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	0	Ibrutinib	First-in-class irreversible BTK inhibitor that disrupts BCR signaling, mobilizes CLL cells from tissue niches, and induces apoptosis. Effective in all risk groups including TP53-mutated CLL. Continuous therapy until progression.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"																											
1477	1542	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	treatment_term	treatment_term	$	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}]}"				acalabrutinib	CHEBI:167707																						
1478	1542	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with improved kinase selectivity and potentially fewer off-target effects than ibrutinib. Effective as monotherapy or combined with obinutuzumab.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"																											
1479	1543	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	2	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	treatment_term	treatment_term	$	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
1480	1543	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	2	Venetoclax plus Obinutuzumab	BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab achieves high rates of undetectable MRD and enables time-limited therapy (12 months). Particularly effective in treatment-naive CLL.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
1481	1544	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	3	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	treatment_term	treatment_term	$	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}]}"				cyclophosphamide	CHEBI:4027																						
1482	1544	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	3	Chemoimmunotherapy (FCR)	Fludarabine, cyclophosphamide, and rituximab combination was standard for fit patients with mutated IGHV without del(17p)/TP53 mutation. Can achieve long remissions in this favorable subgroup but largely replaced by targeted agents.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"																											
1483	1545	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	treatments	4	Watch and Wait	Asymptomatic early-stage CLL does not require immediate treatment. Active surveillance with monitoring for disease progression or treatment indications (cytopenias, symptomatic disease, rapid progression) is appropriate for many patients.	treatment_term	treatment_term	$	Watch and Wait	Asymptomatic early-stage CLL does not require immediate treatment. Active surveillance with monitoring for disease progression or treatment indications (cytopenias, symptomatic disease, rapid progression) is appropriate for many patients.	surveillance for malignancies	MAXO:0001492	surveillance for malignancies		"{""preferred_term"": ""surveillance for malignancies"", ""term"": {""id"": ""MAXO:0001492"", ""label"": ""surveillance for malignancies""}}"																											
1505	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	treatment_term	treatment_term	$	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
1506	1565	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	0	Imatinib	First-generation tyrosine kinase inhibitor that revolutionized CML treatment. Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
1507	1566	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	1	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	treatment_term	treatment_term	$	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}]}"				dasatinib	CHEBI:49375																						
1508	1566	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	1	Dasatinib	Second-generation TKI with greater potency against BCR-ABL1 and activity against many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for imatinib intolerance/resistance or as first-line therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"																											
1509	1567	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	2	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	treatment_term	treatment_term	$	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""nilotinib"", ""term"": {""id"": ""CHEBI:52172"", ""label"": ""nilotinib""}}]}"				nilotinib	CHEBI:52172																						
1510	1567	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	2	Nilotinib	Second-generation TKI designed for improved BCR-ABL1 binding. More selective than dasatinib with different side effect profile. Used for imatinib intolerance/resistance or first-line therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			nilotinib	CHEBI:52172	nilotinib		"{""preferred_term"": ""nilotinib"", ""term"": {""id"": ""CHEBI:52172"", ""label"": ""nilotinib""}}"																											
1511	1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	treatment_term	treatment_term	$	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}]}"				ponatinib	CHEBI:78543																						
1512	1568	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	3	Ponatinib	Third-generation TKI active against the T315I gatekeeper mutation that confers resistance to other TKIs. Reserved for patients with T315I mutation or failure of multiple prior TKIs due to cardiovascular risks.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"																											
1513	1569	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	treatments	4	Allogeneic Stem Cell Transplantation	Potentially curative option historically used as primary therapy before TKI era. Now reserved for patients failing multiple TKIs, those with T315I mutation without ponatinib access, or blast crisis. Significant morbidity and mortality risks.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Potentially curative option historically used as primary therapy before TKI era. Now reserved for patients failing multiple TKIs, those with T315I mutation without ponatinib access, or blast crisis. Significant morbidity and mortality risks.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
1573	1605	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	0	Smoking Cessation	Stopping smoking to slow disease progression and improve outcomes.	treatment_term	treatment_term	$	Smoking Cessation	Stopping smoking to slow disease progression and improve outcomes.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
1574	1606	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	1	Bronchodilators	Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).	treatment_term	treatment_term	$	Bronchodilators	Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1575	1607	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	2	Inhaled Corticosteroids	Reduce airway inflammation and frequency of exacerbations.	treatment_term	treatment_term	$	Inhaled Corticosteroids	Reduce airway inflammation and frequency of exacerbations.	respiratory tract agent therapy	MAXO:0000312	respiratory tract agent therapy		"{""preferred_term"": ""respiratory tract agent therapy"", ""term"": {""id"": ""MAXO:0000312"", ""label"": ""respiratory tract agent therapy""}}"																											
1576	1608	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	3	Phosphodiesterase-4 Inhibitors	Reduce inflammation and relax airways.	treatment_term	treatment_term	$	Phosphodiesterase-4 Inhibitors	Reduce inflammation and relax airways.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1577	1609	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	4	Oxygen Therapy	Long-term oxygen use for patients with severe chronic hypoxemia.	treatment_term	treatment_term	$	Oxygen Therapy	Long-term oxygen use for patients with severe chronic hypoxemia.	artificial respiration	MAXO:0000503	artificial respiration		"{""preferred_term"": ""artificial respiration"", ""term"": {""id"": ""MAXO:0000503"", ""label"": ""artificial respiration""}}"																											
1578	1610	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	5	Pulmonary Rehabilitation	Exercise training, education, and support to improve quality of life and physical conditioning.	treatment_term	treatment_term	$	Pulmonary Rehabilitation	Exercise training, education, and support to improve quality of life and physical conditioning.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
1579	1611	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	6	Lung Volume Reduction Surgery	Surgical removal of damaged lung tissue for severe emphysema.	treatment_term	treatment_term	$	Lung Volume Reduction Surgery	Surgical removal of damaged lung tissue for severe emphysema.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1580	1612	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	7	Lung Transplantation	Considered in end-stage COPD with severe impairment.	treatment_term	treatment_term	$	Lung Transplantation	Considered in end-stage COPD with severe impairment.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
1581	1613	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	8	Mucolytic Therapy	N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.	treatment_term	treatment_term	$	Mucolytic Therapy	N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1582	1614	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	9	Macrolide Antibiotics	Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.	treatment_term	treatment_term	$	Macrolide Antibiotics	Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1583	1615	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	treatments	10	Biologic Therapies	Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.	treatment_term	treatment_term	$	Biologic Therapies	Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1610	1662	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	0	Nephrectomy	Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease.	treatment_term	treatment_term	$	Nephrectomy	Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1611	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term	treatment_term	$	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}, {""preferred_term"": ""pazopanib"", ""term"": {""id"": ""CHEBI:71219"", ""label"": ""pazopanib""}}, {""preferred_term"": ""axitinib"", ""term"": {""id"": ""CHEBI:66910"", ""label"": ""axitinib""}}, {""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}]}"				sunitinib; pazopanib; axitinib; cabozantinib	CHEBI:38940; CHEBI:71219; CHEBI:66910; CHEBI:72317																						
1612	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"																											
1613	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			pazopanib	CHEBI:71219	pazopanib		"{""preferred_term"": ""pazopanib"", ""term"": {""id"": ""CHEBI:71219"", ""label"": ""pazopanib""}}"																											
1614	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			axitinib	CHEBI:66910	axitinib		"{""preferred_term"": ""axitinib"", ""term"": {""id"": ""CHEBI:66910"", ""label"": ""axitinib""}}"																											
1615	1663	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	1	VEGFR Tyrosine Kinase Inhibitors	Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"																											
1616	1664	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	2	Belzutifan	First-in-class HIF-2 inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy.	treatment_term	treatment_term	$	Belzutifan	First-in-class HIF-2 inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1617	1665	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease.	immunotherapy procedure	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy procedure"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
1627	1679	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	0	Wide Surgical Resection	Wide surgical excision with negative margins is the primary treatment. The tendency to arise near tendons and joints may complicate resection. Amputation may be necessary for large or recurrent tumors.	treatment_term	treatment_term	$	Wide Surgical Resection	Wide surgical excision with negative margins is the primary treatment. The tendency to arise near tendons and joints may complicate resection. Amputation may be necessary for large or recurrent tumors.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1628	1680	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	1	Sentinel Lymph Node Biopsy	Given the propensity for lymph node metastasis, sentinel lymph node biopsy is often performed for staging, similar to melanoma management.	treatment_term	treatment_term	$	Sentinel Lymph Node Biopsy	Given the propensity for lymph node metastasis, sentinel lymph node biopsy is often performed for staging, similar to melanoma management.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1629	1681	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	2	Radiation Therapy	Adjuvant radiation may be used for close or positive margins or for unresectable disease. CCS is relatively radioresistant.	treatment_term	treatment_term	$	Radiation Therapy	Adjuvant radiation may be used for close or positive margins or for unresectable disease. CCS is relatively radioresistant.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1630	1682	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	3	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	treatment_term	treatment_term	$	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}"				doxorubicin	CHEBI:28748																						
1631	1682	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	treatments	3	Systemic Therapy	CCS is generally chemoresistant. Doxorubicin-based regimens may be attempted for metastatic disease but response rates are low. Unlike melanoma, checkpoint inhibitors have limited efficacy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
1647	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term	treatment_term	$	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""vancomycin"", ""term"": {""id"": ""NCIT:C288"", ""label"": ""vancomycin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																Oral Route of Administration	NCIT:C38288	NCIT:C38114				vancomycin	NCIT:C288	NCIT:C2259			
1648	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			route of administration	NCIT:C38114	Route of Administration		"{""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}"																											
1649	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			oral route of administration	NCIT:C38288	Oral Route of Administration		"{""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}"																											
1650	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1651	1701	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	0	Vancomycin	Oral vancomycin is first-line treatment for C. difficile infection.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			vancomycin	NCIT:C288	vancomycin		"{""preferred_term"": ""vancomycin"", ""term"": {""id"": ""NCIT:C288"", ""label"": ""vancomycin""}}"																											
1652	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term	treatment_term	$	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""fidaxomicin"", ""term"": {""id"": ""NCIT:C95509"", ""label"": ""fidaxomicin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																Oral Route of Administration	NCIT:C38288	NCIT:C38114				fidaxomicin	NCIT:C95509	NCIT:C2259			
1653	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			route of administration	NCIT:C38114	Route of Administration		"{""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}"																											
1654	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			oral route of administration	NCIT:C38288	Oral Route of Administration		"{""preferred_term"": ""oral route of administration"", ""term"": {""id"": ""NCIT:C38288"", ""label"": ""Oral Route of Administration""}}"																											
1655	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1656	1702	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	1	Fidaxomicin	Alternative antibiotic with lower recurrence rates.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			fidaxomicin	NCIT:C95509	fidaxomicin		"{""preferred_term"": ""fidaxomicin"", ""term"": {""id"": ""NCIT:C95509"", ""label"": ""fidaxomicin""}}"																											
1657	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term	treatment_term	$	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	fecal microbiota transplantation	MAXO:0000748	fecal microbiota transplantation		"{""preferred_term"": ""fecal microbiota transplantation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""clinical course"", ""term"": {""id"": ""NCIT:C28008"", ""label"": ""Clinical Course""}}, ""value"": {""preferred_term"": ""recurrent disease"", ""term"": {""id"": ""MONDO:0700096"", ""label"": ""recurrent disease""}}}], ""term"": {""id"": ""MAXO:0000748"", ""label"": ""fecal microbiota transplantation""}}"						recurrent disease	MONDO:0700096	NCIT:C28008																			
1658	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			clinical course	NCIT:C28008	Clinical Course		"{""preferred_term"": ""clinical course"", ""term"": {""id"": ""NCIT:C28008"", ""label"": ""Clinical Course""}}"																											
1659	1703	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	2	Fecal microbiota transplantation	Restoration of normal gut microbiota for recurrent infections.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			recurrent disease	MONDO:0700096	recurrent disease		"{""preferred_term"": ""recurrent disease"", ""term"": {""id"": ""MONDO:0700096"", ""label"": ""recurrent disease""}}"																											
1660	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term	treatment_term	$	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bezlotoxumab"", ""term"": {""id"": ""NCIT:C121379"", ""label"": ""Bezlotoxumab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Bezlotoxumab	NCIT:C121379	NCIT:C2259			
1661	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1662	1704	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	3	Bezlotoxumab	Monoclonal antibody against toxin B to prevent CDI recurrence when added to standard therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			bezlotoxumab	NCIT:C121379	Bezlotoxumab		"{""preferred_term"": ""bezlotoxumab"", ""term"": {""id"": ""NCIT:C121379"", ""label"": ""Bezlotoxumab""}}"																											
1663	1705	71	Clostridioides difficile Infection	Clostridioides_difficile_Infection.yaml	treatments	4	Loop ileostomy with colonic lavage	Organ-preserving surgical approach for fulminant CDI when medical therapy fails.	treatment_term	treatment_term	$	Loop ileostomy with colonic lavage	Organ-preserving surgical approach for fulminant CDI when medical therapy fails.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1689	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term	treatment_term	$	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	topical corticosteroid therapy	MAXO:0001553	topical corticosteroid therapy		"{""preferred_term"": ""topical corticosteroid therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""budesonide"", ""term"": {""id"": ""NCIT:C66948"", ""label"": ""Budesonide""}}}, {""predicate"": {""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}, ""value"": {""preferred_term"": ""gastrointestinal route"", ""term"": {""id"": ""NCIT:C38295"", ""label"": ""Gastrointestinal Route of Administration""}}}], ""term"": {""id"": ""MAXO:0001553"", ""label"": ""topical corticosteroid therapy""}}"																Gastrointestinal Route of Administration	NCIT:C38295	NCIT:C38114				Budesonide	NCIT:C66948	NCIT:C2259			
1690	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1691	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			budesonide	NCIT:C66948	Budesonide		"{""preferred_term"": ""budesonide"", ""term"": {""id"": ""NCIT:C66948"", ""label"": ""Budesonide""}}"																											
1692	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			route of administration	NCIT:C38114	Route of Administration		"{""preferred_term"": ""route of administration"", ""term"": {""id"": ""NCIT:C38114"", ""label"": ""Route of Administration""}}"																											
1693	1732	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	0	Corticosteroids (Budesonide)	"Topically active corticosteroids, particularly budesonide, are first-line immunosuppressive therapy for collagenous sprue. Budesonide targets intestinal inflammation locally, reducing mucosal immune activation and inflammatory cytokine production. Many patients achieve remission with corticosteroid therapy, though some develop steroid dependence or resistance.
"	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			gastrointestinal route	NCIT:C38295	Gastrointestinal Route of Administration		"{""preferred_term"": ""gastrointestinal route"", ""term"": {""id"": ""NCIT:C38295"", ""label"": ""Gastrointestinal Route of Administration""}}"																											
1694	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term	treatment_term	$	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Azathioprine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Azathioprine	NCIT:C620	NCIT:C2259			
1695	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1696	1733	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	1	Thiopurines (Azathioprine/6-Thioguanine)	"Thiopurine immunosuppressants are used for steroid-refractory or steroid-dependent collagenous sprue. These agents inhibit T cell proliferation, addressing the underlying immune activation.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			azathioprine	NCIT:C620	Azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C620"", ""label"": ""Azathioprine""}}"																											
1697	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	treatment_term	treatment_term	$	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C2894"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Infliximab	NCIT:C2894	NCIT:C2259			
1698	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1699	1734	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	2	Anti-TNF- Therapy	"TNF- inhibitors such as infliximab may be considered for severe, refractory collagenous sprue based on case reports. These agents target TNF--mediated inflammation and immune activation.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			infliximab	NCIT:C2894	Infliximab		"{""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C2894"", ""label"": ""Infliximab""}}"																											
1700	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term	treatment_term	$	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""tacrolimus"", ""term"": {""id"": ""NCIT:C2982"", ""label"": ""Tacrolimus""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Tacrolimus	NCIT:C2982	NCIT:C2259			
1701	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1702	1735	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	3	Calcineurin Inhibitors (Tacrolimus)	"Tacrolimus (FK-506) is a calcineurin inhibitor used for severe, treatment-refractory collagenous sprue. It inhibits T cell activation and cytokine production, providing an alternative mechanism for immune suppression in cases resistant to conventional immunosuppressants. Case reports document successful long-term outcomes with tacrolimus in patients with severe intestinal failure from collagenous sprue.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			tacrolimus	NCIT:C2982	Tacrolimus		"{""preferred_term"": ""tacrolimus"", ""term"": {""id"": ""NCIT:C2982"", ""label"": ""Tacrolimus""}}"																											
1703	1736	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	4	Medication discontinuation (Olmesartan withdrawal)	"Systematic discontinuation of triggering medications, particularly ARBs such as olmesartan, is critical in drug-induced collagenous sprue. Many patients experience clinical and histologic improvement within weeks to months after drug cessation.
"	treatment_term	treatment_term	$	Medication discontinuation (Olmesartan withdrawal)	"Systematic discontinuation of triggering medications, particularly ARBs such as olmesartan, is critical in drug-induced collagenous sprue. Many patients experience clinical and histologic improvement within weeks to months after drug cessation.
"	medication management	MAXO:0000950	supportive care		"{""preferred_term"": ""medication management"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1704	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term	treatment_term	$	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""iron supplement"", ""term"": {""id"": ""NCIT:C2346"", ""label"": ""Iron Supplement""}}}], ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																						Iron Supplement	NCIT:C2346	NCIT:C2259			
1705	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
1706	1737	72	Collagenous Sprue	Collagenous_Sprue.yaml	treatments	5	Nutritional support and supplementation	"Dietary management with nutritional supplementation to address malabsorption-induced deficiencies. Micronutrient repletion, including iron, vitamin B12, fat-soluble vitamins, and protein supplementation, is essential.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			iron supplement	NCIT:C2346	Iron Supplement		"{""preferred_term"": ""iron supplement"", ""term"": {""id"": ""NCIT:C2346"", ""label"": ""Iron Supplement""}}"																											
1713	1744	73	Colon Adenocarcinoma	Colon_Adenocarcinoma.yaml	treatments	0	Surgical Resection	Surgical removal of the colon tumor when localized.	treatment_term	treatment_term	$	Surgical Resection	Surgical removal of the colon tumor when localized.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1728	1763	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	0	Intensive Chemotherapy (7+3) with High-Dose Cytarabine Consolidation	Standard induction with 7 days cytarabine and 3 days anthracycline followed by multiple cycles of high-dose cytarabine (HiDAC) consolidation. HiDAC is particularly effective for CBF-AML and is the standard of care for fit patients, achieving 60-70% cure rates without transplant.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3) with High-Dose Cytarabine Consolidation	Standard induction with 7 days cytarabine and 3 days anthracycline followed by multiple cycles of high-dose cytarabine (HiDAC) consolidation. HiDAC is particularly effective for CBF-AML and is the standard of care for fit patients, achieving 60-70% cure rates without transplant.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
1729	1764	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	1	Gemtuzumab Ozogamicin	CD33-directed antibody-drug conjugate added to chemotherapy improves outcomes in favorable-risk AML including CBF-AML. Particularly beneficial when given in fractionated dosing during induction and consolidation.	treatment_term	treatment_term	$	Gemtuzumab Ozogamicin	CD33-directed antibody-drug conjugate added to chemotherapy improves outcomes in favorable-risk AML including CBF-AML. Particularly beneficial when given in fractionated dosing during induction and consolidation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1730	1765	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	2	MRD-Guided Therapy	Monitoring RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript levels by RT-PCR after consolidation guides decisions about additional therapy. Rising MRD may prompt transplant consideration before overt relapse.	treatment_term	treatment_term	$	MRD-Guided Therapy	Monitoring RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcript levels by RT-PCR after consolidation guides decisions about additional therapy. Rising MRD may prompt transplant consideration before overt relapse.	genetic testing	MAXO:0000127	genetic testing		"{""preferred_term"": ""genetic testing"", ""term"": {""id"": ""MAXO:0000127"", ""label"": ""genetic testing""}}"																											
1731	1766	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Generally reserved for relapsed CBF-AML or patients with persistent MRD after consolidation. Not routinely recommended in first remission given excellent outcomes with chemotherapy alone.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Generally reserved for relapsed CBF-AML or patients with persistent MRD after consolidation. Not routinely recommended in first remission given excellent outcomes with chemotherapy alone.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
1759	1805	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	0	Cardiac Monitoring	"Regular cardiac surveillance for hypertrophic cardiomyopathy and arrhythmias.
"	treatment_term	treatment_term	$	Cardiac Monitoring	"Regular cardiac surveillance for hypertrophic cardiomyopathy and arrhythmias.
"	Cardiac monitoring	MAXO:0000003	diagnostic procedure		"{""preferred_term"": ""Cardiac monitoring"", ""term"": {""id"": ""MAXO:0000003"", ""label"": ""diagnostic procedure""}}"																											
1760	1806	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	1	Tumor Surveillance	"Regular screening for embryonal tumors, particularly in childhood.
"	treatment_term	treatment_term	$	Tumor Surveillance	"Regular screening for embryonal tumors, particularly in childhood.
"	Cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""Cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
1761	1807	76	Costello Syndrome	Costello_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	"MEK inhibitors (e.g., trametinib) are being investigated as targeted therapy for RASopathies to reduce pathway hyperactivation.
"	treatment_term	treatment_term	$	MEK Inhibitor Therapy	"MEK inhibitors (e.g., trametinib) are being investigated as targeted therapy for RASopathies to reduce pathway hyperactivation.
"	Pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1808	1853	77	Crohn Disease	Crohn_Disease.yaml	treatments	0	Aminosalicylates	Anti-inflammatory drugs used for mild to moderate disease.	treatment_term	treatment_term	$	Aminosalicylates	Anti-inflammatory drugs used for mild to moderate disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1809	1854	77	Crohn Disease	Crohn_Disease.yaml	treatments	1	Corticosteroids	Used for short-term control during flare-ups to reduce inflammation.	treatment_term	treatment_term	$	Corticosteroids	Used for short-term control during flare-ups to reduce inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1810	1855	77	Crohn Disease	Crohn_Disease.yaml	treatments	2	Immunomodulators	Drugs like azathioprine and methotrexate to suppress the immune response.	treatment_term	treatment_term	$	Immunomodulators	Drugs like azathioprine and methotrexate to suppress the immune response.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1811	1856	77	Crohn Disease	Crohn_Disease.yaml	treatments	3	Biologics	Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease.	treatment_term	treatment_term	$	Biologics	Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1812	1857	77	Crohn Disease	Crohn_Disease.yaml	treatments	4	Nutritional Therapy	Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition.	treatment_term	treatment_term	$	Nutritional Therapy	Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
1813	1858	77	Crohn Disease	Crohn_Disease.yaml	treatments	5	Surgery	Removal of affected bowel segments, typically reserved for complications like strictures or fistulas.	treatment_term	treatment_term	$	Surgery	Removal of affected bowel segments, typically reserved for complications like strictures or fistulas.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1814	1859	77	Crohn Disease	Crohn_Disease.yaml	treatments	6	Anti-IL-23 Biologics	Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy.	treatment_term	treatment_term	$	Anti-IL-23 Biologics	Biologics targeting IL-23 (e.g., ustekinumab, risankizumab) for moderate to severe Crohn's disease refractory to anti-TNF therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1815	1860	77	Crohn Disease	Crohn_Disease.yaml	treatments	7	TL1A Inhibitors	Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease.	treatment_term	treatment_term	$	TL1A Inhibitors	Emerging precision therapy targeting TL1A-DR3 signaling for fistulizing and fibrostenotic disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1816	1861	77	Crohn Disease	Crohn_Disease.yaml	treatments	8	JAK Inhibitors	Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease.	treatment_term	treatment_term	$	JAK Inhibitors	Small molecule inhibitors targeting JAK-STAT pathway for moderate to severe disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1833	1879	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	0	Corticosteroids	"Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.
"	treatment_term	treatment_term	$	Corticosteroids	"Systemic corticosteroids (prednisone or methylprednisolone) are the first-line treatment for Cronkhite-Canada syndrome. Initial dosages typically range from 30-60 mg/day (1 mg/kg body weight), with gradual dose reduction after symptom improvement. Over 85% of patients respond to dosages above 30 mg/day, often resulting in complete remission of polyps and resolution of cutaneous manifestations. Glucocorticoids work by reducing gastrointestinal inflammation and suppressing autoimmune responses.
"	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
1834	1880	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	1	Immunosuppressive agents	"Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF- expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.
"	treatment_term	treatment_term	$	Immunosuppressive agents	"Azathioprine, cyclosporine, and anti-TNF agents (infliximab) are used in patients with steroid-dependent or steroid-refractory disease. Azathioprine shows high response rates and is often used as steroid-sparing therapy. Pharmacogenetic testing for TPMT and NUDT15 variants is recommended to guide dosing. High TNF- expression in CCS explains responsiveness to anti-TNF therapy. Combination therapy with corticosteroids and azathioprine can lead to marked clinical and endoscopic improvements.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1835	1881	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	treatments	2	Supportive care	"Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.
"	treatment_term	treatment_term	$	Supportive care	"Nutritional support including high-protein diet, micronutrient supplementation, fluid replacement, and electrolyte monitoring are essential for managing complications of protein-losing enteropathy including hypoalbuminemia, anemia, and malnutrition.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1845	1891	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	treatments	0	Cranial Vault Remodeling	"Surgical expansion and reshaping of the skull to manage intracranial pressure and improve head shape. Timing depends on severity.
"	treatment_term	treatment_term	$	Cranial Vault Remodeling	"Surgical expansion and reshaping of the skull to manage intracranial pressure and improve head shape. Timing depends on severity.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1846	1892	79	Crouzon Syndrome	Crouzon_Syndrome.yaml	treatments	1	Midface Advancement	"Le Fort III osteotomy or distraction osteogenesis to advance the hypoplastic midface, improving airway, appearance, and occlusion.
"	treatment_term	treatment_term	$	Midface Advancement	"Le Fort III osteotomy or distraction osteogenesis to advance the hypoplastic midface, improving airway, appearance, and occlusion.
"	Midface surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1857	1901	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	treatments	0	Cranial Vault Surgery	"Surgical management of craniosynostosis similar to classic Crouzon syndrome.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Surgical management of craniosynostosis similar to classic Crouzon syndrome.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1858	1902	80	Crouzon Syndrome with Acanthosis Nigricans	Crouzon_Syndrome_with_Acanthosis_Nigricans.yaml	treatments	1	Midface Advancement	"Surgical advancement of the hypoplastic midface.
"	treatment_term	treatment_term	$	Midface Advancement	"Surgical advancement of the hypoplastic midface.
"	Midface surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Midface surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1870	1914	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	0	Surgical Resection	"First-line treatment for most endogenous Cushing's syndrome: transsphenoidal surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal tumors, or resection of ectopic ACTH-secreting tumors.
"	treatment_term	treatment_term	$	Surgical Resection	"First-line treatment for most endogenous Cushing's syndrome: transsphenoidal surgery for pituitary adenomas (Cushing's disease), adrenalectomy for adrenal tumors, or resection of ectopic ACTH-secreting tumors.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1871	1915	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	1	Medical Therapy	"Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism when surgery is not possible or has failed.
"	treatment_term	treatment_term	$	Medical Therapy	"Steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) or glucocorticoid receptor antagonists (mifepristone) to control hypercortisolism when surgery is not possible or has failed.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1872	1916	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	2	Radiation Therapy	"Pituitary radiation (conventional or stereotactic radiosurgery) for persistent or recurrent Cushing's disease after unsuccessful surgery.
"	treatment_term	treatment_term	$	Radiation Therapy	"Pituitary radiation (conventional or stereotactic radiosurgery) for persistent or recurrent Cushing's disease after unsuccessful surgery.
"	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1873	1917	81	Cushing's Syndrome	Cushings_Syndrome.yaml	treatments	3	Bilateral Adrenalectomy	"Definitive treatment option for patients with persistent hypercortisolism, resulting in permanent adrenal insufficiency requiring lifelong hormone replacement.
"	treatment_term	treatment_term	$	Bilateral Adrenalectomy	"Definitive treatment option for patients with persistent hypercortisolism, resulting in permanent adrenal insufficiency requiring lifelong hormone replacement.
"	adrenalectomy	MAXO:0001030	adrenalectomy		"{""preferred_term"": ""adrenalectomy"", ""term"": {""id"": ""MAXO:0001030"", ""label"": ""adrenalectomy""}}"																											
1876	1922	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	0	Benzimidazole chemotherapy	Benzimidazole carbamates are used as chemotherapy.	treatment_term	treatment_term	$	Benzimidazole chemotherapy	Benzimidazole carbamates are used as chemotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1877	1923	82	Cystic echinococcosis	Cystic_Echinococcosis.yaml	treatments	1	Surgical and percutaneous approaches	Surgical approaches including percutaneous aspiration are used.	treatment_term	treatment_term	$	Surgical and percutaneous approaches	Surgical approaches including percutaneous aspiration are used.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1909	1964	84	Danon disease	Danon_disease.yaml	treatments	0	Heart transplantation	"Cardiac transplantation is the primary disease-modifying treatment for Danon disease patients with advanced heart failure. In male patients with severe cardiomyopathy, heart transplantation is often the only intervention that modifies the disease course.
"	treatment_term	treatment_term	$	Heart transplantation	"Cardiac transplantation is the primary disease-modifying treatment for Danon disease patients with advanced heart failure. In male patients with severe cardiomyopathy, heart transplantation is often the only intervention that modifies the disease course.
"	heart transplantation	MAXO:0000068	transplantation procedure		"{""preferred_term"": ""heart transplantation"", ""term"": {""id"": ""MAXO:0000068"", ""label"": ""transplantation procedure""}}"																											
1910	1965	84	Danon disease	Danon_disease.yaml	treatments	1	Gene therapy (AAV9.LAMP2B)	"Adeno-associated virus vector-based gene therapy delivering functional LAMP2B is under clinical investigation. RP-A501, an AAV9-based gene therapy, has advanced through Phase 1 and into Phase 2 clinical trials for male patients with Danon disease.
"	treatment_term	treatment_term	$	Gene therapy (AAV9.LAMP2B)	"Adeno-associated virus vector-based gene therapy delivering functional LAMP2B is under clinical investigation. RP-A501, an AAV9-based gene therapy, has advanced through Phase 1 and into Phase 2 clinical trials for male patients with Danon disease.
"	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
1918	1976	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	0	Cholinesterase Inhibitors	Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms.	treatment_term	treatment_term	$	Cholinesterase Inhibitors	Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1919	1977	85	Dementia with Lewy Bodies	Dementia_with_Lewy_Bodies.yaml	treatments	1	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support.	treatment_term	treatment_term	$	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1931	1996	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	0	Wide Local Excision	Surgery with wide margins (2-4 cm) or Mohs micrographic surgery is the primary treatment. Mohs technique provides margin control and is associated with the lowest recurrence rates.	treatment_term	treatment_term	$	Wide Local Excision	Surgery with wide margins (2-4 cm) or Mohs micrographic surgery is the primary treatment. Mohs technique provides margin control and is associated with the lowest recurrence rates.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1932	1997	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	1	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	treatment_term	treatment_term	$	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
1933	1997	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	1	Imatinib Targeted Therapy	Imatinib mesylate, a PDGFR inhibitor, is highly effective for unresectable or metastatic DFSP. Response rates exceed 50%. Imatinib may also be used as neoadjuvant therapy to shrink tumors before surgery. Fibrosarcomatous transformation may confer imatinib resistance.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
1934	1998	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	treatments	2	Radiation Therapy	Adjuvant radiation may be considered for positive margins when re-excision is not feasible. Primary radiation is an option for unresectable cases not amenable to imatinib.	treatment_term	treatment_term	$	Radiation Therapy	Adjuvant radiation may be considered for positive margins when re-excision is not feasible. Primary radiation is an option for unresectable cases not amenable to imatinib.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1957	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}]}"				cyclophosphamide; doxorubicin; vincristine; ifosfamide; etoposide	CHEBI:4026; CHEBI:28748; CHEBI:28445; CHEBI:5864; CHEBI:4911																						
1958	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
1959	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
1960	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
1961	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"																											
1962	2031	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	0	Multi-Agent Chemotherapy	Intensive chemotherapy regimens such as P6 protocol (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide) are used. Response rates are variable and usually partial.	treatment_term.therapeutic_agent[4]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
1963	2032	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	1	Cytoreductive Surgery	Aggressive surgical debulking with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown benefit in selected patients. Complete cytoreduction is associated with improved survival but is often not achievable.	treatment_term	treatment_term	$	Cytoreductive Surgery	Aggressive surgical debulking with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown benefit in selected patients. Complete cytoreduction is associated with improved survival but is often not achievable.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1964	2033	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	treatments	2	Radiation Therapy	Whole abdominal radiation or intensity-modulated radiation may improve local control but is challenging given diffuse disease distribution.	treatment_term	treatment_term	$	Radiation Therapy	Whole abdominal radiation or intensity-modulated radiation may improve local control but is challenging given diffuse disease distribution.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
1973	2048	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	0	Endoscopic Mechanical Hemostasis	"Hemostatic clipping or band ligation applied directly to the exposed vessel to achieve primary hemostasis and prevent rebleeding.
"	treatment_term	treatment_term	$	Endoscopic Mechanical Hemostasis	"Hemostatic clipping or band ligation applied directly to the exposed vessel to achieve primary hemostasis and prevent rebleeding.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1974	2049	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	1	Angiographic Embolization	"Transcatheter arterial embolization used as a salvage option when endoscopic methods are not feasible or fail to control bleeding.
"	treatment_term	treatment_term	$	Angiographic Embolization	"Transcatheter arterial embolization used as a salvage option when endoscopic methods are not feasible or fail to control bleeding.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
1975	2050	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	treatments	2	Surgical Ligation or Wedge Resection	"Surgical oversewing or resection of the bleeding segment reserved for refractory cases when endoscopic and radiologic approaches fail.
"	treatment_term	treatment_term	$	Surgical Ligation or Wedge Resection	"Surgical oversewing or resection of the bleeding segment reserved for refractory cases when endoscopic and radiologic approaches fail.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
1992	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term	treatment_term	$	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}]}"				cyclophosphamide; doxorubicin; vincristine; prednisone	CHEBI:4027; CHEBI:28748; CHEBI:28445; CHEBI:8382																						
1993	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4027	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4027"", ""label"": ""cyclophosphamide""}}"																											
1994	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
1995	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
1996	2073	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	0	R-CHOP Immunochemotherapy	Rituximab (anti-CD20), cyclophosphamide, doxorubicin, vincristine, and prednisone is the standard frontline regimen. Six cycles cure approximately 60% of patients overall, with better outcomes in GCB subtype and localized disease.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			prednisone	CHEBI:8382	prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""CHEBI:8382"", ""label"": ""prednisone""}}"																											
1997	2074	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	1	Polatuzumab Vedotin plus R-CHP	CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP.	treatment_term	treatment_term	$	Polatuzumab Vedotin plus R-CHP	CD79b-directed antibody-drug conjugate combined with rituximab, cyclophosphamide, doxorubicin, and prednisone. Approved as frontline therapy providing improved outcomes compared to R-CHOP.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
1998	2075	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	2	Intensive Chemotherapy for Double-Hit Lymphoma	High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL.	treatment_term	treatment_term	$	Intensive Chemotherapy for Double-Hit Lymphoma	High-grade lymphomas with MYC and BCL2 rearrangements require intensified regimens such as DA-EPOCH-R or R-CODOX-M/R-IVAC rather than standard R-CHOP. Outcomes remain inferior to non-double-hit DLBCL.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
1999	2076	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	3	CAR-T Cell Therapy	CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients.	treatment_term	treatment_term	$	CAR-T Cell Therapy	CD19-directed CAR-T cells (axicabtagene ciloleucel, lisocabtagene maraleucel, tisagenlecleucel) are approved for relapsed/refractory DLBCL after two or more prior lines. Achieves durable remissions in 30-40% of patients.	immunotherapy	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
2000	2077	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	4	Autologous Stem Cell Transplantation	For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease.	treatment_term	treatment_term	$	Autologous Stem Cell Transplantation	For chemotherapy-sensitive relapsed disease, high-dose therapy with ASCT remains standard. CAR-T cells are alternative for transplant-eligible and -ineligible patients with relapsed disease.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
2001	2078	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	treatments	5	Radiation Therapy	Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach.	treatment_term	treatment_term	$	Radiation Therapy	Consolidative radiation for localized (stage I-II) disease after abbreviated chemotherapy improves local control. Involved-site radiation therapy (ISRT) is standard approach.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2019	2106	93	Down_syndrome	Down_syndrome.yaml	treatments	0	Early Intervention Programs	Support services including physical, occupational, and speech therapy.	treatment_term	treatment_term	$	Early Intervention Programs	Support services including physical, occupational, and speech therapy.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2020	2107	93	Down_syndrome	Down_syndrome.yaml	treatments	1	Cardiac Surgery	For congenital heart defect correction if needed.	treatment_term	treatment_term	$	Cardiac Surgery	For congenital heart defect correction if needed.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2021	2108	93	Down_syndrome	Down_syndrome.yaml	treatments	2	Hormone Replacement Therapy	For treating hypothyroidism.	treatment_term	treatment_term	$	Hormone Replacement Therapy	For treating hypothyroidism.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
2022	2109	93	Down_syndrome	Down_syndrome.yaml	treatments	3	Educational Support	Tailored educational plans to support learning and development.	treatment_term	treatment_term	$	Educational Support	Tailored educational plans to support learning and development.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2046	2139	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	0	Antiepileptic Medications	Includes clobazam, stiripentol, and valproate as first-line agents. Sodium channel blockers should be avoided as they may worsen seizures.	treatment_term	treatment_term	$	Antiepileptic Medications	Includes clobazam, stiripentol, and valproate as first-line agents. Sodium channel blockers should be avoided as they may worsen seizures.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2047	2140	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	1	Ketogenic Diet	High-fat, low-carbohydrate diet that can provide significant seizure reduction in some patients.	treatment_term	treatment_term	$	Ketogenic Diet	High-fat, low-carbohydrate diet that can provide significant seizure reduction in some patients.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2048	2141	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	2	Supportive Therapies	Therapies such as physical, occupational, and speech therapy to address developmental delays and cognitive impairment.	treatment_term	treatment_term	$	Supportive Therapies	Therapies such as physical, occupational, and speech therapy to address developmental delays and cognitive impairment.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2049	2142	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	3	Vagus Nerve Stimulation (VNS)	Implanted device that may help reduce seizure frequency in drug-resistant cases.	treatment_term	treatment_term	$	Vagus Nerve Stimulation (VNS)	Implanted device that may help reduce seizure frequency in drug-resistant cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2050	2143	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	4	Antisense Oligonucleotide Therapy (STK-001/Zorevunersen)	Investigational antisense oligonucleotide designed to upregulate productive SCN1A transcripts and restore Nav1.1 expression in inhibitory neurons. Preclinical studies show seizure reduction and SUDEP prevention. Early clinical data report good tolerability with reduced seizure frequency in treated individuals.	treatment_term	treatment_term	$	Antisense Oligonucleotide Therapy (STK-001/Zorevunersen)	Investigational antisense oligonucleotide designed to upregulate productive SCN1A transcripts and restore Nav1.1 expression in inhibitory neurons. Preclinical studies show seizure reduction and SUDEP prevention. Early clinical data report good tolerability with reduced seizure frequency in treated individuals.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
2051	2144	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	5	AAV Gene Therapy (ETX101)	Investigational AAV9-based viral vector gene therapy designed to increase SCN1A expression through transcriptional activation in inhibitory neurons. Preclinical models demonstrate seizure reduction and improved survival.	treatment_term	treatment_term	$	AAV Gene Therapy (ETX101)	Investigational AAV9-based viral vector gene therapy designed to increase SCN1A expression through transcriptional activation in inhibitory neurons. Preclinical models demonstrate seizure reduction and improved survival.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
2052	2145	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	6	Cannabidiol	Pharmaceutical-grade cannabidiol approved as add-on therapy for reducing convulsive seizure frequency in Dravet syndrome.	treatment_term	treatment_term	$	Cannabidiol	Pharmaceutical-grade cannabidiol approved as add-on therapy for reducing convulsive seizure frequency in Dravet syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2053	2146	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	7	Fenfluramine	Approved add-on therapy for convulsive seizures in Dravet syndrome, with serotonergic mechanism of action.	treatment_term	treatment_term	$	Fenfluramine	Approved add-on therapy for convulsive seizures in Dravet syndrome, with serotonergic mechanism of action.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2054	2147	95	Dravet_syndrome	Dravet_syndrome.yaml	treatments	8	Stiripentol	Approved antiepileptic drug used in combination with clobazam and valproate for convulsive seizures in Dravet syndrome.	treatment_term	treatment_term	$	Stiripentol	Approved antiepileptic drug used in combination with clobazam and valproate for convulsive seizures in Dravet syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2081	2184	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	0	Surgical Resection	Gastrectomy with lymph node dissection is the primary treatment for localized disease. EBV-positive tumors have relatively favorable prognosis compared to other molecular subtypes.	treatment_term	treatment_term	$	Surgical Resection	Gastrectomy with lymph node dissection is the primary treatment for localized disease. EBV-positive tumors have relatively favorable prognosis compared to other molecular subtypes.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2082	2185	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	1	Chemotherapy	Perioperative or palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX) is standard for advanced disease.	treatment_term	treatment_term	$	Chemotherapy	Perioperative or palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX) is standard for advanced disease.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2083	2186	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	treatments	2	Immune Checkpoint Inhibitors	EBV-positive gastric cancers show high expression of PD-L1 due to 9p24.1 amplification and strong immune infiltration, making them potentially responsive to PD-1/PD-L1 inhibitors such as pembrolizumab or nivolumab. This represents a molecularly-targeted approach based on the unique immunobiology of this subtype.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	EBV-positive gastric cancers show high expression of PD-L1 due to 9p24.1 amplification and strong immune infiltration, making them potentially responsive to PD-1/PD-L1 inhibitors such as pembrolizumab or nivolumab. This represents a molecularly-targeted approach based on the unique immunobiology of this subtype.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2095	2202	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	0	Osimertinib	Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS. Excellent CNS penetration.	treatment_term	treatment_term	$	Osimertinib	Third-generation EGFR TKI that targets both sensitizing mutations and T790M resistance mutation while sparing wild-type EGFR. First-line standard of care for EGFR-mutant NSCLC based on FLAURA trial showing superior OS. Excellent CNS penetration.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2096	2203	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	1	Erlotinib	First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting.	treatment_term	treatment_term	$	Erlotinib	First-generation EGFR TKI. One of the original targeted therapies for EGFR-mutant NSCLC. Now largely replaced by osimertinib in first-line setting.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2097	2204	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	2	Gefitinib	First-generation EGFR TKI approved for EGFR-mutant NSCLC. Similar efficacy to erlotinib. Largely supplanted by osimertinib.	treatment_term	treatment_term	$	Gefitinib	First-generation EGFR TKI approved for EGFR-mutant NSCLC. Similar efficacy to erlotinib. Largely supplanted by osimertinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2098	2205	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	3	Amivantamab	Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations (which are resistant to most TKIs) and in combination with chemotherapy for first-line EGFR-mutant NSCLC.	treatment_term	treatment_term	$	Amivantamab	Bispecific antibody targeting EGFR and MET. Approved for EGFR exon 20 insertion mutations (which are resistant to most TKIs) and in combination with chemotherapy for first-line EGFR-mutant NSCLC.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2099	2206	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy. May be combined with EGFR TKIs in certain settings.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (carboplatin/pemetrexed) used at progression on targeted therapy. May be combined with EGFR TKIs in certain settings.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2109	2221	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	0	Aromatase Inhibitors	First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients.	treatment_term	treatment_term	$	Aromatase Inhibitors	First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2110	2222	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	1	Tamoxifen	Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction.	treatment_term	treatment_term	$	Tamoxifen	Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2111	2223	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	2	CDK4/6 Inhibitors	Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease.	treatment_term	treatment_term	$	CDK4/6 Inhibitors	Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2112	2224	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	3	Fulvestrant	Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy.	treatment_term	treatment_term	$	Fulvestrant	Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2113	2225	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	4	Alpelisib	PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant.	treatment_term	treatment_term	$	Alpelisib	PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2114	2226	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	treatments	5	Elacestrant	Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations.	treatment_term	treatment_term	$	Elacestrant	Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2150	2269	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	0	Supportive Care	Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.	treatment_term	treatment_term	$	Supportive Care	Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2151	2270	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	1	Experimental Therapies	Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.	treatment_term	treatment_term	$	Experimental Therapies	Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
2152	2271	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	treatments	2	Vaccination	The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.	treatment_term	treatment_term	$	Vaccination	The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
2181	2312	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	0	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	treatment_term	treatment_term	$	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2182	2313	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	1	Surgical Interventions	May be needed for severe joint instability or life-threatening complications like arterial dissections.	treatment_term	treatment_term	$	Surgical Interventions	May be needed for severe joint instability or life-threatening complications like arterial dissections.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2183	2314	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	2	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury.	treatment_term	treatment_term	$	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2184	2315	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	treatments	3	Orthotic Interventions	Use of orthotic devices to support unstable joints.	treatment_term	treatment_term	$	Orthotic Interventions	Use of orthotic devices to support unstable joints.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2207	2335	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	0	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	treatment_term	treatment_term	$	Supportive Care	Management of pain, physical therapy to strengthen joints, and prevention of complications.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2208	2336	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	1	Wound Care	Careful attention to wound healing and scar management.	treatment_term	treatment_term	$	Wound Care	Careful attention to wound healing and scar management.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2209	2338	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	3	Gastrointestinal Management	Treatment of gastroesophageal reflux and other GI symptoms as needed.	treatment_term	treatment_term	$	Gastrointestinal Management	Treatment of gastroesophageal reflux and other GI symptoms as needed.	gastrointestinal agent therapy	MAXO:0000267	gastrointestinal agent therapy		"{""preferred_term"": ""gastrointestinal agent therapy"", ""term"": {""id"": ""MAXO:0000267"", ""label"": ""gastrointestinal agent therapy""}}"																											
2210	2339	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	treatments	4	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary.	treatment_term	treatment_term	$	Lifestyle Modifications	Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2220	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}"				vincristine; actinomycin D; cyclophosphamide	CHEBI:28445; CHEBI:27666; CHEBI:4026																						
2221	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
2222	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"																											
2223	2355	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	0	Multi-Agent Chemotherapy	Standard chemotherapy includes vincristine, actinomycin D, and cyclophosphamide (VAC). Treatment intensity is risk-stratified based on stage, site, and resectability. Low-risk patients may receive less intensive therapy.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
2224	2356	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	1	Surgical Resection	Complete surgical resection when feasible without significant morbidity. For favorable sites like orbit, chemotherapy may allow for organ preservation.	treatment_term	treatment_term	$	Surgical Resection	Complete surgical resection when feasible without significant morbidity. For favorable sites like orbit, chemotherapy may allow for organ preservation.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2225	2357	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	treatments	2	Radiation Therapy	Radiation is used for local control in patients with residual disease or unfavorable features. May be omitted in selected low-risk patients.	treatment_term	treatment_term	$	Radiation Therapy	Radiation is used for local control in patients with residual disease or unfavorable features. May be omitted in selected low-risk patients.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2284	2461	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	0	Low-Dose Aspirin	Recommended for all ET patients without contraindications. Reduces microvascular symptoms (erythromelalgia, headache) and thrombotic events. Use with caution if platelet count exceeds 1,000,000/uL due to acquired von Willebrand disease risk.	treatment_term	treatment_term	$	Low-Dose Aspirin	Recommended for all ET patients without contraindications. Reduces microvascular symptoms (erythromelalgia, headache) and thrombotic events. Use with caution if platelet count exceeds 1,000,000/uL due to acquired von Willebrand disease risk.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2285	2462	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	1	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	treatment_term	treatment_term	$	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}"				hydroxyurea	CHEBI:44423																						
2286	2462	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	1	Hydroxyurea	First-line cytoreductive therapy for high-risk ET patients (age >60 years or prior thrombosis) and intermediate-risk patients with cardiovascular risk factors. Well-tolerated and effective at reducing platelet count.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"																											
2287	2463	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	2	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	treatment_term	treatment_term	$	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}]}"				anagrelide	CHEBI:142290																						
2288	2463	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	2	Anagrelide	Selective platelet-lowering agent that inhibits megakaryocyte maturation. Second-line option or used when hydroxyurea is contraindicated. May increase arterial thrombosis and fibrotic transformation risk compared to hydroxyurea.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"																											
2289	2464	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	treatments	3	Interferon-alpha	Effective cytoreductive option particularly for younger patients, during pregnancy, or when disease modification is desired. May reduce driver mutation allele burden.	treatment_term	treatment_term	$	Interferon-alpha	Effective cytoreductive option particularly for younger patients, during pregnancy, or when disease modification is desired. May reduce driver mutation allele burden.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2301	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term	treatment_term	$	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}, {""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}]}"				vincristine; doxorubicin; cyclophosphamide; ifosfamide; etoposide	CHEBI:27375; CHEBI:28748; CHEBI:4026; CHEBI:5864; CHEBI:4911																						
2302	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"																											
2303	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
2304	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
2305	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"																											
2306	2478	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	0	Neoadjuvant Chemotherapy	Intensive multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide/etoposide - VDC/IE) is standard. Neoadjuvant chemotherapy shrinks tumors before local control.	treatment_term.therapeutic_agent[4]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
2307	2479	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	1	Surgical Resection	Wide surgical resection with negative margins is preferred when feasible without excessive morbidity. Reconstruction may be needed for limb salvage.	treatment_term	treatment_term	$	Surgical Resection	Wide surgical resection with negative margins is preferred when feasible without excessive morbidity. Reconstruction may be needed for limb salvage.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2308	2480	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	2	Radiation Therapy	Definitive radiation is used for unresectable tumors or when surgery would cause significant morbidity. Also used post-operatively for close or positive margins.	treatment_term	treatment_term	$	Radiation Therapy	Definitive radiation is used for unresectable tumors or when surgery would cause significant morbidity. Also used post-operatively for close or positive margins.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2309	2481	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	treatments	3	Adjuvant Chemotherapy	Additional chemotherapy after local control to eliminate micrometastatic disease. Total treatment duration is typically 9-12 months.	treatment_term	treatment_term	$	Adjuvant Chemotherapy	Additional chemotherapy after local control to eliminate micrometastatic disease. Total treatment duration is typically 9-12 months.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2323	2500	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	0	Pemigatinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FIGHT-202 trial demonstrated 36% objective response rate with 9.1 months median duration of response. Now also approved in first-line (FIGHT-302).	treatment_term	treatment_term	$	Pemigatinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FIGHT-202 trial demonstrated 36% objective response rate with 9.1 months median duration of response. Now also approved in first-line (FIGHT-302).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2324	2501	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	1	Futibatinib	Irreversible pan-FGFR inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FOENIX-CCA2 trial demonstrated 42% response rate. May retain activity against some resistance mutations due to covalent binding mechanism.	treatment_term	treatment_term	$	Futibatinib	Irreversible pan-FGFR inhibitor approved for previously treated FGFR2 fusion/rearrangement positive cholangiocarcinoma. FOENIX-CCA2 trial demonstrated 42% response rate. May retain activity against some resistance mutations due to covalent binding mechanism.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2325	2502	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	2	Infigratinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion positive cholangiocarcinoma. Demonstrated approximately 23% response rate in pivotal study.	treatment_term	treatment_term	$	Infigratinib	Selective FGFR1-3 inhibitor approved for previously treated FGFR2 fusion positive cholangiocarcinoma. Demonstrated approximately 23% response rate in pivotal study.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2326	2503	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	3	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma. May be used before FGFR inhibitors or in combination approaches. FGFR inhibitors increasingly moving to first-line setting.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma. May be used before FGFR inhibitors or in combination approaches. FGFR inhibitors increasingly moving to first-line setting.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2327	2504	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	4	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin is now standard first-line treatment for advanced biliary tract cancers (TOPAZ-1 trial). Sequencing with FGFR inhibitors being defined.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin is now standard first-line treatment for advanced biliary tract cancers (TOPAZ-1 trial). Sequencing with FGFR inhibitors being defined.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2328	2505	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	treatments	5	Surgical Resection	Surgery offers the only potential cure for cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. FGFR status does not change surgical approach for resectable disease.	treatment_term	treatment_term	$	Surgical Resection	Surgery offers the only potential cure for cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. FGFR status does not change surgical approach for resectable disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2338	2517	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	0	Erdafitinib	Pan-FGFR tyrosine kinase inhibitor approved for FGFR2/3-altered locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Demonstrates meaningful response rates and survival benefits in biomarker-selected patients.	treatment_term	treatment_term	$	Erdafitinib	Pan-FGFR tyrosine kinase inhibitor approved for FGFR2/3-altered locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Demonstrates meaningful response rates and survival benefits in biomarker-selected patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2339	2518	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	1	Platinum-Based Chemotherapy	Cisplatin or carboplatin-based combination regimens remain first-line treatment for metastatic urothelial carcinoma regardless of FGFR status. Gemcitabine plus cisplatin is a standard regimen.	treatment_term	treatment_term	$	Platinum-Based Chemotherapy	Cisplatin or carboplatin-based combination regimens remain first-line treatment for metastatic urothelial carcinoma regardless of FGFR status. Gemcitabine plus cisplatin is a standard regimen.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2340	2519	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	treatments	2	Immune Checkpoint Inhibitors	PD-1/PD-L1 inhibitors are used in metastatic urothelial carcinoma. May be sequenced with erdafitinib in FGFR-altered tumors, though optimal sequencing strategies continue to evolve.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	PD-1/PD-L1 inhibitors are used in metastatic urothelial carcinoma. May be sequenced with erdafitinib in FGFR-altered tumors, though optimal sequencing strategies continue to evolve.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2358	2546	111	FICUS syndrome	FICUS_syndrome.yaml	treatments	0	Family support intervention	"Nurse-led, interprofessional family support intervention aimed at improving family management, quality of care, and mental health for ICU family members.
"	treatment_term	treatment_term	$	Family support intervention	"Nurse-led, interprofessional family support intervention aimed at improving family management, quality of care, and mental health for ICU family members.
"	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2375	2565	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	0	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	treatment_term	treatment_term	$	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""midostaurin"", ""term"": {""id"": ""CHEBI:63452"", ""label"": ""midostaurin""}}]}"				midostaurin	CHEBI:63452																						
2376	2565	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	0	Midostaurin	First-generation multi-kinase inhibitor with FLT3 activity approved in combination with standard chemotherapy (7+3) for newly diagnosed FLT3-mutated AML. Addition of midostaurin to induction and consolidation significantly improves overall survival.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			midostaurin	CHEBI:63452	midostaurin		"{""preferred_term"": ""midostaurin"", ""term"": {""id"": ""CHEBI:63452"", ""label"": ""midostaurin""}}"																											
2377	2566	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	1	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	treatment_term	treatment_term	$	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""gilteritinib"", ""term"": {""id"": ""CHEBI:145372"", ""label"": ""gilteritinib""}}]}"				gilteritinib	CHEBI:145372																						
2378	2566	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	1	Gilteritinib	Second-generation selective FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. More potent and selective than midostaurin with activity against both ITD and TKD mutations, including some resistance mutations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			gilteritinib	CHEBI:145372	gilteritinib		"{""preferred_term"": ""gilteritinib"", ""term"": {""id"": ""CHEBI:145372"", ""label"": ""gilteritinib""}}"																											
2379	2567	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	2	Intensive Chemotherapy (7+3)	Standard induction chemotherapy with cytarabine continuous infusion for 7 days plus anthracycline (daunorubicin or idarubicin) for 3 days. Forms the backbone of treatment combined with FLT3 inhibitors for eligible patients.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3)	Standard induction chemotherapy with cytarabine continuous infusion for 7 days plus anthracycline (daunorubicin or idarubicin) for 3 days. Forms the backbone of treatment combined with FLT3 inhibitors for eligible patients.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2380	2568	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Recommended for FLT3-ITD AML patients in first complete remission due to high relapse risk. Provides graft-versus-leukemia effect. FLT3 inhibitor maintenance post-transplant is being evaluated.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Recommended for FLT3-ITD AML patients in first complete remission due to high relapse risk. Provides graft-versus-leukemia effect. FLT3 inhibitor maintenance post-transplant is being evaluated.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
2409	2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	treatment_term	treatment_term	$	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	enzyme replacement therapy	MAXO:0000933	enzyme replacement or supplementation therapy		"{""preferred_term"": ""enzyme replacement therapy"", ""term"": {""id"": ""MAXO:0000933"", ""label"": ""enzyme replacement or supplementation therapy""}}"																											
2410	2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Proteinuria	HP:0000093	proteinuria		"{""preferred_term"": ""Proteinuria"", ""term"": {""id"": ""HP:0000093"", ""label"": ""proteinuria""}}"																											
2411	2590	113	Fabry disease	Fabry_Disease.yaml	treatments	0	Enzyme replacement therapy	"Recombinant -galactosidase A (agalsidase alfa/beta and pegunigalsidase alfa) restores enzyme activity and reduces Gb3 accumulation. Early initiation improves outcomes but cannot reverse established organ damage or fibrosis.
"	target_phenotypes[1]	target_phenotypes	target_phenotypes			Chronic kidney disease	HP:0012622	Chronic kidney disease		"{""preferred_term"": ""Chronic kidney disease"", ""term"": {""id"": ""HP:0012622"", ""label"": ""Chronic kidney disease""}}"																											
2412	2591	113	Fabry disease	Fabry_Disease.yaml	treatments	1	Pharmacological chaperone therapy	"Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.
"	treatment_term	treatment_term	$	Pharmacological chaperone therapy	"Migalastat stabilizes GLA mutant variants and improves lysosomal trafficking. Useful for approximately 35-50% of patients with amenable mutations.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2413	2592	113	Fabry disease	Fabry_Disease.yaml	treatments	2	Gene therapy	"AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.
"	treatment_term	treatment_term	$	Gene therapy	"AAV and lentiviral-based therapies deliver functional GLA gene for sustained enzyme expression. Shows promise for achieving durable Gb3 clearance and reduced need for repeated infusions.
"	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
2414	2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	treatment_term	treatment_term	$	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2415	2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pain	HP:0012531	Pain		"{""preferred_term"": ""Pain"", ""term"": {""id"": ""HP:0012531"", ""label"": ""Pain""}}"																											
2416	2593	113	Fabry disease	Fabry_Disease.yaml	treatments	3	Supportive care	"Management of complications including pain control, renal protection with ACE inhibitors, cardiac monitoring, and stroke prevention. Pain management and cardiovascular monitoring are essential for quality of life.
"	target_phenotypes[1]	target_phenotypes	target_phenotypes			Arrhythmia	HP:0011675	Arrhythmia		"{""preferred_term"": ""Arrhythmia"", ""term"": {""id"": ""HP:0011675"", ""label"": ""Arrhythmia""}}"																											
2431	2610	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	0	Prophylactic Colectomy	Surgical removal of the colon is the primary management to prevent colorectal cancer. Options include total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or subtotal colectomy with ileorectal anastomosis (IRA). Timing is typically in late teens/early twenties or when polyp burden becomes unmanageable endoscopically.	treatment_term	treatment_term	$	Prophylactic Colectomy	Surgical removal of the colon is the primary management to prevent colorectal cancer. Options include total proctocolectomy with ileal pouch-anal anastomosis (IPAA) or subtotal colectomy with ileorectal anastomosis (IRA). Timing is typically in late teens/early twenties or when polyp burden becomes unmanageable endoscopically.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2432	2611	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	1	Endoscopic Surveillance	Annual colonoscopy beginning at age 10-12 in at-risk individuals to detect polyp development. Upper endoscopy every 1-4 years to monitor duodenal adenomas using Spigelman staging. Surveillance of rectal stump or pouch after colectomy.	treatment_term	treatment_term	$	Endoscopic Surveillance	Annual colonoscopy beginning at age 10-12 in at-risk individuals to detect polyp development. Upper endoscopy every 1-4 years to monitor duodenal adenomas using Spigelman staging. Surveillance of rectal stump or pouch after colectomy.	colonoscopy	MAXO:0001184	colonoscopy		"{""preferred_term"": ""colonoscopy"", ""term"": {""id"": ""MAXO:0001184"", ""label"": ""colonoscopy""}}"																											
2433	2612	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	2	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and reassurance for non-carriers.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and reassurance for non-carriers.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2434	2613	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	treatments	3	Chemoprevention	Sulindac and celecoxib (COX-2 inhibitors) have demonstrated ability to reduce polyp number and size but do not eliminate cancer risk. Used as adjunct to surveillance, not as alternative to surgery.	treatment_term	treatment_term	$	Chemoprevention	Sulindac and celecoxib (COX-2 inhibitors) have demonstrated ability to reduce polyp number and size but do not eliminate cancer risk. Used as adjunct to surveillance, not as alternative to surgery.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2460	2638	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	0	Colchicine	First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis.	treatment_term	treatment_term	$	Colchicine	First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2461	2639	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	1	Anti-IL-1 Therapy	Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab).	treatment_term	treatment_term	$	Anti-IL-1 Therapy	Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2462	2640	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	2	NSAIDs	Used for symptom relief during acute attacks	treatment_term	treatment_term	$	NSAIDs	Used for symptom relief during acute attacks	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2463	2641	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	treatments	3	Lifestyle Modifications	Avoiding known triggers such as stress and infections where possible	treatment_term	treatment_term	$	Lifestyle Modifications	Avoiding known triggers such as stress and infections where possible	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
2701	2815	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	0	Hematopoietic Stem Cell Transplantation (HSCT)	The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation.	treatment_term	treatment_term	$	Hematopoietic Stem Cell Transplantation (HSCT)	The only curative treatment for the hematologic manifestations of FA, using reduced-intensity conditioning regimens due to patient sensitivity to chemotherapy and radiation.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
2702	2816	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	1	Androgen Therapy	Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation.	treatment_term	treatment_term	$	Androgen Therapy	Can stimulate erythropoiesis and improve blood counts, often used as a bridge to transplantation.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
2703	2817	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	2	Growth Hormone Therapy	May be used to improve growth in affected children with short stature.	treatment_term	treatment_term	$	Growth Hormone Therapy	May be used to improve growth in affected children with short stature.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
2704	2818	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	3	Supportive Care	Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy.	treatment_term	treatment_term	$	Supportive Care	Treatment of cytopenias with transfusions, antibiotics, and monitoring for malignancy.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2705	2819	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	4	Cancer Surveillance	Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions.	treatment_term	treatment_term	$	Cancer Surveillance	Regular screenings for early detection of cancers, particularly acute myeloid leukemia and squamous cell carcinomas of the head and neck, oral cavity, and anogenital regions.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
2706	2820	116	Fanconi_Anemia	Fanconi_Anemia.yaml	treatments	5	Genetic Counseling	Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options.	treatment_term	treatment_term	$	Genetic Counseling	Counseling for patients and families regarding inheritance patterns, recurrence risks, carrier testing, and prenatal diagnosis options.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2724	2835	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	0	Palovarotene	Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males).	treatment_term	treatment_term	$	Palovarotene	Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2725	2836	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	1	Corticosteroids	Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit.	treatment_term	treatment_term	$	Corticosteroids	Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2726	2838	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	3	Genetic Counseling	Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden.	treatment_term	treatment_term	$	Genetic Counseling	Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2727	2839	117	Fibrodysplasia Ossificans Progressiva	Fibrodysplasia_Ossificans_Progressiva.yaml	treatments	4	Garetosmab	Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026.	treatment_term	treatment_term	$	Garetosmab	Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2744	2872	118	Fibromyalgia	Fibromyalgia.yaml	treatments	0	Duloxetine	SNRI, FDA-approved for fibromyalgia. Modulates serotonin and norepinephrine for pain relief.	treatment_term	treatment_term	$	Duloxetine	SNRI, FDA-approved for fibromyalgia. Modulates serotonin and norepinephrine for pain relief.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2745	2873	118	Fibromyalgia	Fibromyalgia.yaml	treatments	1	Milnacipran	SNRI, FDA-approved for fibromyalgia. Dual neurotransmitter modulation.	treatment_term	treatment_term	$	Milnacipran	SNRI, FDA-approved for fibromyalgia. Dual neurotransmitter modulation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2746	2874	118	Fibromyalgia	Fibromyalgia.yaml	treatments	2	Pregabalin	Alpha-2-delta ligand, FDA-approved for fibromyalgia. Reduces abnormal neural excitability.	treatment_term	treatment_term	$	Pregabalin	Alpha-2-delta ligand, FDA-approved for fibromyalgia. Reduces abnormal neural excitability.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2747	2875	118	Fibromyalgia	Fibromyalgia.yaml	treatments	3	Gabapentin	Alpha-2-delta ligand, used off-label for neuropathic pain component.	treatment_term	treatment_term	$	Gabapentin	Alpha-2-delta ligand, used off-label for neuropathic pain component.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2748	2876	118	Fibromyalgia	Fibromyalgia.yaml	treatments	4	Amitriptyline	Low-dose tricyclic antidepressant for pain modulation and sleep improvement.	treatment_term	treatment_term	$	Amitriptyline	Low-dose tricyclic antidepressant for pain modulation and sleep improvement.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2749	2877	118	Fibromyalgia	Fibromyalgia.yaml	treatments	5	Aerobic Exercise	Structured physical activity with strong evidence for pain reduction and functional improvement.	treatment_term	treatment_term	$	Aerobic Exercise	Structured physical activity with strong evidence for pain reduction and functional improvement.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2750	2878	118	Fibromyalgia	Fibromyalgia.yaml	treatments	6	Cognitive Behavioral Therapy	Psychological intervention addressing pain catastrophizing, coping strategies, and behavioral modification.	treatment_term	treatment_term	$	Cognitive Behavioral Therapy	Psychological intervention addressing pain catastrophizing, coping strategies, and behavioral modification.	psychotherapy	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""psychotherapy"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2751	2879	118	Fibromyalgia	Fibromyalgia.yaml	treatments	7	Sleep Hygiene Education	Behavioral interventions to improve sleep quality and reduce non-restorative sleep patterns.	treatment_term	treatment_term	$	Sleep Hygiene Education	Behavioral interventions to improve sleep quality and reduce non-restorative sleep patterns.	patient education	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""patient education"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
2752	2880	118	Fibromyalgia	Fibromyalgia.yaml	treatments	8	Mindfulness-Based Stress Reduction	Meditation and mindfulness practices for pain management and stress reduction.	treatment_term	treatment_term	$	Mindfulness-Based Stress Reduction	Meditation and mindfulness practices for pain management and stress reduction.	behavioral intervention	MAXO:0000010	cognitive and behavioral intervention		"{""preferred_term"": ""behavioral intervention"", ""term"": {""id"": ""MAXO:0000010"", ""label"": ""cognitive and behavioral intervention""}}"																											
2753	2881	118	Fibromyalgia	Fibromyalgia.yaml	treatments	9	Aquatic Therapy	Water-based exercise therapy for low-impact conditioning and pain relief.	treatment_term	treatment_term	$	Aquatic Therapy	Water-based exercise therapy for low-impact conditioning and pain relief.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
2782	2920	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	treatments	0	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support.	treatment_term	treatment_term	$	Symptomatic Management	No disease-modifying treatments currently available. Management focuses on behavioral symptoms with selective serotonin reuptake inhibitors for compulsive behaviors and agitation, and non-pharmacological approaches including behavioral interventions and caregiver support.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2783	2921	121	Frontotemporal Dementia	Frontotemporal_Dementia.yaml	treatments	1	Speech and Language Therapy	Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible.	treatment_term	treatment_term	$	Speech and Language Therapy	Speech therapy interventions for patients with language-variant FTD to maintain communication abilities and quality of life for as long as possible.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
2803	2965	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	0	H. pylori Eradication	Triple or quadruple therapy to eradicate H. pylori reduces gastric cancer risk, particularly when given before development of intestinal metaplasia. Also reduces risk of metachronous gastric cancer after endoscopic resection of early tumors.	treatment_term	treatment_term	$	H. pylori Eradication	Triple or quadruple therapy to eradicate H. pylori reduces gastric cancer risk, particularly when given before development of intestinal metaplasia. Also reduces risk of metachronous gastric cancer after endoscopic resection of early tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2804	2966	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	1	Surgical Resection	Gastrectomy (subtotal or total depending on tumor location) with D2 lymphadenectomy is the standard curative treatment for resectable gastric cancer. Reconstruction maintains GI continuity.	treatment_term	treatment_term	$	Surgical Resection	Gastrectomy (subtotal or total depending on tumor location) with D2 lymphadenectomy is the standard curative treatment for resectable gastric cancer. Reconstruction maintains GI continuity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2805	2967	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	2	Perioperative Chemotherapy	Perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard of care for resectable locally advanced gastric cancer in Western countries, improving survival compared to surgery alone.	treatment_term	treatment_term	$	Perioperative Chemotherapy	Perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) is the standard of care for resectable locally advanced gastric cancer in Western countries, improving survival compared to surgery alone.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2806	2968	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	3	Trastuzumab	Anti-HER2 monoclonal antibody added to chemotherapy for HER2-positive (approximately 15-20%) advanced gastric cancer. First targeted therapy to show survival benefit in gastric cancer.	treatment_term	treatment_term	$	Trastuzumab	Anti-HER2 monoclonal antibody added to chemotherapy for HER2-positive (approximately 15-20%) advanced gastric cancer. First targeted therapy to show survival benefit in gastric cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2807	2969	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	treatments	4	Immune Checkpoint Inhibition	PD-1 inhibitors combined with chemotherapy are now standard first-line treatment for advanced gastric cancer. Benefit is greatest in PD-L1 CPS-high and MSI-high tumors.	treatment_term	treatment_term	$	Immune Checkpoint Inhibition	PD-1 inhibitors combined with chemotherapy are now standard first-line treatment for advanced gastric cancer. Benefit is greatest in PD-L1 CPS-high and MSI-high tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2832	3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	treatment_term	treatment_term	$	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
2833	3015	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	0	Imatinib	First-line treatment for unresectable or metastatic GIST. Targets KIT and PDGFRA kinases. Standard dose is 400 mg daily, but exon 9 KIT mutations require 800 mg. Dramatically transformed outcomes for advanced GIST patients.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
2834	3016	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	1	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	treatment_term	treatment_term	$	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}]}"				sunitinib	CHEBI:38940																						
2835	3016	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	1	Sunitinib	Second-line treatment after imatinib failure or intolerance. Multi-kinase inhibitor targeting KIT, PDGFRA, and VEGFR. Active against some imatinib-resistant secondary mutations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			sunitinib	CHEBI:38940	sunitinib		"{""preferred_term"": ""sunitinib"", ""term"": {""id"": ""CHEBI:38940"", ""label"": ""sunitinib""}}"																											
2836	3017	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	2	Avapritinib	Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib.	treatment_term	treatment_term	$	Avapritinib	Selective KIT/PDGFRA inhibitor specifically designed to target PDGFRA D842V mutations and KIT exon 17 mutations. First agent to show efficacy in D842V mutant GIST, which is resistant to imatinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2837	3018	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	treatments	3	Surgical Resection	Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery.	treatment_term	treatment_term	$	Surgical Resection	Primary treatment for localized GIST. Complete resection with negative margins is the goal. Neoadjuvant imatinib may reduce tumor size and facilitate organ-preserving surgery.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2904	3142	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	0	Maximal Safe Resection	Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection.	treatment_term	treatment_term	$	Maximal Safe Resection	Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2905	3143	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	1	Radiation Therapy	External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients.	treatment_term	treatment_term	$	Radiation Therapy	External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
2906	3144	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	2	Temozolomide Chemotherapy	Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors.	treatment_term	treatment_term	$	Temozolomide Chemotherapy	Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
2907	3145	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	3	Tumor Treating Fields (TTFields)	Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma.	treatment_term	treatment_term	$	Tumor Treating Fields (TTFields)	Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma.	cranial electrical stimulation	MAXO:0000944	cranial electrical stimulation		"{""preferred_term"": ""cranial electrical stimulation"", ""term"": {""id"": ""MAXO:0000944"", ""label"": ""cranial electrical stimulation""}}"																											
2908	3146	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	treatments	4	Bevacizumab	Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease.	treatment_term	treatment_term	$	Bevacizumab	Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2936	3171	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	0	Avoidance of Oxidative Stressors	Identifying and avoiding triggers for acute hemolytic episodes	treatment_term	treatment_term	$	Avoidance of Oxidative Stressors	Identifying and avoiding triggers for acute hemolytic episodes	medical action avoidance	MAXO:0001014	medical action avoidance		"{""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}"																											
2937	3172	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	treatments	1	Supportive Care During Acute Hemolysis	Hydration, blood transfusions if needed, and monitoring for complications	treatment_term	treatment_term	$	Supportive Care During Acute Hemolysis	Hydration, blood transfusions if needed, and monitoring for complications	blood transfusion	MAXO:0000756	blood transfusion		"{""preferred_term"": ""blood transfusion"", ""term"": {""id"": ""MAXO:0000756"", ""label"": ""blood transfusion""}}"																											
2953	3196	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	0	Surgical Excision	Surgical removal of basal cell carcinomas is the primary treatment. Mohs micrographic surgery may be preferred for facial lesions to preserve tissue. Given the multiplicity of tumors, repeated surgeries are often necessary.	treatment_term	treatment_term	$	Surgical Excision	Surgical removal of basal cell carcinomas is the primary treatment. Mohs micrographic surgery may be preferred for facial lesions to preserve tissue. Given the multiplicity of tumors, repeated surgeries are often necessary.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2954	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	treatment_term	treatment_term	$	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}]}"				vismodegib	CHEBI:66903																						
2955	3197	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	1	Vismodegib	Hedgehog pathway inhibitor approved for locally advanced BCC. Can reduce tumor burden in patients with multiple BCCs, but side effects (muscle spasms, dysgeusia, alopecia) limit long-term use. Tumors may regrow after discontinuation.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vismodegib	CHEBI:66903	vismodegib		"{""preferred_term"": ""vismodegib"", ""term"": {""id"": ""CHEBI:66903"", ""label"": ""vismodegib""}}"																											
2956	3198	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	2	Sonidegib	Alternative SMO inhibitor for locally advanced BCC. Similar mechanism and side effect profile to vismodegib.	treatment_term	treatment_term	$	Sonidegib	Alternative SMO inhibitor for locally advanced BCC. Similar mechanism and side effect profile to vismodegib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2957	3199	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	3	Laser Ablation Therapy	Laser ablation and photodynamic therapy may be useful for treating multiple superficial BCCs with acceptable cosmetic outcomes. Less effective for nodular or aggressive subtypes.	treatment_term	treatment_term	$	Laser Ablation Therapy	Laser ablation and photodynamic therapy may be useful for treating multiple superficial BCCs with acceptable cosmetic outcomes. Less effective for nodular or aggressive subtypes.	laser ablation therapy	MAXO:0000453	laser ablation therapy		"{""preferred_term"": ""laser ablation therapy"", ""term"": {""id"": ""MAXO:0000453"", ""label"": ""laser ablation therapy""}}"																											
2958	3200	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	4	Topical Therapy	Topical imiquimod or 5-fluorouracil may be used for superficial BCCs to reduce surgical burden.	treatment_term	treatment_term	$	Topical Therapy	Topical imiquimod or 5-fluorouracil may be used for superficial BCCs to reduce surgical burden.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2959	3201	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	5	Sun Avoidance	Rigorous sun protection with sunscreen, protective clothing, and sunlight avoidance is essential to reduce the development of new BCCs.	treatment_term	treatment_term	$	Sun Avoidance	Rigorous sun protection with sunscreen, protective clothing, and sunlight avoidance is essential to reduce the development of new BCCs.	sunlight avoidance	MAXO:0000055	sunlight avoidance		"{""preferred_term"": ""sunlight avoidance"", ""term"": {""id"": ""MAXO:0000055"", ""label"": ""sunlight avoidance""}}"																											
2960	3202	133	Gorlin Syndrome	Gorlin_Syndrome.yaml	treatments	6	Genetic Counseling	Given autosomal dominant inheritance and 50% recurrence risk, genetic counseling is recommended for affected individuals and at-risk family members.	treatment_term	treatment_term	$	Genetic Counseling	Given autosomal dominant inheritance and 50% recurrence risk, genetic counseling is recommended for affected individuals and at-risk family members.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
2980	3241	135	Grange syndrome	Grange_syndrome.yaml	treatments	0	Antithrombotic Therapy	Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis.	treatment_term	treatment_term	$	Antithrombotic Therapy	Antiplatelet agents to reduce thrombotic risk in patients with arterial stenosis.	drug therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""drug therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2981	3242	135	Grange syndrome	Grange_syndrome.yaml	treatments	1	Cardiovascular Management	Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease.	treatment_term	treatment_term	$	Cardiovascular Management	Antihypertensive and lipid-lowering therapy to manage hypertension and dyslipidemia associated with vascular disease.	drug therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""drug therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
2982	3243	135	Grange syndrome	Grange_syndrome.yaml	treatments	2	Neurosurgical Intervention	Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events.	treatment_term	treatment_term	$	Neurosurgical Intervention	Indirect revascularization procedures for severe cerebrovascular stenosis causing ischemic events.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
2983	3245	135	Grange syndrome	Grange_syndrome.yaml	treatments	4	Surgical Correction of Acral Features	Surgical repair of hand syndactyly to improve function and appearance.	treatment_term	treatment_term	$	Surgical Correction of Acral Features	Surgical repair of hand syndactyly to improve function and appearance.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3035	3299	137	Graves' Disease	Graves_Disease.yaml	treatments	0	Antithyroid Medications	Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.	treatment_term	treatment_term	$	Antithyroid Medications	Methimazole and propylthiouracil (PTU) to reduce thyroid hormone production.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3036	3300	137	Graves' Disease	Graves_Disease.yaml	treatments	1	Radioactive Iodine Therapy	Radioactive iodine is taken orally to destroy overactive thyroid cells.	treatment_term	treatment_term	$	Radioactive Iodine Therapy	Radioactive iodine is taken orally to destroy overactive thyroid cells.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
3037	3301	137	Graves' Disease	Graves_Disease.yaml	treatments	2	Thyroidectomy	Surgical removal of part or all of the thyroid gland.	treatment_term	treatment_term	$	Thyroidectomy	Surgical removal of part or all of the thyroid gland.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3038	3302	137	Graves' Disease	Graves_Disease.yaml	treatments	3	Beta Blockers	Used to manage cardiovascular symptoms like tachycardia and palpitations.	treatment_term	treatment_term	$	Beta Blockers	Used to manage cardiovascular symptoms like tachycardia and palpitations.	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy		"{""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
3039	3303	137	Graves' Disease	Graves_Disease.yaml	treatments	4	Corticosteroids	Used to reduce inflammation in severe ophthalmopathy.	treatment_term	treatment_term	$	Corticosteroids	Used to reduce inflammation in severe ophthalmopathy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3065	3340	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	0	Radiation Therapy	Focal radiation therapy (54-59.4 Gy) is the only treatment with established benefit, providing temporary tumor control and symptom improvement. Typically extends survival by 2-3 months compared to supportive care alone.	treatment_term	treatment_term	$	Radiation Therapy	Focal radiation therapy (54-59.4 Gy) is the only treatment with established benefit, providing temporary tumor control and symptom improvement. Typically extends survival by 2-3 months compared to supportive care alone.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3066	3341	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	1	Corticosteroids	Dexamethasone reduces peritumoral edema and provides symptomatic relief. Standard supportive measure during radiation and at progression.	treatment_term	treatment_term	$	Corticosteroids	Dexamethasone reduces peritumoral edema and provides symptomatic relief. Standard supportive measure during radiation and at progression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3067	3342	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	treatments	2	ONC201 (DRD2 Antagonist)	Small molecule DRD2 antagonist and ClpP agonist showing promising activity in H3 K27M-mutant gliomas. Crosses blood-brain barrier. Currently in clinical trials and received FDA Breakthrough Therapy designation.	treatment_term	treatment_term	$	ONC201 (DRD2 Antagonist)	Small molecule DRD2 antagonist and ClpP agonist showing promising activity in H3 K27M-mutant gliomas. Crosses blood-brain barrier. Currently in clinical trials and received FDA Breakthrough Therapy designation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3078	3354	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	0	Trastuzumab	Humanized monoclonal antibody targeting the extracellular domain of HER2. First-line treatment in combination with chemotherapy. Revolutionized HER2+ breast cancer treatment, converting a poor-prognosis subtype into one with excellent outcomes.	treatment_term	treatment_term	$	Trastuzumab	Humanized monoclonal antibody targeting the extracellular domain of HER2. First-line treatment in combination with chemotherapy. Revolutionized HER2+ breast cancer treatment, converting a poor-prognosis subtype into one with excellent outcomes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3079	3355	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	1	Pertuzumab	Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab, preventing HER2 dimerization. Used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings.	treatment_term	treatment_term	$	Pertuzumab	Humanized monoclonal antibody that binds HER2 at a different epitope than trastuzumab, preventing HER2 dimerization. Used in combination with trastuzumab and chemotherapy in the neoadjuvant, adjuvant, and metastatic settings.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3080	3356	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	2	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I inhibitor payload. Highly effective in HER2+ metastatic breast cancer after prior trastuzumab, and also active in HER2-low breast cancer.	treatment_term	treatment_term	$	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of trastuzumab linked to a topoisomerase I inhibitor payload. Highly effective in HER2+ metastatic breast cancer after prior trastuzumab, and also active in HER2-low breast cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3081	3357	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	3	Tucatinib	Oral HER2-selective tyrosine kinase inhibitor with activity against brain metastases. Used in combination with trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer.	treatment_term	treatment_term	$	Tucatinib	Oral HER2-selective tyrosine kinase inhibitor with activity against brain metastases. Used in combination with trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3082	3358	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	treatments	4	Neratinib	Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended adjuvant therapy after trastuzumab-based treatment and for metastatic disease in combination with capecitabine.	treatment_term	treatment_term	$	Neratinib	Irreversible pan-HER tyrosine kinase inhibitor. Approved for extended adjuvant therapy after trastuzumab-based treatment and for metastatic disease in combination with capecitabine.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3095	3375	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	0	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	treatment_term	treatment_term	$	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3096	3375	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	0	Trastuzumab plus Lapatinib	Dual HER2 blockade with trastuzumab (anti-HER2 antibody) and lapatinib (HER1/HER2 TKI). HERACLES trial demonstrated 30% objective response rate in chemotherapy-refractory, HER2-positive, RAS wild-type metastatic CRC.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3097	3376	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	1	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	treatment_term	treatment_term	$	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3098	3376	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	1	Trastuzumab plus Pertuzumab	Dual HER2 antibody blockade with trastuzumab and pertuzumab, which block different HER2 epitopes and prevent HER2/HER3 heterodimerization. MyPathway basket trial showed activity in HER2-amplified CRC.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3099	3377	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	2	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of anti-HER2 antibody linked to topoisomerase I inhibitor payload. DESTINY-CRC01 showed promising activity in HER2-positive metastatic CRC with strong IHC 3+ expression.	treatment_term	treatment_term	$	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate consisting of anti-HER2 antibody linked to topoisomerase I inhibitor payload. DESTINY-CRC01 showed promising activity in HER2-positive metastatic CRC with strong IHC 3+ expression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3100	3378	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	3	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	treatment_term	treatment_term	$	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3101	3378	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	3	Tucatinib plus Trastuzumab	Combination of HER2-selective TKI tucatinib with trastuzumab. MOUNTAINEER trial demonstrated significant activity in HER2-positive metastatic CRC, leading to FDA accelerated approval.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3102	3379	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	treatments	4	Surgical Resection	Surgery for localized disease or selected metastatic cases. HER2 status does not change standard surgical approaches but informs systemic therapy decisions.	treatment_term	treatment_term	$	Surgical Resection	Surgery for localized disease or selected metastatic cases. HER2 status does not change standard surgical approaches but informs systemic therapy decisions.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3117	3397	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	0	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	treatment_term	treatment_term	$	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3118	3397	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	0	Trastuzumab plus Chemotherapy	First-line standard of care for HER2-positive metastatic gastric cancer. ToGA trial demonstrated improved overall survival with trastuzumab added to cisplatin/fluoropyrimidine chemotherapy. Remains backbone of first-line treatment.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3119	3398	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	1	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate with anti-HER2 antibody linked to topoisomerase I inhibitor deruxtecan. DESTINY-Gastric01 demonstrated superior overall survival compared to chemotherapy in previously treated HER2-positive gastric cancer. Bystander effect allows activity even with heterogeneous HER2 expression.	treatment_term	treatment_term	$	Trastuzumab Deruxtecan (T-DXd)	Antibody-drug conjugate with anti-HER2 antibody linked to topoisomerase I inhibitor deruxtecan. DESTINY-Gastric01 demonstrated superior overall survival compared to chemotherapy in previously treated HER2-positive gastric cancer. Bystander effect allows activity even with heterogeneous HER2 expression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3120	3399	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	2	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	treatment_term	treatment_term	$	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}]}"				trastuzumab	CHEBI:231601																						
3121	3399	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	2	Trastuzumab plus Pembrolizumab plus Chemotherapy	Combination of HER2-targeted therapy with PD-1 inhibition and chemotherapy. KEYNOTE-811 showed improved response rates with the addition of pembrolizumab to trastuzumab and chemotherapy in first-line HER2-positive gastric cancer.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			trastuzumab	CHEBI:231601	trastuzumab		"{""preferred_term"": ""trastuzumab"", ""term"": {""id"": ""CHEBI:231601"", ""label"": ""trastuzumab""}}"																											
3122	3400	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	3	Ramucirumab plus Paclitaxel	Anti-VEGFR2 antibody ramucirumab with paclitaxel is standard second-line option. May be used regardless of HER2 status but can be combined with T-DXd in sequencing strategies for HER2-positive disease.	treatment_term	treatment_term	$	Ramucirumab plus Paclitaxel	Anti-VEGFR2 antibody ramucirumab with paclitaxel is standard second-line option. May be used regardless of HER2 status but can be combined with T-DXd in sequencing strategies for HER2-positive disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3123	3401	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	treatments	4	Surgical Resection	Gastrectomy with lymph node dissection for resectable disease. Perioperative chemotherapy (FLOT regimen) is standard for locally advanced disease. Role of HER2-targeted therapy in perioperative setting under investigation.	treatment_term	treatment_term	$	Surgical Resection	Gastrectomy with lymph node dissection for resectable disease. Perioperative chemotherapy (FLOT regimen) is standard for locally advanced disease. Role of HER2-targeted therapy in perioperative setting under investigation.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3145	3422	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	0	Respiratory Support	Non-invasive ventilation such as BiPAP may be required for management of hypoventilation, particularly during sleep or respiratory infections.	treatment_term	treatment_term	$	Respiratory Support	Non-invasive ventilation such as BiPAP may be required for management of hypoventilation, particularly during sleep or respiratory infections.	Respiratory support	MAXO:0000950	supportive care		"{""preferred_term"": ""Respiratory support"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3146	3423	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	1	Anticonvulsant Therapy	Seizures are generally responsive to standard anticonvulsant medications. Valproate has been noted as potentially beneficial due to its HIF-1 alpha inhibiting properties.	treatment_term	treatment_term	$	Anticonvulsant Therapy	Seizures are generally responsive to standard anticonvulsant medications. Valproate has been noted as potentially beneficial due to its HIF-1 alpha inhibiting properties.	Anticonvulsant therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Anticonvulsant therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3147	3424	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	2	Physical Therapy	Rehabilitation to address hypotonia, motor delays, and gait abnormalities.	treatment_term	treatment_term	$	Physical Therapy	Rehabilitation to address hypotonia, motor delays, and gait abnormalities.	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3148	3425	143	HIDEA_Syndrome	HIDEA_Syndrome.yaml	treatments	3	Ophthalmologic Management	Regular ophthalmologic evaluation and management of visual impairments including corrective lenses and treatment of strabismus.	treatment_term	treatment_term	$	Ophthalmologic Management	Regular ophthalmologic evaluation and management of visual impairments including corrective lenses and treatment of strabismus.	Ophthalmologic management	MAXO:0000950	supportive care		"{""preferred_term"": ""Ophthalmologic management"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3168	3450	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	0	Surgical Resection	Primary surgery is preferred for oral cavity cancers and selected laryngeal/pharyngeal tumors. Extent depends on tumor stage and location. Reconstruction may be required for adequate margins.	treatment_term	treatment_term	$	Surgical Resection	Primary surgery is preferred for oral cavity cancers and selected laryngeal/pharyngeal tumors. Extent depends on tumor stage and location. Reconstruction may be required for adequate margins.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3169	3451	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	1	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	treatment_term	treatment_term	$	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
3170	3451	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	1	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with radiation therapy is standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal cancers where organ preservation is desired.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
3171	3452	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	2	Cetuximab	EGFR monoclonal antibody approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease. Alternative to cisplatin in patients unable to tolerate platinum.	treatment_term	treatment_term	$	Cetuximab	EGFR monoclonal antibody approved in combination with radiation for locally advanced disease and with chemotherapy for recurrent/metastatic disease. Alternative to cisplatin in patients unable to tolerate platinum.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3172	3453	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	treatments	3	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC as monotherapy or with chemotherapy. Response rates are modest (approximately 15-20% monotherapy).	treatment_term	treatment_term	$	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC as monotherapy or with chemotherapy. Response rates are modest (approximately 15-20% monotherapy).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3189	3473	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	0	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	treatment_term	treatment_term	$	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
3190	3473	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	0	Definitive Chemoradiation	Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
3191	3474	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	1	Transoral Robotic Surgery	Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features.	treatment_term	treatment_term	$	Transoral Robotic Surgery	Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3192	3475	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	2	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease.	treatment_term	treatment_term	$	Immunotherapy	PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3193	3476	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	treatments	3	HPV Vaccination	Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development.	treatment_term	treatment_term	$	HPV Vaccination	Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
3231	3546	148	Hemochromatosis	Hemochromatosis.yaml	treatments	1	Iron Chelation Therapy	"Deferoxamine or oral chelators (deferasirox, deferiprone) are used when phlebotomy is contraindicated or insufficient, such as in patients with anemia.
"	treatment_term	treatment_term	$	Iron Chelation Therapy	"Deferoxamine or oral chelators (deferasirox, deferiprone) are used when phlebotomy is contraindicated or insufficient, such as in patients with anemia.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3232	3547	148	Hemochromatosis	Hemochromatosis.yaml	treatments	2	Dietary Modification	"Avoiding iron supplements, limiting vitamin C intake (which enhances iron absorption), and reducing alcohol consumption to protect the liver.
"	treatment_term	treatment_term	$	Dietary Modification	"Avoiding iron supplements, limiting vitamin C intake (which enhances iron absorption), and reducing alcohol consumption to protect the liver.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
3233	3548	148	Hemochromatosis	Hemochromatosis.yaml	treatments	3	Screening of Family Members	"Genetic testing of first-degree relatives is recommended given the autosomal recessive inheritance pattern and the benefits of early intervention.
"	treatment_term	treatment_term	$	Screening of Family Members	"Genetic testing of first-degree relatives is recommended given the autosomal recessive inheritance pattern and the benefits of early intervention.
"	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
3242	3570	150	Hemophilia B	Hemophilia_B.yaml	treatments	0	Factor IX Replacement	Plasma-derived or recombinant factor IX concentrates for on-demand or prophylactic therapy.	treatment_term	treatment_term	$	Factor IX Replacement	Plasma-derived or recombinant factor IX concentrates for on-demand or prophylactic therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3243	3571	150	Hemophilia B	Hemophilia_B.yaml	treatments	1	Prophylactic Factor IX Replacement	Regular prophylactic dosing to prevent bleeding and arthropathy.	treatment_term	treatment_term	$	Prophylactic Factor IX Replacement	Regular prophylactic dosing to prevent bleeding and arthropathy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3266	3612	151	Hepatitis B	Hepatitis_B.yaml	treatments	0	Antiviral Medications	Includes drugs like tenofovir and entecavir to suppress HBV replication.	treatment_term	treatment_term	$	Antiviral Medications	Includes drugs like tenofovir and entecavir to suppress HBV replication.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3267	3613	151	Hepatitis B	Hepatitis_B.yaml	treatments	1	Interferon Therapy	Boosts the immune system to fight the virus.	treatment_term	treatment_term	$	Interferon Therapy	Boosts the immune system to fight the virus.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3268	3614	151	Hepatitis B	Hepatitis_B.yaml	treatments	2	Liver Transplant	For end-stage liver disease.	treatment_term	treatment_term	$	Liver Transplant	For end-stage liver disease.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
3269	3616	151	Hepatitis B	Hepatitis_B.yaml	treatments	4	Vaccination	Hepatitis B vaccine provides prevention for uninfected individuals.	treatment_term	treatment_term	$	Vaccination	Hepatitis B vaccine provides prevention for uninfected individuals.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
3287	3639	152	Hepatitis C	Hepatitis_C.yaml	treatments	0	Direct-Acting Antivirals (DAAs)	"Oral medications targeting viral proteins (NS3/4A protease, NS5A, NS5B polymerase) with cure rates exceeding 95%. Regimens include sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and others.
"	treatment_term	treatment_term	$	Direct-Acting Antivirals (DAAs)	"Oral medications targeting viral proteins (NS3/4A protease, NS5A, NS5B polymerase) with cure rates exceeding 95%. Regimens include sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and others.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3288	3640	152	Hepatitis C	Hepatitis_C.yaml	treatments	1	Liver Transplantation	"Treatment option for decompensated cirrhosis or hepatocellular carcinoma. DAA therapy post-transplant prevents graft reinfection.
"	treatment_term	treatment_term	$	Liver Transplantation	"Treatment option for decompensated cirrhosis or hepatocellular carcinoma. DAA therapy post-transplant prevents graft reinfection.
"	liver transplantation	MAXO:0001175	liver transplantation		"{""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}"																											
3289	3641	152	Hepatitis C	Hepatitis_C.yaml	treatments	2	Hepatocellular Carcinoma Surveillance	"Regular ultrasound and AFP monitoring in cirrhotic patients for early detection of hepatocellular carcinoma.
"	treatment_term	treatment_term	$	Hepatocellular Carcinoma Surveillance	"Regular ultrasound and AFP monitoring in cirrhotic patients for early detection of hepatocellular carcinoma.
"	surveillance for malignancies	MAXO:0001492	surveillance for malignancies		"{""preferred_term"": ""surveillance for malignancies"", ""term"": {""id"": ""MAXO:0001492"", ""label"": ""surveillance for malignancies""}}"																											
3306	3669	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	0	Atezolizumab plus Bevacizumab	First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices.	treatment_term	treatment_term	$	Atezolizumab plus Bevacizumab	First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3307	3670	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	1	Durvalumab plus Tremelimumab	Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab.	treatment_term	treatment_term	$	Durvalumab plus Tremelimumab	Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3308	3671	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	2	Sorafenib	Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated.	treatment_term	treatment_term	$	Sorafenib	Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3309	3672	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	3	Lenvatinib	Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.	treatment_term	treatment_term	$	Lenvatinib	Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3310	3673	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	4	Surgical Resection	Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant.	treatment_term	treatment_term	$	Surgical Resection	Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3311	3674	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	5	Liver Transplantation	Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability.	treatment_term	treatment_term	$	Liver Transplantation	Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
3312	3675	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	6	Transarterial Chemoembolization (TACE)	Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy.	treatment_term	treatment_term	$	Transarterial Chemoembolization (TACE)	Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3313	3676	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	treatments	7	Radiofrequency/Microwave Ablation	Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function.	treatment_term	treatment_term	$	Radiofrequency/Microwave Ablation	Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function.	ablation therapy	MAXO:0000452	ablation therapy		"{""preferred_term"": ""ablation therapy"", ""term"": {""id"": ""MAXO:0000452"", ""label"": ""ablation therapy""}}"																											
3323	3692	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	0	Risk-Reducing Mastectomy	Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA mutation carriers. Timing and decision require careful counseling about risks, benefits, reconstruction options, and psychological impact.	treatment_term	treatment_term	$	Risk-Reducing Mastectomy	Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA mutation carriers. Timing and decision require careful counseling about risks, benefits, reconstruction options, and psychological impact.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3324	3693	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	1	Risk-Reducing Salpingo-Oophorectomy	Bilateral salpingo-oophorectomy recommended after completion of childbearing (typically age 35-40 for BRCA1, 40-45 for BRCA2). Reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50% when performed premenopausally.	treatment_term	treatment_term	$	Risk-Reducing Salpingo-Oophorectomy	Bilateral salpingo-oophorectomy recommended after completion of childbearing (typically age 35-40 for BRCA1, 40-45 for BRCA2). Reduces ovarian cancer risk by 80-90% and breast cancer risk by approximately 50% when performed premenopausally.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3325	3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	treatment_term	treatment_term	$	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}]}"				olaparib	CHEBI:83766																						
3326	3694	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	2	PARP Inhibitors	PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) exploit synthetic lethality in BRCA-deficient tumors. PARP inhibition blocks single-strand break repair, causing double-strand breaks that cannot be repaired in HR-deficient cells. Approved for breast, ovarian, pancreatic, and prostate cancers with BRCA mutations.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			olaparib	CHEBI:83766	olaparib		"{""preferred_term"": ""olaparib"", ""term"": {""id"": ""CHEBI:83766"", ""label"": ""olaparib""}}"																											
3327	3695	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	3	Enhanced Surveillance	For women who do not undergo prophylactic surgery, enhanced surveillance includes annual breast MRI (starting age 25-30), mammography (starting age 30), and clinical breast exam. No proven effective ovarian cancer screening exists. Consider transvaginal ultrasound and CA-125, though sensitivity is limited.	treatment_term	treatment_term	$	Enhanced Surveillance	For women who do not undergo prophylactic surgery, enhanced surveillance includes annual breast MRI (starting age 25-30), mammography (starting age 30), and clinical breast exam. No proven effective ovarian cancer screening exists. Consider transvaginal ultrasound and CA-125, though sensitivity is limited.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
3328	3696	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	treatments	4	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows risk-reducing interventions and enhanced surveillance. Prenatal and preimplantation genetic testing available.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows risk-reducing interventions and enhanced surveillance. Prenatal and preimplantation genetic testing available.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
3332	3705	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	0	Desmopressin	Vasopressin analog used to control mild bleeding episodes.	treatment_term	treatment_term	$	Desmopressin	Vasopressin analog used to control mild bleeding episodes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3333	3706	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	treatments	1	von Willebrand Factor/Factor VIII Concentrates	Plasma-derived concentrates containing von Willebrand factor and factor VIII for severe bleeding episodes.	treatment_term	treatment_term	$	von Willebrand Factor/Factor VIII Concentrates	Plasma-derived concentrates containing von Willebrand factor and factor VIII for severe bleeding episodes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3352	3736	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	0	Surgical Resection	Removal of the aganglionic segment of the bowel.	treatment_term	treatment_term	$	Surgical Resection	Removal of the aganglionic segment of the bowel.	surgical procedure	MAXO:0000004	surgical procedure	Operative excision of the non-functional aganglionic bowel segment.	"{""description"": ""Operative excision of the non-functional aganglionic bowel segment."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3353	3737	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	1	Pull-Through Procedure	Connecting the normal ganglionated bowel to the anus to restore bowel function.	treatment_term	treatment_term	$	Pull-Through Procedure	Connecting the normal ganglionated bowel to the anus to restore bowel function.	surgical procedure	MAXO:0000004	surgical procedure	Reconstructive operation anastomosing normal ganglionated bowel to the anus.	"{""description"": ""Reconstructive operation anastomosing normal ganglionated bowel to the anus."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3354	3738	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	treatments	2	Ostomy	Temporary or permanent stoma creation to divert fecal flow.	treatment_term	treatment_term	$	Ostomy	Temporary or permanent stoma creation to divert fecal flow.	surgical procedure	MAXO:0000004	surgical procedure	Creation of a stoma to divert fecal flow, used temporarily or permanently.	"{""description"": ""Creation of a stoma to divert fecal flow, used temporarily or permanently."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3383	3750	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	0	Cardiac monitoring and evaluation	"Regular cardiac evaluation and monitoring is essential to detect and manage arrhythmias, conduction abnormalities, and structural defects. This may include ECG, echocardiography, and long-term monitoring. Severe conduction abnormalities may require pacemaker implantation.
"	treatment_term	treatment_term	$	Cardiac monitoring and evaluation	"Regular cardiac evaluation and monitoring is essential to detect and manage arrhythmias, conduction abnormalities, and structural defects. This may include ECG, echocardiography, and long-term monitoring. Severe conduction abnormalities may require pacemaker implantation.
"	cardiac electrophysiologist evaluation	MAXO:0000683	clinical cardiac electrophysiologist evaluation		"{""preferred_term"": ""cardiac electrophysiologist evaluation"", ""term"": {""id"": ""MAXO:0000683"", ""label"": ""clinical cardiac electrophysiologist evaluation""}}"																											
3384	3751	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	1	Surgical repair of cardiac defects	"Surgical intervention may be necessary for significant atrial or ventricular septal defects and other structural abnormalities, depending on severity and hemodynamic significance.
"	treatment_term	treatment_term	$	Surgical repair of cardiac defects	"Surgical intervention may be necessary for significant atrial or ventricular septal defects and other structural abnormalities, depending on severity and hemodynamic significance.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3385	3752	157	Holt-Oram syndrome	Holt_Oram.yaml	treatments	2	Orthopedic management	"Management of upper limb abnormalities may include orthopedic interventions, physical therapy, and adaptive strategies to optimize limb function and mobility.
"	treatment_term	treatment_term	$	Orthopedic management	"Management of upper limb abnormalities may include orthopedic interventions, physical therapy, and adaptive strategies to optimize limb function and mobility.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3389	3760	158	Human African trypanosomiasis	Human_African_Trypanosomiasis.yaml	treatments	0	Fexinidazole therapy	Oral fexinidazole is a first-line therapy for gambiense HAT without severe meningoencephalitic disease.	treatment_term	treatment_term	$	Fexinidazole therapy	Oral fexinidazole is a first-line therapy for gambiense HAT without severe meningoencephalitic disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3427	3796	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	0	Tetrabenazine	Used to manage chorea by depleting dopamine.	treatment_term	treatment_term	$	Tetrabenazine	Used to manage chorea by depleting dopamine.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3428	3797	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	1	Antipsychotic Medications	Used for psychiatric symptoms like irritability and agitation.	treatment_term	treatment_term	$	Antipsychotic Medications	Used for psychiatric symptoms like irritability and agitation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3429	3798	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	2	Selective Serotonin Reuptake Inhibitors (SSRIs)	Used to manage depression.	treatment_term	treatment_term	$	Selective Serotonin Reuptake Inhibitors (SSRIs)	Used to manage depression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3430	3799	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	3	Physical Therapy	Helps maintain mobility and function.	treatment_term	treatment_term	$	Physical Therapy	Helps maintain mobility and function.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3431	3800	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	4	Speech Therapy	Helps manage dysarthria and dysphagia.	treatment_term	treatment_term	$	Speech Therapy	Helps manage dysarthria and dysphagia.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
3432	3801	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	5	Occupational Therapy	Assists with daily living activities.	treatment_term	treatment_term	$	Occupational Therapy	Assists with daily living activities.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
3433	3802	159	Huntington's Disease	Huntingtons_Disease.yaml	treatments	6	Genetic Counseling	Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.	treatment_term	treatment_term	$	Genetic Counseling	Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
3468	3839	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	0	Antihypertensive Therapy	Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease.	treatment_term	treatment_term	$	Antihypertensive Therapy	Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease.	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy		"{""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
3469	3840	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	1	ACE Inhibitors or ARBs	First-line agents that reduce workload on the heart.	treatment_term	treatment_term	$	ACE Inhibitors or ARBs	First-line agents that reduce workload on the heart.	ACE inhibitor therapy	MAXO:0000652	ACE inhibitor therapy		"{""preferred_term"": ""ACE inhibitor therapy"", ""term"": {""id"": ""MAXO:0000652"", ""label"": ""ACE inhibitor therapy""}}"																											
3470	3841	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	2	Beta Blockers	Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction.	treatment_term	treatment_term	$	Beta Blockers	Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction.	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy		"{""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
3471	3842	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	3	Diuretics	Reduce fluid overload and congestion in heart failure.	treatment_term	treatment_term	$	Diuretics	Reduce fluid overload and congestion in heart failure.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3472	3843	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	4	Mineralocorticoid Receptor Antagonists	Further regulate fluid balance and have direct anti-fibrotic effects on the heart.	treatment_term	treatment_term	$	Mineralocorticoid Receptor Antagonists	Further regulate fluid balance and have direct anti-fibrotic effects on the heart.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3473	3844	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	treatments	5	Lifestyle Modifications	Sodium restriction, physical activity, stress reduction, and other supportive measures.	treatment_term	treatment_term	$	Lifestyle Modifications	Sodium restriction, physical activity, stress reduction, and other supportive measures.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
3515	3878	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	0	Beta Blockers	Used to reduce heart rate and improve symptoms	treatment_term	treatment_term	$	Beta Blockers	Used to reduce heart rate and improve symptoms	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy		"{""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
3516	3879	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	1	Calcium Channel Blockers	Help to relax heart muscle and improve blood flow	treatment_term	treatment_term	$	Calcium Channel Blockers	Help to relax heart muscle and improve blood flow	calcium channel blocking agent therapy	MAXO:0000434	calcium channel blocking agent therapy		"{""preferred_term"": ""calcium channel blocking agent therapy"", ""term"": {""id"": ""MAXO:0000434"", ""label"": ""calcium channel blocking agent therapy""}}"																											
3517	3880	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	2	Septal Myectomy	Surgical removal of part of the thickened heart muscle	treatment_term	treatment_term	$	Septal Myectomy	Surgical removal of part of the thickened heart muscle	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3518	3881	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	3	Alcohol Septal Ablation	Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle	treatment_term	treatment_term	$	Alcohol Septal Ablation	Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3519	3882	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	treatments	4	Implantable Cardioverter Defibrillator (ICD)	Prevents sudden cardiac death in high-risk patients	treatment_term	treatment_term	$	Implantable Cardioverter Defibrillator (ICD)	Prevents sudden cardiac death in high-risk patients	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3542	3902	163	Hypochondroplasia	Hypochondroplasia.yaml	treatments	0	Growth hormone therapy	"Recombinant human growth hormone has been used in some cases with variable response. Effects on final adult height are modest and its use remains controversial.
"	treatment_term	treatment_term	$	Growth hormone therapy	"Recombinant human growth hormone has been used in some cases with variable response. Effects on final adult height are modest and its use remains controversial.
"	Growth hormone therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""Growth hormone therapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3543	3903	163	Hypochondroplasia	Hypochondroplasia.yaml	treatments	1	Orthopedic management	"Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant.
"	treatment_term	treatment_term	$	Orthopedic management	"Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3556	3921	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	0	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	treatment_term	treatment_term	$	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ivosidenib"", ""term"": {""id"": ""CHEBI:145430"", ""label"": ""ivosidenib""}}]}"				ivosidenib	CHEBI:145430																						
3557	3921	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	0	Ivosidenib	Selective IDH1 inhibitor approved for newly diagnosed and relapsed/refractory IDH1-mutated AML. Induces differentiation of leukemic blasts by reducing 2-HG levels. Can be used as monotherapy or combined with azacitidine. Differentiation syndrome is a manageable toxicity.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ivosidenib	CHEBI:145430	ivosidenib		"{""preferred_term"": ""ivosidenib"", ""term"": {""id"": ""CHEBI:145430"", ""label"": ""ivosidenib""}}"																											
3558	3922	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	1	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	treatment_term	treatment_term	$	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""enasidenib"", ""term"": {""id"": ""CHEBI:145374"", ""label"": ""enasidenib""}}]}"				enasidenib	CHEBI:145374																						
3559	3922	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	1	Enasidenib	Selective IDH2 inhibitor approved for relapsed/refractory IDH2-mutated AML. Induces differentiation by suppressing 2-HG production. Effective in patients who have failed multiple prior therapies. Differentiation syndrome requires monitoring.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			enasidenib	CHEBI:145374	enasidenib		"{""preferred_term"": ""enasidenib"", ""term"": {""id"": ""CHEBI:145374"", ""label"": ""enasidenib""}}"																											
3560	3923	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	2	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	treatment_term	treatment_term	$	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
3561	3923	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	2	Venetoclax plus Azacitidine	BCL2 inhibitor venetoclax with hypomethylating agent is effective in IDH-mutated AML, which is particularly sensitive to this combination. IDH mutations may predict enhanced venetoclax sensitivity.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
3562	3924	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	3	Intensive Chemotherapy (7+3)	Standard induction chemotherapy achieves complete remission in many IDH-mutated AML patients. Can be combined with IDH inhibitors for enhanced efficacy.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3)	Standard induction chemotherapy achieves complete remission in many IDH-mutated AML patients. Can be combined with IDH inhibitors for enhanced efficacy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3563	3925	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	treatments	4	Allogeneic Stem Cell Transplantation	Consolidation option for eligible patients in first remission, particularly those with adverse risk features beyond IDH mutation alone.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Consolidation option for eligible patients in first remission, particularly those with adverse risk features beyond IDH mutation alone.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
3576	3943	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	0	Maximal Safe Resection	Surgical resection maximizing extent of resection while preserving neurological function is the initial treatment. Greater extent of resection correlates with improved outcomes.	treatment_term	treatment_term	$	Maximal Safe Resection	Surgical resection maximizing extent of resection while preserving neurological function is the initial treatment. Greater extent of resection correlates with improved outcomes.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3577	3944	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	1	Radiation Therapy	External beam radiation therapy is standard adjuvant treatment. Timing may be delayed in lower-grade tumors with favorable prognostic factors.	treatment_term	treatment_term	$	Radiation Therapy	External beam radiation therapy is standard adjuvant treatment. Timing may be delayed in lower-grade tumors with favorable prognostic factors.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3578	3945	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	2	Temozolomide Chemotherapy	Alkylating chemotherapy with temozolomide is used adjuvantly and at recurrence. MGMT promoter methylation predicts response but is common in IDH-mutant tumors.	treatment_term	treatment_term	$	Temozolomide Chemotherapy	Alkylating chemotherapy with temozolomide is used adjuvantly and at recurrence. MGMT promoter methylation predicts response but is common in IDH-mutant tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3579	3946	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	treatments	3	Vorasidenib (IDH1/2 Inhibitor)	Brain-penetrant dual IDH1/2 inhibitor approved for grade 2 IDH-mutant gliomas. INDIGO trial demonstrated significant improvement in progression-free survival. Represents first targeted therapy for this tumor type.	treatment_term	treatment_term	$	Vorasidenib (IDH1/2 Inhibitor)	Brain-penetrant dual IDH1/2 inhibitor approved for grade 2 IDH-mutant gliomas. INDIGO trial demonstrated significant improvement in progression-free survival. Represents first targeted therapy for this tumor type.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3592	3966	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	0	Ivosidenib	Selective small molecule inhibitor of mutant IDH1 approved for previously treated IDH1-mutant cholangiocarcinoma. ClarIDHy trial demonstrated improved progression-free survival compared to placebo (2.7 vs 1.4 months) with manageable toxicity and maintenance of quality of life.	treatment_term	treatment_term	$	Ivosidenib	Selective small molecule inhibitor of mutant IDH1 approved for previously treated IDH1-mutant cholangiocarcinoma. ClarIDHy trial demonstrated improved progression-free survival compared to placebo (2.7 vs 1.4 months) with manageable toxicity and maintenance of quality of life.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3593	3967	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	1	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma regardless of IDH status. ABC-02 trial established this combination as standard of care. IDH-mutant tumors may have similar or slightly better chemotherapy response.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin	First-line standard chemotherapy for advanced cholangiocarcinoma regardless of IDH status. ABC-02 trial established this combination as standard of care. IDH-mutant tumors may have similar or slightly better chemotherapy response.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3594	3968	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	2	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin improves survival in first-line treatment of biliary tract cancers (TOPAZ-1 trial). Now standard first-line treatment for advanced cholangiocarcinoma.	treatment_term	treatment_term	$	Gemcitabine plus Cisplatin plus Durvalumab	Addition of anti-PD-L1 durvalumab to gemcitabine/cisplatin improves survival in first-line treatment of biliary tract cancers (TOPAZ-1 trial). Now standard first-line treatment for advanced cholangiocarcinoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3595	3969	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	treatments	3	Surgical Resection	Surgery offers the only chance for cure in cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. Limited by advanced stage at presentation in most patients.	treatment_term	treatment_term	$	Surgical Resection	Surgery offers the only chance for cure in cholangiocarcinoma. Hepatectomy with adequate margins for intrahepatic tumors. Limited by advanced stage at presentation in most patients.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3608	3988	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	0	Maximal Safe Resection	Surgical resection aims to maximize extent of resection while preserving function. Complete resection associated with improved survival and seizure control.	treatment_term	treatment_term	$	Maximal Safe Resection	Surgical resection aims to maximize extent of resection while preserving function. Complete resection associated with improved survival and seizure control.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3609	3989	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	1	Radiation Therapy	External beam radiation is standard for anaplastic oligodendroglioma. For grade 2 tumors, timing of radiation may be deferred in favorable cases.	treatment_term	treatment_term	$	Radiation Therapy	External beam radiation is standard for anaplastic oligodendroglioma. For grade 2 tumors, timing of radiation may be deferred in favorable cases.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3610	3990	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	2	PCV Chemotherapy	Procarbazine, CCNU (lomustine), and vincristine (PCV) combination chemotherapy shows exceptional efficacy in 1p/19q-codeleted oligodendrogliomas. RTOG 9402 and EORTC 26951 trials demonstrated major survival benefit for PCV added to radiation in anaplastic oligodendroglioma.	treatment_term	treatment_term	$	PCV Chemotherapy	Procarbazine, CCNU (lomustine), and vincristine (PCV) combination chemotherapy shows exceptional efficacy in 1p/19q-codeleted oligodendrogliomas. RTOG 9402 and EORTC 26951 trials demonstrated major survival benefit for PCV added to radiation in anaplastic oligodendroglioma.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3611	3991	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	treatments	3	Temozolomide Chemotherapy	Temozolomide is an alternative to PCV with better tolerability. Often used concurrently with radiation followed by adjuvant cycles. Efficacy appears similar to PCV in 1p/19q-codeleted tumors.	treatment_term	treatment_term	$	Temozolomide Chemotherapy	Temozolomide is an alternative to PCV with better tolerability. Often used concurrently with radiation followed by adjuvant cycles. Efficacy appears similar to PCV in 1p/19q-codeleted tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3635	4030	170	Infectious Disease	Infectious_Disease.yaml	treatments	0	Vaccination	Vaccines are key preventive strategies against infectious pathogens.	treatment_term	treatment_term	$	Vaccination	Vaccines are key preventive strategies against infectious pathogens.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
3636	4031	170	Infectious Disease	Infectious_Disease.yaml	treatments	1	Antimicrobial Therapy	Antimicrobial drugs are used to treat infections caused by pathogens.	treatment_term	treatment_term	$	Antimicrobial Therapy	Antimicrobial drugs are used to treat infections caused by pathogens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3669	4073	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Surgical correction of craniosynostosis when clinically indicated.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Surgical correction of craniosynostosis when clinically indicated.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3670	4074	172	Jackson-Weiss Syndrome	Jackson-Weiss_Syndrome.yaml	treatments	1	Foot Surgery	"Surgical management of foot deformities if causing functional problems.
"	treatment_term	treatment_term	$	Foot Surgery	"Surgical management of foot deformities if causing functional problems.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3682	4101	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	0	Valproic Acid	First-line treatment, effective in controlling seizures in many patients.	treatment_term	treatment_term	$	Valproic Acid	First-line treatment, effective in controlling seizures in many patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy	First-line anticonvulsant treatment using valproic acid for seizure control.	"{""description"": ""First-line anticonvulsant treatment using valproic acid for seizure control."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3683	4102	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	1	Ethosuximide	May be used as an alternative or adjunctive therapy.	treatment_term	treatment_term	$	Ethosuximide	May be used as an alternative or adjunctive therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Anticonvulsant treatment primarily targeting absence seizures.	"{""description"": ""Anticonvulsant treatment primarily targeting absence seizures."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3684	4103	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	2	Levetiracetam	May be used as an alternative or adjunctive therapy.	treatment_term	treatment_term	$	Levetiracetam	May be used as an alternative or adjunctive therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Broad-spectrum anticonvulsant that may be used as alternative or adjunctive therapy.	"{""description"": ""Broad-spectrum anticonvulsant that may be used as alternative or adjunctive therapy."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3685	4104	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	3	Avoidance of Provocative Stimuli	Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.	treatment_term	treatment_term	$	Avoidance of Provocative Stimuli	Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.	medical action avoidance	MAXO:0001014	medical action avoidance	Behavioral intervention to avoid exposure to known seizure triggers.	"{""description"": ""Behavioral intervention to avoid exposure to known seizure triggers."", ""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}"																											
3686	4105	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	4	Avoidance of Triggering Stimuli	Minimizing exposure to known triggers such as flashing lights or sleep deprivation.	treatment_term	treatment_term	$	Avoidance of Triggering Stimuli	Minimizing exposure to known triggers such as flashing lights or sleep deprivation.	medical action avoidance	MAXO:0001014	medical action avoidance	Lifestyle modification to minimize exposure to photic and other seizure triggers.	"{""description"": ""Lifestyle modification to minimize exposure to photic and other seizure triggers."", ""preferred_term"": ""medical action avoidance"", ""term"": {""id"": ""MAXO:0001014"", ""label"": ""medical action avoidance""}}"																											
3687	4106	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	treatments	5	Sunglasses or Blue Light Filtering Glasses	Wear to reduce light sensitivity and potentially prevent seizures.	treatment_term	treatment_term	$	Sunglasses or Blue Light Filtering Glasses	Wear to reduce light sensitivity and potentially prevent seizures.	supportive care	MAXO:0000950	supportive care	Use of protective eyewear to reduce light-induced seizure triggers.	"{""description"": ""Use of protective eyewear to reduce light-induced seizure triggers."", ""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3698	4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	treatment_term	treatment_term	$	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				imatinib	CHEBI:45783																						
3699	4121	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	0	Imatinib	Tyrosine kinase inhibitor with activity against KIT, ABL, and PDGFR. Shows clinical benefit in KIT-mutant melanoma, particularly for exon 11 and 13 mutations. Response rates of approximately 20-30% with meaningful disease stabilization in additional patients.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
3700	4122	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	1	Nilotinib	Second-generation KIT inhibitor with increased potency compared to imatinib. May have activity in some imatinib-resistant cases depending on the specific mutation conferring resistance.	treatment_term	treatment_term	$	Nilotinib	Second-generation KIT inhibitor with increased potency compared to imatinib. May have activity in some imatinib-resistant cases depending on the specific mutation conferring resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3701	4123	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	2	Dasatinib	Multi-kinase inhibitor with activity against KIT, ABL, and SRC family kinases. Has demonstrated activity in KIT-mutant melanoma in clinical trials.	treatment_term	treatment_term	$	Dasatinib	Multi-kinase inhibitor with activity against KIT, ABL, and SRC family kinases. Has demonstrated activity in KIT-mutant melanoma in clinical trials.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3702	4124	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) are also used in KIT-mutant melanoma. The optimal sequencing of KIT inhibitors versus immunotherapy depends on mutation status and patient characteristics.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) are also used in KIT-mutant melanoma. The optimal sequencing of KIT inhibitors versus immunotherapy depends on mutation status and patient characteristics.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3713	4140	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	0	Sotorasib	First-in-class KRAS G12C inhibitor. Covalently binds mutant cysteine in the GDP-bound inactive state, locking KRAS in the off position. FDA approved for previously treated KRAS G12C NSCLC based on CodeBreaK 100 trial.	treatment_term	treatment_term	$	Sotorasib	First-in-class KRAS G12C inhibitor. Covalently binds mutant cysteine in the GDP-bound inactive state, locking KRAS in the off position. FDA approved for previously treated KRAS G12C NSCLC based on CodeBreaK 100 trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3714	4141	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	1	Adagrasib	Second KRAS G12C inhibitor to gain FDA approval. Has longer half-life than sotorasib and demonstrated intracranial activity. Approved based on KRYSTAL-1 trial.	treatment_term	treatment_term	$	Adagrasib	Second KRAS G12C inhibitor to gain FDA approval. Has longer half-life than sotorasib and demonstrated intracranial activity. Approved based on KRYSTAL-1 trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3715	4142	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	2	KRAS G12C Inhibitor Combinations	Combinations with SHP2 inhibitors, SOS1 inhibitors, or EGFR inhibitors are being explored to prevent adaptive resistance and improve response durability. Rational combinations target feedback reactivation of RTK-RAS signaling.	treatment_term	treatment_term	$	KRAS G12C Inhibitor Combinations	Combinations with SHP2 inhibitors, SOS1 inhibitors, or EGFR inhibitors are being explored to prevent adaptive resistance and improve response durability. Rational combinations target feedback reactivation of RTK-RAS signaling.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3716	4143	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors (pembrolizumab, nivolumab) are used for KRAS-mutant NSCLC, particularly those without STK11 co-mutation. KRAS-mutant tumors often have high TMB from smoking. Combination with KRAS G12C inhibitors is under investigation.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors (pembrolizumab, nivolumab) are used for KRAS-mutant NSCLC, particularly those without STK11 co-mutation. KRAS-mutant tumors often have high TMB from smoking. Combination with KRAS G12C inhibitors is under investigation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3717	4144	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy remains standard for patients who progress on targeted therapy or as first-line with immunotherapy.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy remains standard for patients who progress on targeted therapy or as first-line with immunotherapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
3734	4166	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	0	Antiretroviral Therapy	For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment.	treatment_term	treatment_term	$	Antiretroviral Therapy	For AIDS-associated KS, initiation or optimization of antiretroviral therapy (ART) is the most important intervention. Immune reconstitution leads to regression in many cases without KS-specific treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3735	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term	treatment_term	$	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}, {""preferred_term"": ""paclitaxel"", ""term"": {""id"": ""CHEBI:45863"", ""label"": ""paclitaxel""}}]}"				doxorubicin; paclitaxel	CHEBI:28748; CHEBI:45863																						
3736	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
3737	4167	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	1	Chemotherapy	For advanced or rapidly progressive disease, liposomal doxorubicin or paclitaxel are first-line systemic chemotherapies. Reserved for patients with visceral involvement or disease not controlled by ART.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			paclitaxel	CHEBI:45863	paclitaxel		"{""preferred_term"": ""paclitaxel"", ""term"": {""id"": ""CHEBI:45863"", ""label"": ""paclitaxel""}}"																											
3738	4168	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	2	Local Therapy	Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis.	treatment_term	treatment_term	$	Local Therapy	Localized lesions may be treated with radiation, intralesional chemotherapy, cryotherapy, or surgical excision for palliation or cosmesis.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
3739	4169	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	treatments	3	Reduction of Immunosuppression	For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression.	treatment_term	treatment_term	$	Reduction of Immunosuppression	For iatrogenic KS in transplant recipients, reduction or modification of immunosuppressive therapy may lead to regression. Switching to sirolimus (mTOR inhibitor) may have anti-tumor effects in addition to immunosuppression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3769	4214	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	0	Intravenous Immunoglobulin (IVIG)	First-line treatment to reduce inflammation and risk of coronary artery complications.	treatment_term	treatment_term	$	Intravenous Immunoglobulin (IVIG)	First-line treatment to reduce inflammation and risk of coronary artery complications.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment of disease through the administration of medications.	"{""description"": ""Treatment of disease through the administration of medications."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3770	4215	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	1	Aspirin	Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.	treatment_term	treatment_term	$	Aspirin	Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy	Treatment using medications that affect the cardiovascular system, including antiplatelet agents.	"{""description"": ""Treatment using medications that affect the cardiovascular system, including antiplatelet agents."", ""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
3771	4216	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	2	Anakinra	IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.	treatment_term	treatment_term	$	Anakinra	IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using IL-1 pathway inhibition for refractory inflammation.	"{""description"": ""Treatment using IL-1 pathway inhibition for refractory inflammation."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3772	4217	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	3	Cyclosporine	Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.	treatment_term	treatment_term	$	Cyclosporine	Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using calcineurin inhibition to reduce T-cell activation.	"{""description"": ""Treatment using calcineurin inhibition to reduce T-cell activation."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3773	4218	177	Kawasaki Disease	Kawasaki_Disease.yaml	treatments	4	Corticosteroids	Used in cases resistant to IVIG or with severe inflammation.	treatment_term	treatment_term	$	Corticosteroids	Used in cases resistant to IVIG or with severe inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using corticosteroids to reduce inflammation in refractory cases.	"{""description"": ""Treatment using corticosteroids to reduce inflammation in refractory cases."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3823	4271	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	0	Testosterone Replacement Therapy	Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido.	treatment_term	treatment_term	$	Testosterone Replacement Therapy	Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
3824	4272	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	1	Educational Support	Special education services and speech therapy to improve language and academic skills.	treatment_term	treatment_term	$	Educational Support	Special education services and speech therapy to improve language and academic skills.	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
3825	4273	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	2	Fertility Treatment	Assisted reproductive technologies such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) may help those who wish to have children.	treatment_term	treatment_term	$	Fertility Treatment	Assisted reproductive technologies such as testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) may help those who wish to have children.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3826	4274	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	3	Psychological Support	Counseling and psychological support to address social, emotional, and behavioral challenges.	treatment_term	treatment_term	$	Psychological Support	Counseling and psychological support to address social, emotional, and behavioral challenges.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
3827	4275	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	treatments	4	Multidisciplinary Care	Comprehensive monitoring for metabolic, cardiovascular, and bone health complications.	treatment_term	treatment_term	$	Multidisciplinary Care	Comprehensive monitoring for metabolic, cardiovascular, and bone health complications.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
3842	4289	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	0	Orthopedic Management	"Management of joint contractures, spinal abnormalities, and hip dysplasia. Physical therapy to maintain joint mobility.
"	treatment_term	treatment_term	$	Orthopedic Management	"Management of joint contractures, spinal abnormalities, and hip dysplasia. Physical therapy to maintain joint mobility.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3843	4292	180	Kniest Dysplasia	Kniest_Dysplasia.yaml	treatments	3	Cleft Palate Repair	"Surgical repair of cleft palate in affected individuals.
"	treatment_term	treatment_term	$	Cleft Palate Repair	"Surgical repair of cleft palate in affected individuals.
"	Cleft repair surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3867	4314	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	0	Gluten-free diet	"Elimination of gluten from diet is foundational therapy for Lane Hamilton Syndrome, as it addresses the underlying celiac disease trigger. Many LHS cases achieve remission or significant improvement with strict, lifelong gluten-free diet adherence. Relapse commonly occurs with dietary nonadherence, emphasizing the critical importance of sustained dietary compliance for disease control.
"	treatment_term	treatment_term	$	Gluten-free diet	"Elimination of gluten from diet is foundational therapy for Lane Hamilton Syndrome, as it addresses the underlying celiac disease trigger. Many LHS cases achieve remission or significant improvement with strict, lifelong gluten-free diet adherence. Relapse commonly occurs with dietary nonadherence, emphasizing the critical importance of sustained dietary compliance for disease control.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
3868	4315	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	1	Corticosteroids	"Systemic corticosteroids are commonly used as first-line therapy for acute diffuse alveolar hemorrhage or when gluten-free diet alone is insufficient. Approximately 95% of IPH/LHS patients receive corticosteroids for acute management, though 60% of LHS patients may be discharged on gluten-free diet alone without steroids after stabilization. Corticosteroids are particularly important during acute exacerbations or in severe presentations.
"	treatment_term	treatment_term	$	Corticosteroids	"Systemic corticosteroids are commonly used as first-line therapy for acute diffuse alveolar hemorrhage or when gluten-free diet alone is insufficient. Approximately 95% of IPH/LHS patients receive corticosteroids for acute management, though 60% of LHS patients may be discharged on gluten-free diet alone without steroids after stabilization. Corticosteroids are particularly important during acute exacerbations or in severe presentations.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3869	4316	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	treatments	2	Immunosuppressive therapy	"Steroid-sparing agents such as azathioprine have been used in selected cases of Lane Hamilton Syndrome for long-term management or when corticosteroid monotherapy is insufficient. These agents allow reduction of corticosteroid exposure and may be considered in patients with frequent relapses or corticosteroid-dependent disease.
"	treatment_term	treatment_term	$	Immunosuppressive therapy	"Steroid-sparing agents such as azathioprine have been used in selected cases of Lane Hamilton Syndrome for long-term management or when corticosteroid monotherapy is insufficient. These agents allow reduction of corticosteroid exposure and may be considered in patients with frequent relapses or corticosteroid-dependent disease.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3915	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term	treatment_term	$	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																			Laser Surgery	NCIT:C15268	NCIT:C15329						
3916	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
3917	4356	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	0	Endoscopic laser repair (type 1)	Endoscopic laser repair used for type 1 laryngeal clefts.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser surgery	NCIT:C15268	Laser Surgery		"{""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}"																											
3918	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term	treatment_term	$	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	laser surgical procedure	MAXO:0001578	laser surgical procedure		"{""preferred_term"": ""laser surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""carbon dioxide"", ""term"": {""id"": ""NCIT:C65288"", ""label"": ""Carbon Dioxide""}}}], ""term"": {""id"": ""MAXO:0001578"", ""label"": ""laser surgical procedure""}}"																			Laser Surgery	NCIT:C15268	NCIT:C15329	Carbon Dioxide	NCIT:C65288	NCIT:C2259			
3919	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
3920	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			laser surgery	NCIT:C15268	Laser Surgery		"{""preferred_term"": ""laser surgery"", ""term"": {""id"": ""NCIT:C15268"", ""label"": ""Laser Surgery""}}"																											
3921	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
3922	4357	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	1	Endoscopic CO2 laser repair (type 3)	Staged endoscopic CO2 laser-assisted repair for type 3 clefts.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			carbon dioxide	NCIT:C65288	Carbon Dioxide		"{""preferred_term"": ""carbon dioxide"", ""term"": {""id"": ""NCIT:C65288"", ""label"": ""Carbon Dioxide""}}"																											
3923	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term	treatment_term	$	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""hyaluronic acid"", ""term"": {""id"": ""CHEBI:16336"", ""label"": ""hyaluronic acid""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																						hyaluronic acid	CHEBI:16336	NCIT:C2259			
3924	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
3925	4358	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	2	Injection laryngoplasty	Injection laryngoplasty used as a diagnostic or temporizing intervention in laryngeal cleft.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			hyaluronic acid	CHEBI:16336	hyaluronic acid		"{""preferred_term"": ""hyaluronic acid"", ""term"": {""id"": ""CHEBI:16336"", ""label"": ""hyaluronic acid""}}"																											
3926	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term	treatment_term	$	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""NCIT:C16546"", ""label"": ""Endoscopic Procedure""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																			Endoscopic Procedure	NCIT:C16546	NCIT:C15329						
3927	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
3928	4359	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	3	Surgical repair of laryngeal cleft	Operative repair of laryngeal cleft improves aspiration symptoms.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			endoscopic procedure	NCIT:C16546	Endoscopic Procedure		"{""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""NCIT:C16546"", ""label"": ""Endoscopic Procedure""}}"																											
3929	4360	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	4	Anterior laryngofissure repair with posterior cartilage grafting	Anterior approach surgical repair with posterior cartilage grafting for type III/IV LTEC.	treatment_term	treatment_term	$	Anterior laryngofissure repair with posterior cartilage grafting	Anterior approach surgical repair with posterior cartilage grafting for type III/IV LTEC.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3930	4361	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	treatments	5	Combined open and endoscopic repair for long clefts	Combined open and endoscopic approaches may be required for long clefts with tracheal extension.	treatment_term	treatment_term	$	Combined open and endoscopic repair for long clefts	Combined open and endoscopic approaches may be required for long clefts with tracheal extension.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3937	4369	183	Leishmaniasis	Leishmaniasis.yaml	treatments	0	Liposomal amphotericin B therapy	Liposomal amphotericin B is a standard therapy for visceral leishmaniasis in many regions.	treatment_term	treatment_term	$	Liposomal amphotericin B therapy	Liposomal amphotericin B is a standard therapy for visceral leishmaniasis in many regions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3941	4376	184	Leprosy	Leprosy.yaml	treatments	0	Multidrug therapy with rifampicin, dapsone, and clofazimine	Multidrug therapy includes rifampicin, dapsone, and clofazimine for multibacillary disease.	treatment_term	treatment_term	$	Multidrug therapy with rifampicin, dapsone, and clofazimine	Multidrug therapy includes rifampicin, dapsone, and clofazimine for multibacillary disease.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
3956	4394	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	0	Cancer Surveillance Protocol	Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood.	treatment_term	treatment_term	$	Cancer Surveillance Protocol	Intensive cancer surveillance (Toronto Protocol) includes annual whole-body MRI, brain MRI, breast MRI (women), abdominal ultrasound, and biochemical markers. Early detection significantly improves outcomes. Surveillance should begin in childhood.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
3957	4395	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	1	Risk-Reducing Mastectomy	Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits.	treatment_term	treatment_term	$	Risk-Reducing Mastectomy	Prophylactic bilateral mastectomy may be considered for women with LFS given the extremely high lifetime breast cancer risk (85-90%). Decision requires careful counseling about risks and benefits.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
3958	4396	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	treatments	2	Genetic Counseling	Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling is essential for affected families to discuss inheritance, testing of at-risk relatives, reproductive options, and psychological support. Cascade testing of family members is recommended.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
4026	4478	188	Long COVID	Long_COVID.yaml	treatments	1	Symptom-directed Pharmacotherapy	"Medications targeting specific symptoms such as beta-blockers for tachycardia, antihistamines for mast cell activation, and low-dose naltrexone for neuroinflammation.
"	treatment_term	treatment_term	$	Symptom-directed Pharmacotherapy	"Medications targeting specific symptoms such as beta-blockers for tachycardia, antihistamines for mast cell activation, and low-dose naltrexone for neuroinflammation.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4027	4479	188	Long COVID	Long_COVID.yaml	treatments	2	Rehabilitation Therapy	"Physical therapy, occupational therapy, and cognitive rehabilitation tailored to individual tolerance.
"	treatment_term	treatment_term	$	Rehabilitation Therapy	"Physical therapy, occupational therapy, and cognitive rehabilitation tailored to individual tolerance.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
4028	4480	188	Long COVID	Long_COVID.yaml	treatments	3	Antihistamine Therapy	"H1 and H2 receptor antagonists (such as fexofenadine and famotidine) to address mast cell activation symptoms.
"	treatment_term	treatment_term	$	Antihistamine Therapy	"H1 and H2 receptor antagonists (such as fexofenadine and famotidine) to address mast cell activation symptoms.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4055	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term	treatment_term	$	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tracheostomy"", ""term"": {""id"": ""NCIT:C50458"", ""label"": ""Tracheostomy""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																									Tracheostomy	NCIT:C50458	NCIT:C49236
4056	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
4057	4505	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	0	Airway Protection (Tracheostomy or Secured Airway)	Early airway control including elective tracheostomy when obstruction risk is high.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			tracheostomy	NCIT:C50458	Tracheostomy		"{""preferred_term"": ""tracheostomy"", ""term"": {""id"": ""NCIT:C50458"", ""label"": ""Tracheostomy""}}"																											
4058	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term	treatment_term	$	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Broad Spectrum Antibiotic	NCIT:C2883	NCIT:C2259			
4059	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
4060	4506	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	1	Broad-Spectrum Intravenous Antibiotics	Empiric IV antibiotics targeting polymicrobial oral flora.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			broad spectrum antibiotic	NCIT:C2883	Broad Spectrum Antibiotic		"{""preferred_term"": ""broad spectrum antibiotic"", ""term"": {""id"": ""NCIT:C2883"", ""label"": ""Broad Spectrum Antibiotic""}}"																											
4061	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term	treatment_term	$	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""drainage procedure"", ""term"": {""id"": ""NCIT:C15286"", ""label"": ""Drainage Procedure""}}}, {""predicate"": {""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}, ""value"": {""preferred_term"": ""tooth extraction"", ""term"": {""id"": ""NCIT:C5189"", ""label"": ""Tooth Extraction""}}}], ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																									Drainage Procedure; Tooth Extraction	NCIT:C15286; NCIT:C5189	NCIT:C49236
4062	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
4063	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			drainage procedure	NCIT:C15286	Drainage Procedure		"{""preferred_term"": ""drainage procedure"", ""term"": {""id"": ""NCIT:C15286"", ""label"": ""Drainage Procedure""}}"																											
4064	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic procedure	NCIT:C49236	Therapeutic Procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""NCIT:C49236"", ""label"": ""Therapeutic Procedure""}}"																											
4065	4507	189	Ludwig's Angina	Ludwigs_Angina.yaml	treatments	2	Surgical Drainage and Odontogenic Source Control	Drain involved spaces and extract offending tooth to halt infection spread.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			tooth extraction	NCIT:C5189	Tooth Extraction		"{""preferred_term"": ""tooth extraction"", ""term"": {""id"": ""NCIT:C5189"", ""label"": ""Tooth Extraction""}}"																											
4075	4518	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	0	Chemotherapy	Systemic chemotherapy, particularly for small cell lung cancer.	treatment_term	treatment_term	$	Chemotherapy	Systemic chemotherapy, particularly for small cell lung cancer.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4076	4519	190	Lung Carcinoma	Lung_Carcinoma.yaml	treatments	1	Surgical Resection	Surgical removal of localized non-small cell lung carcinoma.	treatment_term	treatment_term	$	Surgical Resection	Surgical removal of localized non-small cell lung carcinoma.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4105	4555	191	Lyme Disease	Lyme_Disease.yaml	treatments	0	Oral Doxycycline	"First-line treatment for early localized and early disseminated Lyme disease in adults. Typical dose is 100mg twice daily for 10-21 days. Also provides prophylaxis for tick bites in endemic areas.
"	treatment_term	treatment_term	$	Oral Doxycycline	"First-line treatment for early localized and early disseminated Lyme disease in adults. Typical dose is 100mg twice daily for 10-21 days. Also provides prophylaxis for tick bites in endemic areas.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4106	4556	191	Lyme Disease	Lyme_Disease.yaml	treatments	1	Oral Amoxicillin	"Alternative first-line agent for early Lyme disease, preferred in children under 8 years and pregnant women. Typical dose is 500mg three times daily.
"	treatment_term	treatment_term	$	Oral Amoxicillin	"Alternative first-line agent for early Lyme disease, preferred in children under 8 years and pregnant women. Typical dose is 500mg three times daily.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4107	4557	191	Lyme Disease	Lyme_Disease.yaml	treatments	2	Intravenous Ceftriaxone	"Recommended for neurological Lyme disease (neuroborreliosis), Lyme carditis with high-degree AV block, and some cases of Lyme arthritis. Duration typically 14-28 days.
"	treatment_term	treatment_term	$	Intravenous Ceftriaxone	"Recommended for neurological Lyme disease (neuroborreliosis), Lyme carditis with high-degree AV block, and some cases of Lyme arthritis. Duration typically 14-28 days.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4116	4567	192	Lymphatic filariasis	Lymphatic_Filariasis.yaml	treatments	0	Mass drug administration with albendazole plus ivermectin or DEC	WHO-recommended antifilarial drug combinations used to interrupt transmission.	treatment_term	treatment_term	$	Mass drug administration with albendazole plus ivermectin or DEC	WHO-recommended antifilarial drug combinations used to interrupt transmission.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4125	4577	193	Lymphoma	Lymphoma.yaml	treatments	0	Chemotherapy	Systemic chemotherapy regimens tailored to lymphoma subtype.	treatment_term	treatment_term	$	Chemotherapy	Systemic chemotherapy regimens tailored to lymphoma subtype.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4126	4578	193	Lymphoma	Lymphoma.yaml	treatments	1	Radiation Therapy	Radiotherapy combined with chemotherapy for selected lymphoma subtypes.	treatment_term	treatment_term	$	Radiation Therapy	Radiotherapy combined with chemotherapy for selected lymphoma subtypes.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4175	4610	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	1	Prophylactic Surgery	Preventive removal of the colon, uterus, or ovaries may be considered in some cases.	treatment_term	treatment_term	$	Prophylactic Surgery	Preventive removal of the colon, uterus, or ovaries may be considered in some cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4176	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	treatment_term	treatment_term	$	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acetylsalicylic acid"", ""term"": {""id"": ""CHEBI:15365"", ""label"": ""acetylsalicylic acid""}}]}"				acetylsalicylic acid	CHEBI:15365																						
4177	4611	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	2	Chemoprevention	Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			acetylsalicylic acid	CHEBI:15365	acetylsalicylic acid		"{""preferred_term"": ""acetylsalicylic acid"", ""term"": {""id"": ""CHEBI:15365"", ""label"": ""acetylsalicylic acid""}}"																											
4178	4612	194	Lynch Syndrome	Lynch_Syndrome.yaml	treatments	3	Targeted Therapies	Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers.	treatment_term	treatment_term	$	Targeted Therapies	Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4188	4623	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	0	Avoidance of fasting	"Frequent feeding and avoidance of prolonged fasting is the cornerstone of management. Infants should not fast more than 4-6 hours; older children can tolerate longer intervals.
"	treatment_term	treatment_term	$	Avoidance of fasting	"Frequent feeding and avoidance of prolonged fasting is the cornerstone of management. Infants should not fast more than 4-6 hours; older children can tolerate longer intervals.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4189	4624	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	1	Emergency glucose administration	"During illness or metabolic stress, intravenous glucose (10% dextrose) should be administered promptly to prevent hypoglycemia.
"	treatment_term	treatment_term	$	Emergency glucose administration	"During illness or metabolic stress, intravenous glucose (10% dextrose) should be administered promptly to prevent hypoglycemia.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4190	4625	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	2	L-carnitine supplementation	"Carnitine supplementation may be used in some patients to enhance excretion of accumulated acylcarnitines, though its routine use is debated.
"	treatment_term	treatment_term	$	L-carnitine supplementation	"Carnitine supplementation may be used in some patients to enhance excretion of accumulated acylcarnitines, though its routine use is debated.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4191	4626	195	Medium Chain Acyl-CoA Dehydrogenase Deficiency	MCAD_Deficiency.yaml	treatments	3	Dietary modification	"Some patients benefit from a diet emphasizing complex carbohydrates and limiting medium-chain triglycerides.
"	treatment_term	treatment_term	$	Dietary modification	"Some patients benefit from a diet emphasizing complex carbohydrates and limiting medium-chain triglycerides.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4203	4641	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	0	Capmatinib	Selective MET inhibitor approved for METex14 NSCLC based on GEOMETRY mono-1 trial. Active in both treatment-naive and previously treated patients. Demonstrated intracranial activity.	treatment_term	treatment_term	$	Capmatinib	Selective MET inhibitor approved for METex14 NSCLC based on GEOMETRY mono-1 trial. Active in both treatment-naive and previously treated patients. Demonstrated intracranial activity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4204	4642	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	1	Tepotinib	Selective MET inhibitor approved for METex14 NSCLC based on VISION trial. Once-daily dosing. Shown activity in CNS metastases.	treatment_term	treatment_term	$	Tepotinib	Selective MET inhibitor approved for METex14 NSCLC based on VISION trial. Once-daily dosing. Shown activity in CNS metastases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4205	4643	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	2	Crizotinib	Multi-kinase inhibitor (ALK/ROS1/MET) with activity against METex14. Less potent and selective than capmatinib/tepotinib but may be used off-label where specific MET inhibitors unavailable.	treatment_term	treatment_term	$	Crizotinib	Multi-kinase inhibitor (ALK/ROS1/MET) with activity against METex14. Less potent and selective than capmatinib/tepotinib but may be used off-label where specific MET inhibitors unavailable.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4206	4644	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for METex14 NSCLC, though response rates appear lower than in smoking-associated NSCLC. Often used after MET inhibitor progression.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors may be used for METex14 NSCLC, though response rates appear lower than in smoking-associated NSCLC. Often used after MET inhibitor progression.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4207	4645	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy used at progression or in combination with immunotherapy. Standard option when targeted therapy fails.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy used at progression or in combination with immunotherapy. Standard option when targeted therapy fails.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4220	4668	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	0	Pembrolizumab	Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival compared to chemotherapy with durable responses in a subset of patients.	treatment_term	treatment_term	$	Pembrolizumab	Anti-PD-1 immune checkpoint inhibitor approved as first-line monotherapy for metastatic MSI-H/dMMR colorectal cancer. KEYNOTE-177 demonstrated superior progression-free survival compared to chemotherapy with durable responses in a subset of patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4221	4669	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	1	Nivolumab plus Ipilimumab	Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and durable disease control with combined checkpoint inhibition.	treatment_term	treatment_term	$	Nivolumab plus Ipilimumab	Combination checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) approved for MSI-H/dMMR metastatic CRC. CheckMate 142 showed high response rates and durable disease control with combined checkpoint inhibition.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4222	4670	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	2	Dostarlimab	Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer, allowing organ preservation without surgery or radiation.	treatment_term	treatment_term	$	Dostarlimab	Anti-PD-1 antibody with remarkable activity in MSI-H rectal cancer. A single-arm study demonstrated 100% clinical complete response rate in locally advanced MSI-H rectal cancer, allowing organ preservation without surgery or radiation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4223	4671	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	treatments	3	Surgical Resection	Surgery remains the primary curative treatment for localized MSI-H colorectal cancer. Patients with Lynch syndrome may benefit from extended colectomy due to risk of metachronous tumors.	treatment_term	treatment_term	$	Surgical Resection	Surgery remains the primary curative treatment for localized MSI-H colorectal cancer. Patients with Lynch syndrome may benefit from extended colectomy due to risk of metachronous tumors.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4233	4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	treatment_term	treatment_term	$	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}"				lenvatinib	CHEBI:85994																						
4234	4687	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	0	Pembrolizumab Plus Lenvatinib	Combination of PD-1 inhibitor pembrolizumab with multi-kinase inhibitor lenvatinib is approved for advanced endometrial cancer including MSI-H tumors. Shows remarkable efficacy in dMMR/MSI-H patients with durable responses.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"																											
4235	4688	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	1	Pembrolizumab Monotherapy	PD-1 inhibitor pembrolizumab has tumor-agnostic approval for MSI-H/dMMR cancers. Highly effective in MSI-H endometrial cancer with significant response rates and durable remissions.	treatment_term	treatment_term	$	Pembrolizumab Monotherapy	PD-1 inhibitor pembrolizumab has tumor-agnostic approval for MSI-H/dMMR cancers. Highly effective in MSI-H endometrial cancer with significant response rates and durable remissions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4236	4689	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	2	Dostarlimab	PD-1 inhibitor approved for dMMR recurrent or advanced endometrial cancer. Another effective immunotherapy option for MSI-H tumors.	treatment_term	treatment_term	$	Dostarlimab	PD-1 inhibitor approved for dMMR recurrent or advanced endometrial cancer. Another effective immunotherapy option for MSI-H tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4237	4690	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	treatments	3	Hysterectomy	Total hysterectomy with bilateral salpingo-oophorectomy is standard surgical treatment for localized endometrial cancer regardless of MSI status.	treatment_term	treatment_term	$	Hysterectomy	Total hysterectomy with bilateral salpingo-oophorectomy is standard surgical treatment for localized endometrial cancer regardless of MSI status.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4274	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term	treatment_term	$	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}, {""preferred_term"": ""pemetrexed"", ""term"": {""id"": ""CHEBI:63616"", ""label"": ""pemetrexed""}}]}"				cisplatin; pemetrexed	CHEBI:27899; CHEBI:63616																						
4275	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4276	4745	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	0	Platinum-Based Chemotherapy	First-line treatment combines cisplatin or carboplatin with pemetrexed. This regimen improves median survival from approximately 9 to 12-14 months compared to platinum alone.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			pemetrexed	CHEBI:63616	pemetrexed		"{""preferred_term"": ""pemetrexed"", ""term"": {""id"": ""CHEBI:63616"", ""label"": ""pemetrexed""}}"																											
4277	4746	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	1	Immune Checkpoint Inhibition	Nivolumab plus ipilimumab is approved for unresectable pleural mesothelioma based on the CheckMate 743 trial, which showed improved overall survival compared to chemotherapy. Response rates are highest in non-epithelioid subtypes.	treatment_term	treatment_term	$	Immune Checkpoint Inhibition	Nivolumab plus ipilimumab is approved for unresectable pleural mesothelioma based on the CheckMate 743 trial, which showed improved overall survival compared to chemotherapy. Response rates are highest in non-epithelioid subtypes.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4278	4747	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	2	Surgical Resection	Extended pleurectomy/decortication (EPD) or extrapleural pneumonectomy (EPP) may be considered in select patients with early-stage epithelioid disease. Complete cytoreduction is rarely achievable due to diffuse growth pattern.	treatment_term	treatment_term	$	Surgical Resection	Extended pleurectomy/decortication (EPD) or extrapleural pneumonectomy (EPP) may be considered in select patients with early-stage epithelioid disease. Complete cytoreduction is rarely achievable due to diffuse growth pattern.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4279	4748	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	treatments	3	Radiation Therapy	Used for palliation of pain and prevention of tumor seeding at intervention sites. Intensity-modulated radiation therapy (IMRT) may be used as adjuvant therapy after surgery in multimodality treatment approaches.	treatment_term	treatment_term	$	Radiation Therapy	Used for palliation of pain and prevention of tumor seeding at intervention sites. Intensity-modulated radiation therapy (IMRT) may be used as adjuvant therapy after surgery in multimodality treatment approaches.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4299	4772	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	0	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	treatment_term	treatment_term	$	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}]}"				ibrutinib	CHEBI:76612																						
4300	4772	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	0	Ibrutinib	First-in-class BTK inhibitor with high activity in relapsed/refractory MCL. Achieves overall response rates of 65-70%. Also being studied in frontline combinations. Continuous therapy until progression or intolerance.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ibrutinib	CHEBI:76612	ibrutinib		"{""preferred_term"": ""ibrutinib"", ""term"": {""id"": ""CHEBI:76612"", ""label"": ""ibrutinib""}}"																											
4301	4773	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	treatment_term	treatment_term	$	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}]}"				acalabrutinib	CHEBI:167707																						
4302	4773	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	1	Acalabrutinib	Second-generation selective BTK inhibitor with efficacy in relapsed MCL and potentially improved tolerability compared to ibrutinib.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			acalabrutinib	CHEBI:167707	acalabrutinib		"{""preferred_term"": ""acalabrutinib"", ""term"": {""id"": ""CHEBI:167707"", ""label"": ""acalabrutinib""}}"																											
4303	4774	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	2	Intensive Chemotherapy with ASCT	For younger, fit patients, intensive induction regimens (R-DHAP, R-HyperCVAD) followed by high-dose therapy and autologous stem cell transplant consolidation achieves prolonged remissions. Standard approach for transplant-eligible patients.	treatment_term	treatment_term	$	Intensive Chemotherapy with ASCT	For younger, fit patients, intensive induction regimens (R-DHAP, R-HyperCVAD) followed by high-dose therapy and autologous stem cell transplant consolidation achieves prolonged remissions. Standard approach for transplant-eligible patients.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4304	4775	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	3	Bendamustine-Rituximab	Effective frontline regimen for older or transplant-ineligible patients. Achieves high response rates with manageable toxicity.	treatment_term	treatment_term	$	Bendamustine-Rituximab	Effective frontline regimen for older or transplant-ineligible patients. Achieves high response rates with manageable toxicity.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4305	4776	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	4	CAR-T Cell Therapy	CD19-directed CAR-T cells (brexucabtagene autoleucel) approved for relapsed/refractory MCL after BTK inhibitor failure. Achieves durable remissions in heavily pretreated patients.	treatment_term	treatment_term	$	CAR-T Cell Therapy	CD19-directed CAR-T cells (brexucabtagene autoleucel) approved for relapsed/refractory MCL after BTK inhibitor failure. Achieves durable remissions in heavily pretreated patients.	immunotherapy	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
4306	4777	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	5	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	treatment_term	treatment_term	$	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
4307	4777	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	treatments	5	Venetoclax	BCL2 inhibitor with activity in relapsed MCL, particularly in combination with BTK inhibitors. Being evaluated in multiple combination regimens.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
4325	4810	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	0	BCAA-Restricted Diet	Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment.	treatment_term	treatment_term	$	BCAA-Restricted Diet	Lifelong dietary restriction of leucine, isoleucine, and valine intake, mainstay of treatment.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4326	4811	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	1	Medical Formula	BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids.	treatment_term	treatment_term	$	Medical Formula	BCAA-free amino acid supplements to provide protein needs while restricting toxic amino acids.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4327	4812	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	2	Thiamine Supplementation	High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding.	treatment_term	treatment_term	$	Thiamine Supplementation	High-dose thiamine for thiamine-responsive variant patients who have specific mutations affecting cofactor binding.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4328	4813	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	3	Liver Transplantation	Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet.	treatment_term	treatment_term	$	Liver Transplantation	Curative treatment providing sufficient BCKD enzyme activity from donor hepatocytes, allowing unrestricted protein diet.	liver transplantation	MAXO:0001175	liver transplantation		"{""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}"																											
4329	4814	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	4	Intravenous BCAA-Free Solution	IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible.	treatment_term	treatment_term	$	Intravenous BCAA-Free Solution	IV amino acid solution without branched-chain amino acids for acute crisis management when enteral feeding is not possible.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4330	4815	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	5	Acute Crisis Management	IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises.	treatment_term	treatment_term	$	Acute Crisis Management	IV glucose, insulin, and lipids to promote anabolism and reduce protein catabolism during metabolic crises.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4331	4816	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	6	Phenylbutyrate	BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity.	treatment_term	treatment_term	$	Phenylbutyrate	BCKDK inhibitor that increases BCKDH enzyme activity by preventing phosphorylation, may benefit subset of patients with residual enzyme activity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4332	4817	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	treatments	7	Metformin	Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models.	treatment_term	treatment_term	$	Metformin	Potential adjunctive therapy that reduces KIC production by downregulating mitochondrial BCAT; shown to improve metabolic homeostasis in preclinical models.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4375	4852	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	0	Beta Blockers	Used to reduce stress on the aorta and prevent its enlargement.	treatment_term	treatment_term	$	Beta Blockers	Used to reduce stress on the aorta and prevent its enlargement.	beta adrenergic agent therapy	MAXO:0000186	beta adrenergic agent therapy	Treatment using medications that block beta-adrenergic receptors to reduce heart rate and blood pressure.	"{""description"": ""Treatment using medications that block beta-adrenergic receptors to reduce heart rate and blood pressure."", ""preferred_term"": ""beta adrenergic agent therapy"", ""term"": {""id"": ""MAXO:0000186"", ""label"": ""beta adrenergic agent therapy""}}"																											
4376	4853	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	1	Angiotensin Receptor Blockers	ARBs such as losartan reduce aortic root growth by blocking angiotensin II type 1 receptor signaling and modulating TGF-beta pathways. Pediatric data show superior tolerability and efficacy compared to beta-blockers.	treatment_term	treatment_term	$	Angiotensin Receptor Blockers	ARBs such as losartan reduce aortic root growth by blocking angiotensin II type 1 receptor signaling and modulating TGF-beta pathways. Pediatric data show superior tolerability and efficacy compared to beta-blockers.	pharmacotherapy	MAXO:0000058	pharmacotherapy	Treatment using medications such as losartan to modulate pathological signaling pathways.	"{""description"": ""Treatment using medications such as losartan to modulate pathological signaling pathways."", ""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4377	4854	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	2	Aortic Surgery	Recommended for severe aortic dilation to prevent dissection.	treatment_term	treatment_term	$	Aortic Surgery	Recommended for severe aortic dilation to prevent dissection.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention to repair or replace damaged anatomical structures.	"{""description"": ""Operative intervention to repair or replace damaged anatomical structures."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4378	4855	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	3	Orthopedic Interventions	Treatments for scoliosis and other skeletal abnormalities.	treatment_term	treatment_term	$	Orthopedic Interventions	Treatments for scoliosis and other skeletal abnormalities.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention to correct skeletal abnormalities such as scoliosis.	"{""description"": ""Operative intervention to correct skeletal abnormalities such as scoliosis."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4379	4856	204	Marfan Syndrome	Marfan_Syndrome.yaml	treatments	4	Vision Correction	Management of ocular issues such as ectopia lentis with glasses or surgery.	treatment_term	treatment_term	$	Vision Correction	Management of ocular issues such as ectopia lentis with glasses or surgery.	surgical procedure	MAXO:0000004	surgical procedure	Operative intervention to correct lens dislocation or other ocular abnormalities.	"{""description"": ""Operative intervention to correct lens dislocation or other ocular abnormalities."", ""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4385	4866	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	0	Surgical Resection for Symptomatic Cases	All symptomatic Meckel diverticula should be surgically removed, typically with a segment of adjacent ileum.	treatment_term	treatment_term	$	Surgical Resection for Symptomatic Cases	All symptomatic Meckel diverticula should be surgically removed, typically with a segment of adjacent ileum.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4386	4867	205	Meckel Diverticulum	Meckel_Diverticulum.yaml	treatments	1	Incidental Diverticulectomy with Stapling Devices	For incidentally discovered Meckel diverticula during surgery, removal using stapling devices is reasonable if the diverticulum easily fits in the device.	treatment_term	treatment_term	$	Incidental Diverticulectomy with Stapling Devices	For incidentally discovered Meckel diverticula during surgery, removal using stapling devices is reasonable if the diverticulum easily fits in the device.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4453	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term	treatment_term	$	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	surgical repair	MAXO:0009072	surgical repair		"{""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}"																			Excision	NCIT:C15232	NCIT:C15329						
4454	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
4455	4920	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	0	Occipital encephalocele repair	Surgical excision/repair of occipital encephalocele or meningocele in MKS.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			excision	NCIT:C15232	Excision		"{""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}"																											
4456	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term	treatment_term	$	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	surgical repair	MAXO:0009072	surgical repair		"{""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""shunt device"", ""term"": {""id"": ""NCIT:C50174"", ""label"": ""Shunt Device""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}"																			Shunt Device	NCIT:C50174	NCIT:C15329						
4457	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
4458	4921	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	1	Cerebrospinal fluid shunting for hydrocephalus	Surgical CSF diversion for hydrocephalus associated with MKS.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			shunt device	NCIT:C50174	Shunt Device		"{""preferred_term"": ""shunt device"", ""term"": {""id"": ""NCIT:C50174"", ""label"": ""Shunt Device""}}"																											
4459	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term	treatment_term	$	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	surgical repair	MAXO:0009072	surgical repair		"{""preferred_term"": ""surgical repair"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}, ""value"": {""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}}], ""term"": {""id"": ""MAXO:0009072"", ""label"": ""surgical repair""}}"																			Excision	NCIT:C15232	NCIT:C15329						
4460	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			surgical procedure	NCIT:C15329	Surgical Procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""NCIT:C15329"", ""label"": ""Surgical Procedure""}}"																											
4461	4922	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	2	Cranial decompression	Acute cranial decompression reported in MKS with craniocephalic disproportion.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			excision	NCIT:C15232	Excision		"{""preferred_term"": ""excision"", ""term"": {""id"": ""NCIT:C15232"", ""label"": ""Excision""}}"																											
4462	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term	treatment_term	$	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""has participant"", ""term"": {""id"": ""RO:0000057"", ""label"": ""has participant""}}, ""value"": {""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}}], ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"									CC2D2A	hgnc:29253	RO:0000057																
4463	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			has participant	RO:0000057	has participant		"{""preferred_term"": ""has participant"", ""term"": {""id"": ""RO:0000057"", ""label"": ""has participant""}}"																											
4464	4923	206	Meckel Syndrome	Meckel_Syndrome.yaml	treatments	3	Mutation-specific exon skipping therapy (proposed)	Proposed therapeutic exon-skipping strategies for CC2D2A-related MKS.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			CC2D2A	hgnc:29253	CC2D2A		"{""preferred_term"": ""CC2D2A"", ""term"": {""id"": ""hgnc:29253"", ""label"": ""CC2D2A""}}"																											
4477	4937	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with central neck dissection is the primary treatment for MTC. In hereditary cases, prophylactic thyroidectomy is recommended based on genotype, often in early childhood for MEN2B.	treatment_term	treatment_term	$	Thyroidectomy	Total thyroidectomy with central neck dissection is the primary treatment for MTC. In hereditary cases, prophylactic thyroidectomy is recommended based on genotype, often in early childhood for MEN2B.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4478	4938	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	1	Selpercatinib	Highly selective RET inhibitor approved for RET-mutant MTC. Demonstrates remarkable efficacy with durable responses in both treatment-naive and previously treated patients. Generally well-tolerated.	treatment_term	treatment_term	$	Selpercatinib	Highly selective RET inhibitor approved for RET-mutant MTC. Demonstrates remarkable efficacy with durable responses in both treatment-naive and previously treated patients. Generally well-tolerated.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4479	4939	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	2	Pralsetinib	Another selective RET inhibitor approved for RET-mutant MTC. Similar efficacy to selpercatinib with different side effect profile.	treatment_term	treatment_term	$	Pralsetinib	Another selective RET inhibitor approved for RET-mutant MTC. Similar efficacy to selpercatinib with different side effect profile.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4480	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term	treatment_term	$	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""vandetanib"", ""term"": {""id"": ""CHEBI:49960"", ""label"": ""vandetanib""}}, {""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}]}"				vandetanib; cabozantinib	CHEBI:49960; CHEBI:72317																						
4481	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			vandetanib	CHEBI:49960	vandetanib		"{""preferred_term"": ""vandetanib"", ""term"": {""id"": ""CHEBI:49960"", ""label"": ""vandetanib""}}"																											
4482	4940	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	treatments	3	Vandetanib/Cabozantinib	Multi-kinase inhibitors with RET activity approved for advanced MTC. Broader kinase inhibition profile leads to more side effects compared to selective RET inhibitors.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			cabozantinib	CHEBI:72317	cabozantinib		"{""preferred_term"": ""cabozantinib"", ""term"": {""id"": ""CHEBI:72317"", ""label"": ""cabozantinib""}}"																											
4495	4958	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	0	Surgical Resection	Maximal safe resection is first-line treatment. Lateral/hemispheric location often allows gross total resection. Extent of resection is prognostic.	treatment_term	treatment_term	$	Surgical Resection	Maximal safe resection is first-line treatment. Lateral/hemispheric location often allows gross total resection. Extent of resection is prognostic.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4496	4959	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	1	Craniospinal Irradiation	Craniospinal irradiation is standard for children >3 years due to risk of leptomeningeal spread. Radiation is typically avoided in infants (<3 years) due to severe neurocognitive effects.	treatment_term	treatment_term	$	Craniospinal Irradiation	Craniospinal irradiation is standard for children >3 years due to risk of leptomeningeal spread. Radiation is typically avoided in infants (<3 years) due to severe neurocognitive effects.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4497	4960	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	2	Chemotherapy	Multi-agent chemotherapy is standard. For infants, intensive chemotherapy regimens aim to delay or avoid radiation. Standard agents include cisplatin, vincristine, cyclophosphamide, and lomustine.	treatment_term	treatment_term	$	Chemotherapy	Multi-agent chemotherapy is standard. For infants, intensive chemotherapy regimens aim to delay or avoid radiation. Standard agents include cisplatin, vincristine, cyclophosphamide, and lomustine.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4498	4961	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	treatments	3	SHH Pathway Inhibitors (Vismodegib/Sonidegib)	SMO inhibitors show activity in recurrent SHH-activated medulloblastoma with upstream pathway mutations (PTCH1). Resistance develops through SMO mutations or pathway activation downstream of SMO (GLI amplification, SUFU mutations). Growth plate toxicity limits use in children.	treatment_term	treatment_term	$	SHH Pathway Inhibitors (Vismodegib/Sonidegib)	SMO inhibitors show activity in recurrent SHH-activated medulloblastoma with upstream pathway mutations (PTCH1). Resistance develops through SMO mutations or pathway activation downstream of SMO (GLI amplification, SUFU mutations). Growth plate toxicity limits use in children.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4511	4979	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	0	Surgical Resection	Maximal safe resection is first-line treatment. Near-total or gross total resection is achieved in most cases. Complete resection associated with excellent outcomes.	treatment_term	treatment_term	$	Surgical Resection	Maximal safe resection is first-line treatment. Near-total or gross total resection is achieved in most cases. Complete resection associated with excellent outcomes.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4512	4980	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	1	Craniospinal Irradiation	Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk of leptomeningeal dissemination. Treatment de-escalation trials are exploring reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors given excellent prognosis.	treatment_term	treatment_term	$	Craniospinal Irradiation	Craniospinal irradiation (CSI) is standard for medulloblastoma due to risk of leptomeningeal dissemination. Treatment de-escalation trials are exploring reduced-dose CSI (18-23.4 Gy vs standard 23.4-36 Gy) for WNT-activated tumors given excellent prognosis.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4513	4981	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	treatments	2	Chemotherapy	Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine) is standard. De-escalation trials are exploring reduced-intensity or chemotherapy-omitting regimens for WNT-activated tumors to minimize long-term toxicity while maintaining excellent survival.	treatment_term	treatment_term	$	Chemotherapy	Multi-agent chemotherapy (cisplatin, vincristine, cyclophosphamide, lomustine) is standard. De-escalation trials are exploring reduced-intensity or chemotherapy-omitting regimens for WNT-activated tumors to minimize long-term toxicity while maintaining excellent survival.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4532	5010	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	0	Surgical Excision	Removal of the melanoma and surrounding tissue	treatment_term	treatment_term	$	Surgical Excision	Removal of the melanoma and surrounding tissue	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4533	5011	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	1	Immunotherapy	Use of drugs to stimulate the immune system to target melanoma cells	treatment_term	treatment_term	$	Immunotherapy	Use of drugs to stimulate the immune system to target melanoma cells	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4534	5012	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	2	Targeted Therapy	Drugs that target specific genetic mutations in melanoma cells, such as BRAF inhibitors	treatment_term	treatment_term	$	Targeted Therapy	Drugs that target specific genetic mutations in melanoma cells, such as BRAF inhibitors	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4535	5013	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	3	Radiation Therapy	Use of high-energy radiation to kill cancer cells or shrink tumors	treatment_term	treatment_term	$	Radiation Therapy	Use of high-energy radiation to kill cancer cells or shrink tumors	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4536	5014	210	Melanoma_in_Congenital_Melanocytic_Nevus	Melanoma_in_Congenital_Melanocytic_Nevus.yaml	treatments	4	Chemotherapy	Use of drugs to kill rapidly dividing cells, including cancer cells	treatment_term	treatment_term	$	Chemotherapy	Use of drugs to kill rapidly dividing cells, including cancer cells	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4558	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term	treatment_term	$	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	corticosteroid injection	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid injection"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}], ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																						Triamcinolone	NCIT:C901	NCIT:C2259			
4559	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
4560	5036	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	0	Intralesional corticosteroid injection	"Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			triamcinolone	NCIT:C901	Triamcinolone		"{""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}"																											
4561	5037	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	1	Systemic corticosteroids	"Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.
"	treatment_term	treatment_term	$	Systemic corticosteroids	"Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.
"	corticosteroid therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
4562	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term	treatment_term	$	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Infliximab	NCIT:C1789	NCIT:C2259			
4563	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
4564	5038	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	2	Anti-TNF therapy (infliximab)	"TNF- antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF--driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
"	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			infliximab	NCIT:C1789	Infliximab		"{""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}"																											
4565	5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	treatment_term	treatment_term	$	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	immunosuppressive therapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""immunosuppressive therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent class"", ""term"": {""id"": ""NCIT:C20401"", ""label"": ""Monoclonal Antibody""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"															NCIT:C20401												
4566	5039	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	3	Anti-IL-12/23 therapy (ustekinumab)	"Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
"	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent class	NCIT:C20401	Monoclonal Antibody		"{""preferred_term"": ""therapeutic agent class"", ""term"": {""id"": ""NCIT:C20401"", ""label"": ""Monoclonal Antibody""}}"																											
4567	5040	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	treatments	4	Supportive care	"Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.
"	treatment_term	treatment_term	$	Supportive care	"Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4580	5050	212	Meniere's Disease	Menieres_Disease.yaml	treatments	0	Low-Sodium Diet	"Dietary sodium restriction to reduce fluid retention and minimize endolymphatic hydrops. Often combined with diuretics. First-line conservative management that is recommended as part of long-term treatment strategy.
"	treatment_term	treatment_term	$	Low-Sodium Diet	"Dietary sodium restriction to reduce fluid retention and minimize endolymphatic hydrops. Often combined with diuretics. First-line conservative management that is recommended as part of long-term treatment strategy.
"	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
4581	5051	212	Meniere's Disease	Menieres_Disease.yaml	treatments	1	Diuretic Therapy	"Thiazide diuretics or acetazolamide to reduce endolymph volume and pressure, decreasing the frequency of vertigo attacks. Used as part of first-line conservative management.
"	treatment_term	treatment_term	$	Diuretic Therapy	"Thiazide diuretics or acetazolamide to reduce endolymph volume and pressure, decreasing the frequency of vertigo attacks. Used as part of first-line conservative management.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4582	5052	212	Meniere's Disease	Menieres_Disease.yaml	treatments	2	Betahistine	"Histamine analog that improves inner ear blood flow and reduces vestibular symptoms. Widely used outside North America as part of conservative medical management.
"	treatment_term	treatment_term	$	Betahistine	"Histamine analog that improves inner ear blood flow and reduces vestibular symptoms. Widely used outside North America as part of conservative medical management.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4583	5053	212	Meniere's Disease	Menieres_Disease.yaml	treatments	3	Intratympanic Injections	"Injection of corticosteroids or gentamicin through the tympanic membrane to reduce vertigo. Gentamicin reduces vestibular function; corticosteroids provide nonablative alternative. Used when medical management fails.
"	treatment_term	treatment_term	$	Intratympanic Injections	"Injection of corticosteroids or gentamicin through the tympanic membrane to reduce vertigo. Gentamicin reduces vestibular function; corticosteroids provide nonablative alternative. Used when medical management fails.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4584	5054	212	Meniere's Disease	Menieres_Disease.yaml	treatments	4	Vestibular Rehabilitation	"Physical therapy exercises to improve balance and reduce dizziness by promoting central compensation for vestibular dysfunction. Complements medical and surgical interventions.
"	treatment_term	treatment_term	$	Vestibular Rehabilitation	"Physical therapy exercises to improve balance and reduce dizziness by promoting central compensation for vestibular dysfunction. Complements medical and surgical interventions.
"	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
4585	5055	212	Meniere's Disease	Menieres_Disease.yaml	treatments	5	Endolymphatic Sac Surgery	"Surgical decompression of the endolymphatic sac to improve endolymph drainage and reduce hydrops. Nonablative surgical alternative used when conservative measures and intratympanic therapies fail.
"	treatment_term	treatment_term	$	Endolymphatic Sac Surgery	"Surgical decompression of the endolymphatic sac to improve endolymph drainage and reduce hydrops. Nonablative surgical alternative used when conservative measures and intratympanic therapies fail.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4599	5071	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	0	Avelumab	Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint inhibitor approved for MCC based on durable responses in the JAVELIN Merkel 200 trial. Response rates of approximately 30-35% in previously treated patients and higher in first-line setting.	treatment_term	treatment_term	$	Avelumab	Anti-PD-L1 antibody approved for metastatic MCC. First immune checkpoint inhibitor approved for MCC based on durable responses in the JAVELIN Merkel 200 trial. Response rates of approximately 30-35% in previously treated patients and higher in first-line setting.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4600	5072	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	1	Pembrolizumab	Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately 50-70% with durable responses. Both virus-positive and virus-negative MCC respond to checkpoint inhibition.	treatment_term	treatment_term	$	Pembrolizumab	Anti-PD-1 antibody approved for advanced MCC. Response rates of approximately 50-70% with durable responses. Both virus-positive and virus-negative MCC respond to checkpoint inhibition.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4601	5073	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	2	Surgical Excision	Wide local excision with adequate margins (1-2 cm) is the primary treatment for localized MCC. Sentinel lymph node biopsy is recommended given high rate of occult nodal metastases.	treatment_term	treatment_term	$	Surgical Excision	Wide local excision with adequate margins (1-2 cm) is the primary treatment for localized MCC. Sentinel lymph node biopsy is recommended given high rate of occult nodal metastases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4602	5074	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	3	Radiation Therapy	MCC is radiosensitive. Adjuvant radiation improves local control, particularly for tumors with high-risk features. Radiation may be used as primary treatment for unresectable tumors.	treatment_term	treatment_term	$	Radiation Therapy	MCC is radiosensitive. Adjuvant radiation improves local control, particularly for tumors with high-risk features. Radiation may be used as primary treatment for unresectable tumors.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4603	5075	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	treatments	4	Chemotherapy	MCC is chemosensitive (like other small cell carcinomas) with initial response rates of 50-60% to platinum/etoposide regimens. However, responses are typically short-lived and chemotherapy has been largely supplanted by immunotherapy.	treatment_term	treatment_term	$	Chemotherapy	MCC is chemosensitive (like other small cell carcinomas) with initial response rates of 50-60% to platinum/etoposide regimens. However, responses are typically short-lived and chemotherapy has been largely supplanted by immunotherapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4677	5175	216	Monkeypox	Monkeypox.yaml	treatments	0	Supportive Care	Management of symptoms including fever, pain, and dehydration.	treatment_term	treatment_term	$	Supportive Care	Management of symptoms including fever, pain, and dehydration.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4678	5176	216	Monkeypox	Monkeypox.yaml	treatments	1	Antiviral Therapy	Investigational treatments such as tecovirimat (TPOXX).	treatment_term	treatment_term	$	Antiviral Therapy	Investigational treatments such as tecovirimat (TPOXX).	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
4679	5177	216	Monkeypox	Monkeypox.yaml	treatments	2	Vaccination	Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox.	treatment_term	treatment_term	$	Vaccination	Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
4680	5178	216	Monkeypox	Monkeypox.yaml	treatments	3	Cidofovir	DNA polymerase inhibitor considered for severe cases.	treatment_term	treatment_term	$	Cidofovir	DNA polymerase inhibitor considered for severe cases.	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
4681	5179	216	Monkeypox	Monkeypox.yaml	treatments	4	Brincidofovir	Lipid conjugate of cidofovir explored as oral antiviral candidate.	treatment_term	treatment_term	$	Brincidofovir	Lipid conjugate of cidofovir explored as oral antiviral candidate.	antiviral agent therapy	MAXO:0000168	antiviral agent therapy		"{""preferred_term"": ""antiviral agent therapy"", ""term"": {""id"": ""MAXO:0000168"", ""label"": ""antiviral agent therapy""}}"																											
4682	5180	216	Monkeypox	Monkeypox.yaml	treatments	5	Isolation and Infection Control	Preventing the spread through quarantine of infected individuals and proper hygiene practices.	treatment_term	treatment_term	$	Isolation and Infection Control	Preventing the spread through quarantine of infected individuals and proper hygiene practices.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
4692	5190	217	Muenke Syndrome	Muenke_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Surgical correction of craniosynostosis when indicated. Timing and approach depend on severity and uni- vs bilateral involvement.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Surgical correction of craniosynostosis when indicated. Timing and approach depend on severity and uni- vs bilateral involvement.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4707	5209	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	0	Prophylactic Thyroidectomy	Total thyroidectomy prevents MTC development. Timing is based on ATA risk stratification: highest risk (M918T) in first year of life; high risk (codon 634, A883F) before age 5; moderate risk individualized based on calcitonin levels and family history. Central lymph node dissection may be included.	treatment_term	treatment_term	$	Prophylactic Thyroidectomy	Total thyroidectomy prevents MTC development. Timing is based on ATA risk stratification: highest risk (M918T) in first year of life; high risk (codon 634, A883F) before age 5; moderate risk individualized based on calcitonin levels and family history. Central lymph node dissection may be included.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4708	5210	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	1	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	treatment_term	treatment_term	$	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""selpercatinib"", ""term"": {""id"": ""CHEBI:175074"", ""label"": ""selpercatinib""}}]}"				selpercatinib	CHEBI:175074																						
4709	5210	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	1	RET Kinase Inhibitors	Selective RET inhibitors (selpercatinib, pralsetinib) provide targeted therapy for advanced/metastatic MTC. These agents have revolutionized treatment of RET-driven cancers with high response rates and durable responses. Used when surgery is not curative.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			selpercatinib	CHEBI:175074	selpercatinib		"{""preferred_term"": ""selpercatinib"", ""term"": {""id"": ""CHEBI:175074"", ""label"": ""selpercatinib""}}"																											
4710	5211	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	2	Surveillance Protocol	Annual biochemical screening includes serum calcitonin, plasma metanephrines, calcium, and PTH. Imaging as indicated. After thyroidectomy, lifelong thyroid hormone replacement and calcitonin monitoring for recurrence. Screening starts from genetic diagnosis, which may be prenatally or in infancy.	treatment_term	treatment_term	$	Surveillance Protocol	Annual biochemical screening includes serum calcitonin, plasma metanephrines, calcium, and PTH. Imaging as indicated. After thyroidectomy, lifelong thyroid hormone replacement and calcitonin monitoring for recurrence. Screening starts from genetic diagnosis, which may be prenatally or in infancy.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
4711	5212	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	treatments	3	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows prophylactic thyroidectomy before MTC development. Prenatal and preimplantation genetic testing available.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling for at-risk family members with cascade testing. Children of affected parents have 50% risk. Early identification allows prophylactic thyroidectomy before MTC development. Prenatal and preimplantation genetic testing available.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
4738	5244	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	0	Disease-Modifying Therapies (DMTs)	Medications that can slow the progression of the disease and reduce the frequency and severity of relapses.	treatment_term	treatment_term	$	Disease-Modifying Therapies (DMTs)	Medications that can slow the progression of the disease and reduce the frequency and severity of relapses.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4739	5245	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	1	Symptomatic Treatments	Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues.	treatment_term	treatment_term	$	Symptomatic Treatments	Range of therapies to manage symptoms like spasticity, pain, fatigue, and bladder issues.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4740	5246	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	2	Physical Therapy and Rehabilitation	Exercise programs and physical therapy to maintain mobility, strength, and function.	treatment_term	treatment_term	$	Physical Therapy and Rehabilitation	Exercise programs and physical therapy to maintain mobility, strength, and function.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
4741	5247	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	treatments	3	Corticosteroids	Used to reduce inflammation and speed recovery during acute exacerbations.	treatment_term	treatment_term	$	Corticosteroids	Used to reduce inflammation and speed recovery during acute exacerbations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4801	5291	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	0	Intravenous Immunoglobulin (IVIG)	Used to modulate the immune response and reduce inflammation.	treatment_term	treatment_term	$	Intravenous Immunoglobulin (IVIG)	Used to modulate the immune response and reduce inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4802	5292	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	1	Corticosteroids	Anti-inflammatory medicines to reduce immune system activity and inflammation.	treatment_term	treatment_term	$	Corticosteroids	Anti-inflammatory medicines to reduce immune system activity and inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4803	5293	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	2	Aspirin	Used in cases with high risk of blood clots to prevent thrombotic complications.	treatment_term	treatment_term	$	Aspirin	Used in cases with high risk of blood clots to prevent thrombotic complications.	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy		"{""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
4804	5294	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	treatments	3	Supportive Care	Including fluids, blood pressure support, and respiratory support as needed.	treatment_term	treatment_term	$	Supportive Care	Including fluids, blood pressure support, and respiratory support as needed.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4832	5318	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	0	Pacing	Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise.	treatment_term	treatment_term	$	Pacing	Activity management strategy to stay within energy limits and avoid triggering post-exertional malaise.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4833	5319	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	1	Symptomatic Treatment	Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance.	treatment_term	treatment_term	$	Symptomatic Treatment	Treatment of individual symptoms including sleep disturbance, pain, and orthostatic intolerance.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4834	5320	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	treatments	2	Low-Dose Naltrexone	Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation.	treatment_term	treatment_term	$	Low-Dose Naltrexone	Off-label use targeting TRPM3 ion channel dysfunction and neuroinflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4846	5346	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	0	Acetylcholinesterase Inhibitors	First-line symptomatic treatment (pyridostigmine).	treatment_term	treatment_term	$	Acetylcholinesterase Inhibitors	First-line symptomatic treatment (pyridostigmine).	acetylcholinesterase inhibitor therapy	MAXO:0000645	acetylcholinesterase inhibitor therapy		"{""preferred_term"": ""acetylcholinesterase inhibitor therapy"", ""term"": {""id"": ""MAXO:0000645"", ""label"": ""acetylcholinesterase inhibitor therapy""}}"																											
4847	5347	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	1	Corticosteroids	Prednisone for immunosuppression, mainstay of therapy.	treatment_term	treatment_term	$	Corticosteroids	Prednisone for immunosuppression, mainstay of therapy.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
4848	5348	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	2	Thymectomy	Surgical removal of thymus, improves outcomes in appropriate patients.	treatment_term	treatment_term	$	Thymectomy	Surgical removal of thymus, improves outcomes in appropriate patients.	thymectomy	MAXO:0001079	thymectomy		"{""preferred_term"": ""thymectomy"", ""term"": {""id"": ""MAXO:0001079"", ""label"": ""thymectomy""}}"																											
4849	5349	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	3	Azathioprine	Steroid-sparing immunosuppressant.	treatment_term	treatment_term	$	Azathioprine	Steroid-sparing immunosuppressant.	immune suppressant agent therapy	MAXO:0000297	immune suppressant agent therapy		"{""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}"																											
4850	5350	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	4	Mycophenolate Mofetil	Alternative immunosuppressant.	treatment_term	treatment_term	$	Mycophenolate Mofetil	Alternative immunosuppressant.	immune suppressant agent therapy	MAXO:0000297	immune suppressant agent therapy		"{""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}"																											
4851	5351	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	5	Rituximab	Anti-CD20 antibody, effective in refractory cases.	treatment_term	treatment_term	$	Rituximab	Anti-CD20 antibody, effective in refractory cases.	immune suppressant agent therapy	MAXO:0000297	immune suppressant agent therapy		"{""preferred_term"": ""immune suppressant agent therapy"", ""term"": {""id"": ""MAXO:0000297"", ""label"": ""immune suppressant agent therapy""}}"																											
4852	5352	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	treatments	6	Eculizumab	Complement inhibitor (anti-C5), approved for refractory AChR+ MG.	treatment_term	treatment_term	$	Eculizumab	Complement inhibitor (anti-C5), approved for refractory AChR+ MG.	complement 5 inhibitor agent therapy	MAXO:0001483	complement 5 inhibitor agent therapy		"{""preferred_term"": ""complement 5 inhibitor agent therapy"", ""term"": {""id"": ""MAXO:0001483"", ""label"": ""complement 5 inhibitor agent therapy""}}"																											
4867	5371	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	0	Intensive Chemotherapy (7+3)	Standard induction with 7 days cytarabine and 3 days anthracycline achieves high complete remission rates in NPM1-mutated AML. Consolidation with high-dose cytarabine is particularly effective for this subtype.	treatment_term	treatment_term	$	Intensive Chemotherapy (7+3)	Standard induction with 7 days cytarabine and 3 days anthracycline achieves high complete remission rates in NPM1-mutated AML. Consolidation with high-dose cytarabine is particularly effective for this subtype.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
4868	5372	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	1	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	treatment_term	treatment_term	$	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}]}"				venetoclax	CHEBI:133021																						
4869	5372	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	1	Venetoclax plus Azacitidine	For older or unfit patients, the combination of BCL2 inhibitor venetoclax with hypomethylating agent azacitidine achieves high response rates in NPM1-mutated AML, particularly in the absence of adverse features.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			venetoclax	CHEBI:133021	venetoclax		"{""preferred_term"": ""venetoclax"", ""term"": {""id"": ""CHEBI:133021"", ""label"": ""venetoclax""}}"																											
4870	5373	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Generally reserved for patients with NPM1 mutation plus FLT3-ITD or other adverse features in first remission, or for patients who relapse. May not be necessary for favorable-risk NPM1-mutated AML in first remission.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Generally reserved for patients with NPM1 mutation plus FLT3-ITD or other adverse features in first remission, or for patients who relapse. May not be necessary for favorable-risk NPM1-mutated AML in first remission.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
4871	5374	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	treatments	3	MRD-Guided Therapy	NPM1 mutation transcript levels by RT-PCR provide sensitive minimal residual disease monitoring. Rising MRD levels can guide preemptive treatment before overt relapse.	treatment_term	treatment_term	$	MRD-Guided Therapy	NPM1 mutation transcript levels by RT-PCR provide sensitive minimal residual disease monitoring. Rising MRD levels can guide preemptive treatment before overt relapse.	genetic testing	MAXO:0000127	genetic testing		"{""preferred_term"": ""genetic testing"", ""term"": {""id"": ""MAXO:0000127"", ""label"": ""genetic testing""}}"																											
4882	5385	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	0	MEK Inhibitors	MEK inhibitors (binimetinib, trametinib) have demonstrated modest activity in NRAS-mutant melanoma. Response rates are lower than in BRAF-mutant disease (approximately 15-20%), but MEK inhibition represents one of the few targeted options for this molecular subtype.	treatment_term	treatment_term	$	MEK Inhibitors	MEK inhibitors (binimetinib, trametinib) have demonstrated modest activity in NRAS-mutant melanoma. Response rates are lower than in BRAF-mutant disease (approximately 15-20%), but MEK inhibition represents one of the few targeted options for this molecular subtype.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4883	5386	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	1	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are the primary treatment for advanced NRAS-mutant melanoma. NRAS-mutant tumors may have higher tumor mutational burden, potentially enhancing immunotherapy responsiveness.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 antibodies (pembrolizumab, nivolumab) alone or combined with anti-CTLA-4 (ipilimumab) are the primary treatment for advanced NRAS-mutant melanoma. NRAS-mutant tumors may have higher tumor mutational burden, potentially enhancing immunotherapy responsiveness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4884	5387	225	NRAS Mutant Melanoma	NRAS_Mutant_Melanoma.yaml	treatments	2	Combination Targeted Therapy	Clinical trials are investigating combinations targeting both MAPK and PI3K pathways, as well as CDK4/6 inhibitors given the importance of cell cycle dysregulation in NRAS-mutant melanoma.	treatment_term	treatment_term	$	Combination Targeted Therapy	Clinical trials are investigating combinations targeting both MAPK and PI3K pathways, as well as CDK4/6 inhibitors given the importance of cell cycle dysregulation in NRAS-mutant melanoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4891	5401	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	0	Larotrectinib	Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval.	treatment_term	treatment_term	$	Larotrectinib	Highly selective TRK inhibitor approved for adult and pediatric solid tumors with NTRK gene fusions. Demonstrates remarkable efficacy across tumor types with overall response rate of approximately 75% and durable responses. First tumor-agnostic TRK inhibitor approval.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4892	5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	treatment_term	treatment_term	$	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""entrectinib"", ""term"": {""id"": ""CHEBI:195558"", ""label"": ""entrectinib""}}]}"				entrectinib	CHEBI:195558																						
4893	5402	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	1	Entrectinib	TRK inhibitor with additional activity against ROS1 and ALK. Approved for NTRK fusion-positive solid tumors in adults and children. Penetrates CNS, providing activity against brain metastases.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			entrectinib	CHEBI:195558	entrectinib		"{""preferred_term"": ""entrectinib"", ""term"": {""id"": ""CHEBI:195558"", ""label"": ""entrectinib""}}"																											
4894	5403	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	treatments	2	Repotrectinib	Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors.	treatment_term	treatment_term	$	Repotrectinib	Next-generation TRK inhibitor designed to overcome resistance mutations including solvent front mutations (G595R, G623R). Option for patients who progress on first-generation TRK inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4903	5420	227	Narcolepsy	Narcolepsy.yaml	treatments	0	Sodium Oxybate	First-line for cataplexy and daytime sleepiness, improves nighttime sleep.	treatment_term	treatment_term	$	Sodium Oxybate	First-line for cataplexy and daytime sleepiness, improves nighttime sleep.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4904	5421	227	Narcolepsy	Narcolepsy.yaml	treatments	1	Modafinil	Wake-promoting agent for excessive daytime sleepiness.	treatment_term	treatment_term	$	Modafinil	Wake-promoting agent for excessive daytime sleepiness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4905	5422	227	Narcolepsy	Narcolepsy.yaml	treatments	2	Pitolisant	Histamine H3 receptor antagonist, promotes wakefulness.	treatment_term	treatment_term	$	Pitolisant	Histamine H3 receptor antagonist, promotes wakefulness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4906	5423	227	Narcolepsy	Narcolepsy.yaml	treatments	3	Solriamfetol	Dopamine/norepinephrine reuptake inhibitor for sleepiness.	treatment_term	treatment_term	$	Solriamfetol	Dopamine/norepinephrine reuptake inhibitor for sleepiness.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4907	5424	227	Narcolepsy	Narcolepsy.yaml	treatments	4	Amphetamines	Traditional stimulants (amphetamine, methylphenidate).	treatment_term	treatment_term	$	Amphetamines	Traditional stimulants (amphetamine, methylphenidate).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4908	5425	227	Narcolepsy	Narcolepsy.yaml	treatments	5	Antidepressants	SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).	treatment_term	treatment_term	$	Antidepressants	SNRIs/SSRIs for cataplexy (venlafaxine, fluoxetine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4909	5426	227	Narcolepsy	Narcolepsy.yaml	treatments	6	Scheduled Naps	Short planned naps can improve alertness.	treatment_term	treatment_term	$	Scheduled Naps	Short planned naps can improve alertness.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
4926	5448	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	0	Intensity-Modulated Radiation Therapy	NPC is highly radiosensitive. IMRT is the standard of care for locoregional disease, allowing precise dose delivery while sparing critical structures including parotid glands, temporal lobes, and brainstem.	treatment_term	treatment_term	$	Intensity-Modulated Radiation Therapy	NPC is highly radiosensitive. IMRT is the standard of care for locoregional disease, allowing precise dose delivery while sparing critical structures including parotid glands, temporal lobes, and brainstem.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4927	5449	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	1	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	treatment_term	treatment_term	$	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				cisplatin	CHEBI:27899																						
4928	5449	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	1	Concurrent Chemoradiation	Concurrent cisplatin during radiation followed by adjuvant chemotherapy is standard for locally advanced NPC (stages III-IVA). This approach improves overall survival compared to radiation alone.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4929	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term	treatment_term	$	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""gemcitabine"", ""term"": {""id"": ""CHEBI:175901"", ""label"": ""gemcitabine""}}, {""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}]}"				gemcitabine; cisplatin	CHEBI:175901; CHEBI:27899																						
4930	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			gemcitabine	CHEBI:175901	gemcitabine		"{""preferred_term"": ""gemcitabine"", ""term"": {""id"": ""CHEBI:175901"", ""label"": ""gemcitabine""}}"																											
4931	5450	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	2	Induction Chemotherapy	Induction chemotherapy (gemcitabine-cisplatin or TPF) before chemoradiation is increasingly used for locally advanced disease based on recent trials showing improved survival.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4932	5451	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	treatments	3	Immunotherapy	PD-1 inhibitors have shown significant activity in recurrent/metastatic NPC, with durable responses in a subset of patients. EBV antigens may serve as targets for immunotherapy, and adoptive T cell therapy targeting EBV is under investigation.	treatment_term	treatment_term	$	Immunotherapy	PD-1 inhibitors have shown significant activity in recurrent/metastatic NPC, with durable responses in a subset of patients. EBV antigens may serve as targets for immunotherapy, and adoptive T cell therapy targeting EBV is under investigation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4962	5488	229	Nephronophthisis	Nephronophthisis.yaml	treatments	0	Renal Replacement Therapy	Dialysis or kidney transplantation for end-stage renal disease.	treatment_term	treatment_term	$	Renal Replacement Therapy	Dialysis or kidney transplantation for end-stage renal disease.	renal dialysis	MAXO:0000601	renal dialysis		"{""preferred_term"": ""renal dialysis"", ""term"": {""id"": ""MAXO:0000601"", ""label"": ""renal dialysis""}}"																											
4963	5489	229	Nephronophthisis	Nephronophthisis.yaml	treatments	1	Antihypertensive Therapy	Management of blood pressure with medications.	treatment_term	treatment_term	$	Antihypertensive Therapy	Management of blood pressure with medications.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
4964	5490	229	Nephronophthisis	Nephronophthisis.yaml	treatments	2	Supportive Care	Symptomatic treatment and monitoring to manage associated complications.	treatment_term	treatment_term	$	Supportive Care	Symptomatic treatment and monitoring to manage associated complications.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
4981	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term	treatment_term	$	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}, {""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}]}"				cisplatin; etoposide; cyclophosphamide	CHEBI:27899; CHEBI:4911; CHEBI:4026																						
4982	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			cisplatin	CHEBI:27899	cisplatin		"{""preferred_term"": ""cisplatin"", ""term"": {""id"": ""CHEBI:27899"", ""label"": ""cisplatin""}}"																											
4983	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
4984	5511	230	Neuroblastoma	Neuroblastoma.yaml	treatments	0	Risk-Adapted Chemotherapy	Chemotherapy intensity varies by risk group. Low-risk patients may need only observation or minimal chemotherapy. High-risk patients receive intensive induction chemotherapy including cisplatin, etoposide, vincristine, cyclophosphamide, doxorubicin, and topotecan.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			cyclophosphamide	CHEBI:4026	cyclophosphamide		"{""preferred_term"": ""cyclophosphamide"", ""term"": {""id"": ""CHEBI:4026"", ""label"": ""cyclophosphamide""}}"																											
4985	5512	230	Neuroblastoma	Neuroblastoma.yaml	treatments	1	Surgical Resection	Surgery for primary tumor resection is performed after chemotherapy for high-risk disease. Complete resection is associated with better outcomes when achievable without significant morbidity.	treatment_term	treatment_term	$	Surgical Resection	Surgery for primary tumor resection is performed after chemotherapy for high-risk disease. Complete resection is associated with better outcomes when achievable without significant morbidity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
4986	5513	230	Neuroblastoma	Neuroblastoma.yaml	treatments	2	Autologous Stem Cell Transplant	High-dose chemotherapy with autologous stem cell rescue is standard for high-risk neuroblastoma following induction chemotherapy and surgical resection. Tandem transplant may provide additional benefit.	treatment_term	treatment_term	$	Autologous Stem Cell Transplant	High-dose chemotherapy with autologous stem cell rescue is standard for high-risk neuroblastoma following induction chemotherapy and surgical resection. Tandem transplant may provide additional benefit.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
4987	5514	230	Neuroblastoma	Neuroblastoma.yaml	treatments	3	Radiation Therapy	Radiation to the primary tumor bed is used in high-risk disease following surgical resection and stem cell transplant.	treatment_term	treatment_term	$	Radiation Therapy	Radiation to the primary tumor bed is used in high-risk disease following surgical resection and stem cell transplant.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
4988	5515	230	Neuroblastoma	Neuroblastoma.yaml	treatments	4	Anti-GD2 Immunotherapy	Anti-GD2 monoclonal antibody (dinutuximab) combined with GM-CSF and IL-2 has significantly improved outcomes in high-risk neuroblastoma during maintenance therapy. GD2 is highly expressed on neuroblastoma cells.	treatment_term	treatment_term	$	Anti-GD2 Immunotherapy	Anti-GD2 monoclonal antibody (dinutuximab) combined with GM-CSF and IL-2 has significantly improved outcomes in high-risk neuroblastoma during maintenance therapy. GD2 is highly expressed on neuroblastoma cells.	immunotherapy procedure	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy procedure"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
4989	5516	230	Neuroblastoma	Neuroblastoma.yaml	treatments	5	Isotretinoin (Retinoic Acid)	13-cis-retinoic acid (isotretinoin) is given during maintenance therapy to promote differentiation of residual neuroblastoma cells and reduce relapse risk.	treatment_term	treatment_term	$	Isotretinoin (Retinoic Acid)	13-cis-retinoic acid (isotretinoin) is given during maintenance therapy to promote differentiation of residual neuroblastoma cells and reduce relapse risk.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5003	5531	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	0	MEK Inhibitors	Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials.	treatment_term	treatment_term	$	MEK Inhibitors	Selumetinib is FDA-approved for symptomatic, inoperable plexiform neurofibromas in children aged 2 years and older. As a MEK inhibitor, it targets the downstream effector of hyperactive RAS signaling. Shrinkage of plexiform neurofibromas observed in clinical trials.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5004	5532	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	1	Surgical Management	Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST.	treatment_term	treatment_term	$	Surgical Management	Surgery for symptomatic neurofibromas causing pain, functional impairment, or disfigurement. Complete resection of plexiform neurofibromas often impossible due to infiltrative nature. Surgery is primary treatment for operable MPNST.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5005	5533	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	2	Surveillance Protocol	Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma.	treatment_term	treatment_term	$	Surveillance Protocol	Annual clinical evaluation including skin, skeletal, neurologic, and ophthalmologic examination. Annual ophthalmologic evaluation in children (optic glioma screening). MRI for symptomatic lesions or suspected MPNST. Blood pressure monitoring for renovascular disease or pheochromocytoma.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
5006	5534	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	treatments	3	Genetic Counseling	Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling for affected individuals and at-risk family members. Children of affected parents have 50% risk. High rate of de novo mutations means negative family history does not exclude NF1. Variable expressivity makes predicting severity difficult.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5035	5541	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	0	Eculizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	treatment_term	treatment_term	$	Eculizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5036	5542	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	1	Inebilizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	treatment_term	treatment_term	$	Inebilizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5037	5543	232	Neuromyelitis Optica	Neuromyelitis_Optica.yaml	treatments	2	Satralizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	treatment_term	treatment_term	$	Satralizumab	Maintenance therapy approved for AQP-4 seropositive NMOSD.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5050	5557	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	0	Acute Attack Treatment - Corticosteroids	"High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.
"	treatment_term	treatment_term	$	Acute Attack Treatment - Corticosteroids	"High-dose intravenous methylprednisolone (1g daily for 3-5 days) is first-line therapy for acute attacks.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5051	5559	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	2	Rituximab	"Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.
"	treatment_term	treatment_term	$	Rituximab	"Anti-CD20 monoclonal antibody that depletes B cells. Widely used as maintenance therapy to prevent relapses.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5052	5560	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	3	Eculizumab	"Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.
"	treatment_term	treatment_term	$	Eculizumab	"Complement C5 inhibitor approved for AQP4-positive NMOSD. Prevents complement-mediated astrocyte destruction by blocking terminal complement activation.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5053	5561	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	4	Inebilizumab	"Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.
"	treatment_term	treatment_term	$	Inebilizumab	"Anti-CD19 monoclonal antibody approved for AQP4-positive NMOSD. Provides broader B cell depletion than rituximab by targeting CD19.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5054	5562	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	treatments	5	Satralizumab	"IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.
"	treatment_term	treatment_term	$	Satralizumab	"IL-6 receptor inhibitor approved for AQP4-positive NMOSD. IL-6 promotes plasmablast survival and antibody production.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5084	5599	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	0	Surgery	Lobectomy or pneumonectomy for localized disease	treatment_term	treatment_term	$	Surgery	Lobectomy or pneumonectomy for localized disease	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5085	5600	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	1	Chemotherapy	Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5086	5601	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	2	Targeted Therapy	Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)	treatment_term	treatment_term	$	Targeted Therapy	Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5087	5602	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5088	5603	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	treatments	4	Radiation Therapy	Used for localized disease, palliation of symptoms, or brain metastases	treatment_term	treatment_term	$	Radiation Therapy	Used for localized disease, palliation of symptoms, or brain metastases	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
5129	5637	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	0	Growth Hormone Therapy	Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation.	treatment_term	treatment_term	$	Growth Hormone Therapy	Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation.	human growth hormone replacement therapy	MAXO:0000780	human growth hormone replacement therapy		"{""preferred_term"": ""human growth hormone replacement therapy"", ""term"": {""id"": ""MAXO:0000780"", ""label"": ""human growth hormone replacement therapy""}}"																											
5130	5637	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	0	Growth Hormone Therapy	Recombinant human growth hormone (rhGH) is FDA-approved for treatment of short stature in Noonan syndrome. Can improve final adult height by approximately 1 standard deviation.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Short stature	HP:0004322	Short stature		"{""preferred_term"": ""Short stature"", ""term"": {""id"": ""HP:0004322"", ""label"": ""Short stature""}}"																											
5131	5638	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	1	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	treatment_term	treatment_term	$	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5132	5638	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	1	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonic stenosis	HP:0001642	Pulmonic stenosis		"{""preferred_term"": ""Pulmonic stenosis"", ""term"": {""id"": ""HP:0001642"", ""label"": ""Pulmonic stenosis""}}"																											
5133	5638	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	1	Cardiac Surgical Intervention	Balloon valvuloplasty or surgical valvotomy for pulmonary valve stenosis; septal myectomy or alcohol ablation for severe hypertrophic cardiomyopathy.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
5134	5639	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	treatment_term	treatment_term	$	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5135	5639	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Hypertrophic cardiomyopathy	HP:0001639	Hypertrophic cardiomyopathy		"{""preferred_term"": ""Hypertrophic cardiomyopathy"", ""term"": {""id"": ""HP:0001639"", ""label"": ""Hypertrophic cardiomyopathy""}}"																											
5136	5639	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	2	MEK Inhibitor Therapy	Trametinib (MEK1/2 inhibitor) has shown promising results in case reports for treatment-refractory hypertrophic cardiomyopathy and lymphatic complications. MEK inhibition can reverse cardiomyocyte hypertrophy in animal models.	target_phenotypes[1]	target_phenotypes	target_phenotypes			Lymphedema	HP:0001004	Lymphedema		"{""preferred_term"": ""Lymphedema"", ""term"": {""id"": ""HP:0001004"", ""label"": ""Lymphedema""}}"																											
5137	5640	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	3	Early Intervention Services	Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities.	treatment_term	treatment_term	$	Early Intervention Services	Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities.	early intervention services	MAXO:0009101	early intervention services		"{""preferred_term"": ""early intervention services"", ""term"": {""id"": ""MAXO:0009101"", ""label"": ""early intervention services""}}"																											
5138	5640	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	3	Early Intervention Services	Developmental support including speech therapy, physical therapy, occupational therapy, and special education services for developmental delays and learning disabilities.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5139	5641	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	4	Speech Therapy	Speech and language therapy for articulation difficulties and language delays.	treatment_term	treatment_term	$	Speech Therapy	Speech and language therapy for articulation difficulties and language delays.	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
5140	5641	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	4	Speech Therapy	Speech and language therapy for articulation difficulties and language delays.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5141	5642	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	5	Physical Therapy	Physical therapy to address motor delays and hypotonia common in Noonan syndrome.	treatment_term	treatment_term	$	Physical Therapy	Physical therapy to address motor delays and hypotonia common in Noonan syndrome.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5142	5642	236	Noonan Syndrome	Noonan_Syndrome.yaml	treatments	5	Physical Therapy	Physical therapy to address motor delays and hypotonia common in Noonan syndrome.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Global developmental delay	HP:0001263	Global developmental delay		"{""preferred_term"": ""Global developmental delay"", ""term"": {""id"": ""HP:0001263"", ""label"": ""Global developmental delay""}}"																											
5173	5673	237	Obesity	Obesity.yaml	treatments	0	Lifestyle Modification	Dietary changes and increased physical activity as foundation of treatment.	treatment_term	treatment_term	$	Lifestyle Modification	Dietary changes and increased physical activity as foundation of treatment.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5174	5674	237	Obesity	Obesity.yaml	treatments	1	GLP-1 Receptor Agonists	Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects.	treatment_term	treatment_term	$	GLP-1 Receptor Agonists	Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5175	5675	237	Obesity	Obesity.yaml	treatments	2	GLP-1/GIP Dual Agonists	Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation.	treatment_term	treatment_term	$	GLP-1/GIP Dual Agonists	Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5176	5676	237	Obesity	Obesity.yaml	treatments	3	Bariatric Surgery	Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity.	treatment_term	treatment_term	$	Bariatric Surgery	Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5177	5677	237	Obesity	Obesity.yaml	treatments	4	Behavioral Therapy	Cognitive behavioral therapy for eating behaviors.	treatment_term	treatment_term	$	Behavioral Therapy	Cognitive behavioral therapy for eating behaviors.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
5178	5678	237	Obesity	Obesity.yaml	treatments	5	Orlistat	Lipase inhibitor reducing fat absorption.	treatment_term	treatment_term	$	Orlistat	Lipase inhibitor reducing fat absorption.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5194	5713	239	Onchocerciasis	Onchocerciasis.yaml	treatments	0	Ivermectin therapy	Ivermectin is the drug of choice for skin and ocular manifestations.	treatment_term	treatment_term	$	Ivermectin therapy	Ivermectin is the drug of choice for skin and ocular manifestations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5216	5749	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates (pamidronate, zoledronic acid) are used to increase bone mineral density and reduce fracture frequency, particularly in children.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates (pamidronate, zoledronic acid) are used to increase bone mineral density and reduce fracture frequency, particularly in children.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5217	5750	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	1	Physical Therapy	"Exercise and physical therapy to strengthen muscles and improve mobility while protecting fragile bones.
"	treatment_term	treatment_term	$	Physical Therapy	"Exercise and physical therapy to strengthen muscles and improve mobility while protecting fragile bones.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5218	5751	241	Osteogenesis Imperfecta Type I	Osteogenesis_Imperfecta_Type_I.yaml	treatments	2	Fracture Management	"Standard orthopedic management of fractures with appropriate immobilization.
"	treatment_term	treatment_term	$	Fracture Management	"Standard orthopedic management of fractures with appropriate immobilization.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5229	5762	242	Osteogenesis Imperfecta Type II	Osteogenesis_Imperfecta_Type_II.yaml	treatments	0	Supportive Care	"Palliative supportive care given the lethal nature of the condition. Focus on comfort and family support.
"	treatment_term	treatment_term	$	Supportive Care	"Palliative supportive care given the lethal nature of the condition. Focus on comfort and family support.
"	Supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5241	5774	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	0	Bisphosphonate Therapy	"Intravenous bisphosphonates (pamidronate, zoledronic acid) to increase bone density and reduce fracture frequency. Most beneficial in childhood.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Intravenous bisphosphonates (pamidronate, zoledronic acid) to increase bone density and reduce fracture frequency. Most beneficial in childhood.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5242	5775	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	1	Rodding Surgery	"Intramedullary rodding (telescoping rods) to stabilize long bones, correct deformities, and prevent fractures. Multiple surgeries typically required as the child grows.
"	treatment_term	treatment_term	$	Rodding Surgery	"Intramedullary rodding (telescoping rods) to stabilize long bones, correct deformities, and prevent fractures. Multiple surgeries typically required as the child grows.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5243	5776	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	2	Spinal Fusion	"Surgical stabilization of severe scoliosis to prevent respiratory compromise.
"	treatment_term	treatment_term	$	Spinal Fusion	"Surgical stabilization of severe scoliosis to prevent respiratory compromise.
"	Spinal surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Spinal surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5244	5777	243	Osteogenesis Imperfecta Type III	Osteogenesis_Imperfecta_Type_III.yaml	treatments	3	Physical Therapy	"Careful physical therapy to maintain mobility and muscle strength while minimizing fracture risk.
"	treatment_term	treatment_term	$	Physical Therapy	"Careful physical therapy to maintain mobility and muscle strength while minimizing fracture risk.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5254	5787	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates to increase bone density and reduce fractures, particularly beneficial in childhood.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates to increase bone density and reduce fractures, particularly beneficial in childhood.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5255	5788	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	1	Orthopedic Management	"Fracture treatment and corrective surgery for deformities as needed. Intramedullary rodding for severe cases.
"	treatment_term	treatment_term	$	Orthopedic Management	"Fracture treatment and corrective surgery for deformities as needed. Intramedullary rodding for severe cases.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5256	5789	244	Osteogenesis Imperfecta Type IV	Osteogenesis_Imperfecta_Type_IV.yaml	treatments	2	Physical Therapy	"Exercise programs to strengthen muscles and maintain bone health.
"	treatment_term	treatment_term	$	Physical Therapy	"Exercise programs to strengthen muscles and maintain bone health.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5267	5800	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates may reduce fracture frequency, though hyperplastic callus can still occur.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates may reduce fracture frequency, though hyperplastic callus can still occur.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5268	5801	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	1	Surgical Management	"Orthopedic surgery for fractures and deformities. Care must be taken regarding hyperplastic callus formation after procedures.
"	treatment_term	treatment_term	$	Surgical Management	"Orthopedic surgery for fractures and deformities. Care must be taken regarding hyperplastic callus formation after procedures.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5269	5802	245	Osteogenesis Imperfecta Type V	Osteogenesis_Imperfecta_Type_V.yaml	treatments	2	Interosseous Membrane Excision	"Surgical removal of calcified interosseous membrane to restore forearm rotation in selected cases.
"	treatment_term	treatment_term	$	Interosseous Membrane Excision	"Surgical removal of calcified interosseous membrane to restore forearm rotation in selected cases.
"	Surgical excision	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Surgical excision"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5280	5813	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	0	Bisphosphonate Therapy	"Bisphosphonates to improve bone density, though response may differ from classical OI due to distinct pathophysiology.
"	treatment_term	treatment_term	$	Bisphosphonate Therapy	"Bisphosphonates to improve bone density, though response may differ from classical OI due to distinct pathophysiology.
"	Bisphosphonate therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""Bisphosphonate therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5281	5814	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	1	Orthopedic Management	"Fracture management and corrective surgery for deformities. Rodding procedures for long bone stabilization.
"	treatment_term	treatment_term	$	Orthopedic Management	"Fracture management and corrective surgery for deformities. Rodding procedures for long bone stabilization.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5282	5815	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	2	Physical Therapy	"Careful rehabilitation to maintain mobility while minimizing fracture risk.
"	treatment_term	treatment_term	$	Physical Therapy	"Careful rehabilitation to maintain mobility while minimizing fracture risk.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5283	5816	246	Osteogenesis Imperfecta Type VII	Osteogenesis_Imperfecta_Type_VII.yaml	treatments	3	Genetic Counseling	"Genetic counseling for families regarding recurrence risk and carrier testing for at-risk relatives.
"	treatment_term	treatment_term	$	Genetic Counseling	"Genetic counseling for families regarding recurrence risk and carrier testing for at-risk relatives.
"	Genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""Genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5293	5839	247	Osteoporosis	Osteoporosis.yaml	treatments	0	Bisphosphonates	First-line antiresorptives (alendronate, risedronate, zoledronic acid).	treatment_term	treatment_term	$	Bisphosphonates	First-line antiresorptives (alendronate, risedronate, zoledronic acid).	bisphosphonate agent therapy	MAXO:0000954	bisphosphonate agent therapy		"{""preferred_term"": ""bisphosphonate agent therapy"", ""term"": {""id"": ""MAXO:0000954"", ""label"": ""bisphosphonate agent therapy""}}"																											
5294	5840	247	Osteoporosis	Osteoporosis.yaml	treatments	1	Denosumab	RANKL inhibitor, potent antiresorptive.	treatment_term	treatment_term	$	Denosumab	RANKL inhibitor, potent antiresorptive.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5295	5841	247	Osteoporosis	Osteoporosis.yaml	treatments	2	Teriparatide	PTH analog, anabolic agent for severe osteoporosis.	treatment_term	treatment_term	$	Teriparatide	PTH analog, anabolic agent for severe osteoporosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5296	5842	247	Osteoporosis	Osteoporosis.yaml	treatments	3	Romosozumab	Sclerostin inhibitor with dual anabolic/antiresorptive effect.	treatment_term	treatment_term	$	Romosozumab	Sclerostin inhibitor with dual anabolic/antiresorptive effect.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5297	5843	247	Osteoporosis	Osteoporosis.yaml	treatments	4	Calcium Supplementation	Ensure adequate intake (1000-1200 mg/day).	treatment_term	treatment_term	$	Calcium Supplementation	Ensure adequate intake (1000-1200 mg/day).	calcium supplementation	MAXO:0001139	calcium supplementation		"{""preferred_term"": ""calcium supplementation"", ""term"": {""id"": ""MAXO:0001139"", ""label"": ""calcium supplementation""}}"																											
5298	5844	247	Osteoporosis	Osteoporosis.yaml	treatments	5	Vitamin D Supplementation	Maintain 25(OH)D >30 ng/mL.	treatment_term	treatment_term	$	Vitamin D Supplementation	Maintain 25(OH)D >30 ng/mL.	vitamin D supplementation	MAXO:0000110	vitamin D supplementation		"{""preferred_term"": ""vitamin D supplementation"", ""term"": {""id"": ""MAXO:0000110"", ""label"": ""vitamin D supplementation""}}"																											
5299	5845	247	Osteoporosis	Osteoporosis.yaml	treatments	6	Weight-Bearing Exercise	Helps maintain bone density.	treatment_term	treatment_term	$	Weight-Bearing Exercise	Helps maintain bone density.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5308	5852	248	Osteosarcoma	Osteosarcoma.yaml	treatments	0	Surgical Resection	Surgical removal of the primary tumor when feasible.	treatment_term	treatment_term	$	Surgical Resection	Surgical removal of the primary tumor when feasible.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5309	5853	248	Osteosarcoma	Osteosarcoma.yaml	treatments	1	Multi-Agent Chemotherapy	Combination chemotherapy used in neoadjuvant and adjuvant settings.	treatment_term	treatment_term	$	Multi-Agent Chemotherapy	Combination chemotherapy used in neoadjuvant and adjuvant settings.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5321	5864	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	0	Alpelisib	PI3K alpha-selective inhibitor FDA-approved for HR+/HER2- metastatic breast cancer with PIK3CA mutation, in combination with fulvestrant, after progression on endocrine therapy. SOLAR-1 trial demonstrated significant PFS benefit. Key toxicity is hyperglycemia due to PI3K role in insulin signaling.	treatment_term	treatment_term	$	Alpelisib	PI3K alpha-selective inhibitor FDA-approved for HR+/HER2- metastatic breast cancer with PIK3CA mutation, in combination with fulvestrant, after progression on endocrine therapy. SOLAR-1 trial demonstrated significant PFS benefit. Key toxicity is hyperglycemia due to PI3K role in insulin signaling.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5322	5865	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	1	Endocrine Therapy Plus CDK4/6 Inhibitors	First-line treatment for metastatic ER+/HER2- disease typically combines aromatase inhibitors with CDK4/6 inhibitors, regardless of PIK3CA status. Alpelisib is used after progression on this regimen.	treatment_term	treatment_term	$	Endocrine Therapy Plus CDK4/6 Inhibitors	First-line treatment for metastatic ER+/HER2- disease typically combines aromatase inhibitors with CDK4/6 inhibitors, regardless of PIK3CA status. Alpelisib is used after progression on this regimen.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5323	5866	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	treatments	2	Capivasertib	AKT inhibitor that has shown activity in PIK3CA-mutated, AKT1-mutated, or PTEN-altered breast cancer. Approved in combination with fulvestrant for HR+/HER2- advanced breast cancer after prior endocrine therapy.	treatment_term	treatment_term	$	Capivasertib	AKT inhibitor that has shown activity in PIK3CA-mutated, AKT1-mutated, or PTEN-altered breast cancer. Approved in combination with fulvestrant for HR+/HER2- advanced breast cancer after prior endocrine therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5377	5904	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	0	Levodopa/Carbidopa	Gold standard treatment, replaces dopamine precursor.	treatment_term	treatment_term	$	Levodopa/Carbidopa	Gold standard treatment, replaces dopamine precursor.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5378	5905	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	1	Dopamine Agonists	Directly stimulate dopamine receptors.	treatment_term	treatment_term	$	Dopamine Agonists	Directly stimulate dopamine receptors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5379	5906	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	2	MAO-B Inhibitors	Prevent dopamine breakdown (selegiline, rasagiline).	treatment_term	treatment_term	$	MAO-B Inhibitors	Prevent dopamine breakdown (selegiline, rasagiline).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5380	5907	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	3	COMT Inhibitors	Extend levodopa duration (entacapone).	treatment_term	treatment_term	$	COMT Inhibitors	Extend levodopa duration (entacapone).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5381	5908	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	4	Deep Brain Stimulation	Surgical therapy for advanced motor fluctuations.	treatment_term	treatment_term	$	Deep Brain Stimulation	Surgical therapy for advanced motor fluctuations.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5382	5909	250	Parkinson's Disease	Parkinsons_Disease.yaml	treatments	5	Physical Therapy	Maintains mobility and reduces fall risk.	treatment_term	treatment_term	$	Physical Therapy	Maintains mobility and reduces fall risk.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5412	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term	treatment_term	$	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""prednisone"", ""term"": {""id"": ""NCIT:C770"", ""label"": ""Prednisone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Triamcinolone; Prednisone	NCIT:C901; NCIT:C770	NCIT:C2259			
5413	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5414	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			triamcinolone	NCIT:C901	Triamcinolone		"{""preferred_term"": ""triamcinolone"", ""term"": {""id"": ""NCIT:C901"", ""label"": ""Triamcinolone""}}"																											
5415	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5416	5939	251	Pars Planitis	Pars_Planitis.yaml	treatments	0	Corticosteroids	First-line treatment for reducing inflammation in pars planitis.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			prednisone	NCIT:C770	Prednisone		"{""preferred_term"": ""prednisone"", ""term"": {""id"": ""NCIT:C770"", ""label"": ""Prednisone""}}"																											
5417	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term	treatment_term	$	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""methotrexate"", ""term"": {""id"": ""NCIT:C642"", ""label"": ""Methotrexate""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""NCIT:C1468"", ""label"": ""Mycophenolate Mofetil""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""cyclosporine"", ""term"": {""id"": ""NCIT:C406"", ""label"": ""Cyclosporine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Methotrexate; Mycophenolate Mofetil; Azathioprine; Cyclosporine	NCIT:C642; NCIT:C1468; NCIT:C290; NCIT:C406	NCIT:C2259			
5418	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5419	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			methotrexate	NCIT:C642	Methotrexate		"{""preferred_term"": ""methotrexate"", ""term"": {""id"": ""NCIT:C642"", ""label"": ""Methotrexate""}}"																											
5420	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5421	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			mycophenolate mofetil	NCIT:C1468	Mycophenolate Mofetil		"{""preferred_term"": ""mycophenolate mofetil"", ""term"": {""id"": ""NCIT:C1468"", ""label"": ""Mycophenolate Mofetil""}}"																											
5422	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[2].predicate	treatment_term	treatment_term.qualifiers[2]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5423	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[2].value	treatment_term	treatment_term.qualifiers[2]			azathioprine	NCIT:C290	Azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}"																											
5424	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[3].predicate	treatment_term	treatment_term.qualifiers[3]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5425	5940	251	Pars Planitis	Pars_Planitis.yaml	treatments	1	Immunosuppressive Agents	Second-line therapy for chronic or steroid-resistant cases.	treatment_term.qualifiers[3].value	treatment_term	treatment_term.qualifiers[3]			cyclosporine	NCIT:C406	Cyclosporine		"{""preferred_term"": ""cyclosporine"", ""term"": {""id"": ""NCIT:C406"", ""label"": ""Cyclosporine""}}"																											
5426	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term	treatment_term	$	Biological Therapy	TNF-alpha inhibitors for refractory cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""adalimumab"", ""term"": {""id"": ""NCIT:C65216"", ""label"": ""Adalimumab""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Adalimumab; Infliximab	NCIT:C65216; NCIT:C1789	NCIT:C2259			
5427	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5428	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			adalimumab	NCIT:C65216	Adalimumab		"{""preferred_term"": ""adalimumab"", ""term"": {""id"": ""NCIT:C65216"", ""label"": ""Adalimumab""}}"																											
5429	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5430	5941	251	Pars Planitis	Pars_Planitis.yaml	treatments	2	Biological Therapy	TNF-alpha inhibitors for refractory cases.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			infliximab	NCIT:C1789	Infliximab		"{""preferred_term"": ""infliximab"", ""term"": {""id"": ""NCIT:C1789"", ""label"": ""Infliximab""}}"																											
5431	5942	251	Pars Planitis	Pars_Planitis.yaml	treatments	3	Pars Plana Vitrectomy	Surgical intervention for severe vitreous opacities or complications.	treatment_term	treatment_term	$	Pars Plana Vitrectomy	Surgical intervention for severe vitreous opacities or complications.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5456	5965	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	0	Supportive Care	Includes rest, fluids, and analgesics for managing symptoms.	treatment_term	treatment_term	$	Supportive Care	Includes rest, fluids, and analgesics for managing symptoms.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5457	5966	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	treatments	1	Intravenous Immunoglobulin (IVIG)	Used in severe cases, particularly for individuals with immunodeficiency or severe anemia.	treatment_term	treatment_term	$	Intravenous Immunoglobulin (IVIG)	Used in severe cases, particularly for individuals with immunodeficiency or severe anemia.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5518	6052	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	0	Symptomatic Management	Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management.	treatment_term	treatment_term	$	Symptomatic Management	Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5519	6053	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	1	Nutritional Support	Specialized diet and supplements to manage biochemical abnormalities.	treatment_term	treatment_term	$	Nutritional Support	Specialized diet and supplements to manage biochemical abnormalities.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5520	6054	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	2	Liver Transplant	Considered in severe cases with significant liver dysfunction.	treatment_term	treatment_term	$	Liver Transplant	Considered in severe cases with significant liver dysfunction.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
5521	6055	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	treatments	3	Genetic Counseling	Providing information and support to families regarding inheritance and implications.	treatment_term	treatment_term	$	Genetic Counseling	Providing information and support to families regarding inheritance and implications.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5546	6073	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	0	Endoscopic polypectomy	"Regular surveillance endoscopy with removal of polyps >10-15 mm reduces bleeding complications and cancer risk. Multiple sessions may be needed given the polyp burden.
"	treatment_term	treatment_term	$	Endoscopic polypectomy	"Regular surveillance endoscopy with removal of polyps >10-15 mm reduces bleeding complications and cancer risk. Multiple sessions may be needed given the polyp burden.
"	endoscopic procedure	MAXO:0000130	endoscopic procedure		"{""preferred_term"": ""endoscopic procedure"", ""term"": {""id"": ""MAXO:0000130"", ""label"": ""endoscopic procedure""}}"																											
5547	6074	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	1	Surgical resection	"Reserved for cases with severe polyp burden, recurrent intussusception, or malignant transformation.
"	treatment_term	treatment_term	$	Surgical resection	"Reserved for cases with severe polyp burden, recurrent intussusception, or malignant transformation.
"	surgical resection	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical resection"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5548	6075	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	treatments	2	Genetic counseling	"Family members should receive counseling and cascade genetic testing for STK11 mutations.
"	treatment_term	treatment_term	$	Genetic counseling	"Family members should receive counseling and cascade genetic testing for STK11 mutations.
"	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5559	6086	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	treatments	0	Cranial Vault Surgery	"Early surgical intervention for craniosynostosis, especially urgent in Types 2 and 3 to manage intracranial pressure.
"	treatment_term	treatment_term	$	Cranial Vault Surgery	"Early surgical intervention for craniosynostosis, especially urgent in Types 2 and 3 to manage intracranial pressure.
"	Craniofacial surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Craniofacial surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5560	6087	257	Pfeiffer Syndrome	Pfeiffer_Syndrome.yaml	treatments	1	Airway Management	"Tracheostomy may be required in severe cases (Types 2 and 3) due to combined midface hypoplasia and choanal stenosis.
"	treatment_term	treatment_term	$	Airway Management	"Tracheostomy may be required in severe cases (Types 2 and 3) due to combined midface hypoplasia and choanal stenosis.
"	Airway management	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Airway management"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5576	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term	treatment_term	$	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}, {""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}]}"				dasatinib; imatinib	CHEBI:49375; CHEBI:45783																						
5577	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			dasatinib	CHEBI:49375	dasatinib		"{""preferred_term"": ""dasatinib"", ""term"": {""id"": ""CHEBI:49375"", ""label"": ""dasatinib""}}"																											
5578	6104	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	0	Tyrosine Kinase Inhibitor plus Chemotherapy	Addition of TKIs (imatinib, dasatinib) to multi-agent chemotherapy dramatically improves remission rates and survival in Ph+ ALL. Dasatinib achieves better CNS penetration. TKIs are continued through all phases of treatment including maintenance.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			imatinib	CHEBI:45783	imatinib		"{""preferred_term"": ""imatinib"", ""term"": {""id"": ""CHEBI:45783"", ""label"": ""imatinib""}}"																											
5579	6105	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	1	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	treatment_term	treatment_term	$	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}]}"				ponatinib	CHEBI:78543																						
5580	6105	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	1	Ponatinib	Third-generation TKI with activity against T315I mutation. Used for patients with TKI-resistant mutations or as frontline therapy in combination with chemotherapy for enhanced efficacy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ponatinib	CHEBI:78543	ponatinib		"{""preferred_term"": ""ponatinib"", ""term"": {""id"": ""CHEBI:78543"", ""label"": ""ponatinib""}}"																											
5581	6106	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	2	Blinatumomab	CD19-CD3 bispecific T-cell engager antibody effective in relapsed/refractory Ph+ ALL. Can be combined with TKIs. Achieves molecular remissions in many patients, potentially enabling chemotherapy-free regimens.	treatment_term	treatment_term	$	Blinatumomab	CD19-CD3 bispecific T-cell engager antibody effective in relapsed/refractory Ph+ ALL. Can be combined with TKIs. Achieves molecular remissions in many patients, potentially enabling chemotherapy-free regimens.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5582	6107	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	3	Allogeneic Stem Cell Transplantation	Historically considered standard for all Ph+ ALL patients in first remission. With improved TKI-based regimens, transplant may be reserved for patients with persistent MRD or high-risk features. Provides graft-versus-leukemia effect.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Historically considered standard for all Ph+ ALL patients in first remission. With improved TKI-based regimens, transplant may be reserved for patients with persistent MRD or high-risk features. Provides graft-versus-leukemia effect.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
5583	6108	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	treatments	4	CAR-T Cell Therapy	CD19-directed CAR-T cells are effective in relapsed/refractory Ph+ ALL. Can achieve durable remissions in patients who have failed TKIs and chemotherapy.	treatment_term	treatment_term	$	CAR-T Cell Therapy	CD19-directed CAR-T cells are effective in relapsed/refractory Ph+ ALL. Can achieve durable remissions in patients who have failed TKIs and chemotherapy.	immunotherapy	MAXO:0001002	immunotherapy procedure		"{""preferred_term"": ""immunotherapy"", ""term"": {""id"": ""MAXO:0001002"", ""label"": ""immunotherapy procedure""}}"																											
5597	6132	259	Phenylketonuria	Phenylketonuria.yaml	treatments	0	Phenylalanine-Restricted Diet	Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.	treatment_term	treatment_term	$	Phenylalanine-Restricted Diet	Lifelong dietary restriction of phenylalanine intake, mainstay of treatment.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5598	6133	259	Phenylketonuria	Phenylketonuria.yaml	treatments	1	Medical Formula	Phenylalanine-free amino acid supplements to provide protein needs.	treatment_term	treatment_term	$	Medical Formula	Phenylalanine-free amino acid supplements to provide protein needs.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5599	6134	259	Phenylketonuria	Phenylketonuria.yaml	treatments	2	Sapropterin (Kuvan)	BH4 cofactor replacement for responsive patients, allows dietary liberalization.	treatment_term	treatment_term	$	Sapropterin (Kuvan)	BH4 cofactor replacement for responsive patients, allows dietary liberalization.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5600	6135	259	Phenylketonuria	Phenylketonuria.yaml	treatments	3	Pegvaliase (Palynziq)	Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.	treatment_term	treatment_term	$	Pegvaliase (Palynziq)	Enzyme substitution therapy using PEGylated phenylalanine ammonia lyase.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5601	6136	259	Phenylketonuria	Phenylketonuria.yaml	treatments	4	Large Neutral Amino Acids	Compete with phenylalanine for brain transport, adjunctive therapy.	treatment_term	treatment_term	$	Large Neutral Amino Acids	Compete with phenylalanine for brain transport, adjunctive therapy.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
5613	6156	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	0	Surgical Resection	Complete surgical resection is the primary treatment for localized PPGL. Requires careful preoperative alpha-blockade followed by beta-blockade to prevent perioperative hypertensive crisis.	treatment_term	treatment_term	$	Surgical Resection	Complete surgical resection is the primary treatment for localized PPGL. Requires careful preoperative alpha-blockade followed by beta-blockade to prevent perioperative hypertensive crisis.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5614	6157	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	1	Alpha-Adrenergic Blockade	Preoperative alpha-blockade with phenoxybenzamine or doxazosin is essential to control hypertension and allow volume expansion before surgery.	treatment_term	treatment_term	$	Alpha-Adrenergic Blockade	Preoperative alpha-blockade with phenoxybenzamine or doxazosin is essential to control hypertension and allow volume expansion before surgery.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5615	6158	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	2	MIBG Therapy	131I-MIBG (metaiodobenzylguanidine) is a targeted radiotherapy for MIBG-avid metastatic PPGL. High-specific-activity 131I-MIBG is FDA-approved.	treatment_term	treatment_term	$	MIBG Therapy	131I-MIBG (metaiodobenzylguanidine) is a targeted radiotherapy for MIBG-avid metastatic PPGL. High-specific-activity 131I-MIBG is FDA-approved.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
5616	6159	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	3	Temozolomide	Alkylating chemotherapy showing activity in metastatic PPGL, particularly SDHB-mutated tumors with MGMT promoter methylation.	treatment_term	treatment_term	$	Temozolomide	Alkylating chemotherapy showing activity in metastatic PPGL, particularly SDHB-mutated tumors with MGMT promoter methylation.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5617	6160	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	treatments	4	Sunitinib	Multi-kinase inhibitor with antiangiogenic activity showing benefit in progressive metastatic PPGL. Used in clinical practice despite limited prospective data.	treatment_term	treatment_term	$	Sunitinib	Multi-kinase inhibitor with antiangiogenic activity showing benefit in progressive metastatic PPGL. Used in clinical practice despite limited prospective data.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5642	6186	261	Pick Disease	Pick_Disease.yaml	treatments	0	Symptomatic Management	Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function.	treatment_term	treatment_term	$	Symptomatic Management	Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5643	6187	261	Pick Disease	Pick_Disease.yaml	treatments	1	Physical Therapy	Physical therapy to maintain mobility and manage motor symptoms that may emerge in later disease stages.	treatment_term	treatment_term	$	Physical Therapy	Physical therapy to maintain mobility and manage motor symptoms that may emerge in later disease stages.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5644	6188	261	Pick Disease	Pick_Disease.yaml	treatments	2	Occupational Therapy	Occupational therapy to support daily living activities and maintain independence as cognitive and behavioral symptoms progress.	treatment_term	treatment_term	$	Occupational Therapy	Occupational therapy to support daily living activities and maintain independence as cognitive and behavioral symptoms progress.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
5645	6189	261	Pick Disease	Pick_Disease.yaml	treatments	3	Speech Therapy	Speech therapy for patients with language variant (primary progressive aphasia) to support communication abilities.	treatment_term	treatment_term	$	Speech Therapy	Speech therapy for patients with language variant (primary progressive aphasia) to support communication abilities.	speech therapy	MAXO:0000930	speech therapy		"{""preferred_term"": ""speech therapy"", ""term"": {""id"": ""MAXO:0000930"", ""label"": ""speech therapy""}}"																											
5646	6190	261	Pick Disease	Pick_Disease.yaml	treatments	4	Caregiver Support	Education and resources for caregivers to manage progressive symptoms and provide quality care.	treatment_term	treatment_term	$	Caregiver Support	Education and resources for caregivers to manage progressive symptoms and provide quality care.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
5648	6193	262	Pinta	Pinta.yaml	treatments	0	Penicillin injection	Single-dose intramuscular penicillin treats all stages of pinta.	treatment_term	treatment_term	$	Penicillin injection	Single-dose intramuscular penicillin treats all stages of pinta.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5661	6208	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	0	Albendazole therapy	Benzimidazole antiparasitic used for smaller or inoperable hydatid cysts and as adjunct around surgery.	treatment_term	treatment_term	$	Albendazole therapy	Benzimidazole antiparasitic used for smaller or inoperable hydatid cysts and as adjunct around surgery.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5662	6209	263	Polycystic echinococcosis	Polycystic_Echinococcosis.yaml	treatments	1	Radical hepatic resection	Surgical removal of involved hepatic segments for large polycystic echinococcosis lesions or when malignancy is suspected.	treatment_term	treatment_term	$	Radical hepatic resection	Surgical removal of involved hepatic segments for large polycystic echinococcosis lesions or when malignancy is suspected.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5687	6233	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	0	Tolvaptan	"Vasopressin V2 receptor antagonist that slows cyst growth and kidney enlargement in ADPKD. First disease-modifying therapy approved for ADPKD. Requires hepatic monitoring due to risk of elevated liver enzymes.
"	treatment_term	treatment_term	$	Tolvaptan	"Vasopressin V2 receptor antagonist that slows cyst growth and kidney enlargement in ADPKD. First disease-modifying therapy approved for ADPKD. Requires hepatic monitoring due to risk of elevated liver enzymes.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5688	6234	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	1	Blood Pressure Control	"Aggressive hypertension management with ACE inhibitors or ARBs to slow disease progression and reduce cardiovascular risk.
"	treatment_term	treatment_term	$	Blood Pressure Control	"Aggressive hypertension management with ACE inhibitors or ARBs to slow disease progression and reduce cardiovascular risk.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5689	6235	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	2	Renal Dialysis	"Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease. PKD is one of the leading causes of kidney failure requiring dialysis.
"	treatment_term	treatment_term	$	Renal Dialysis	"Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease. PKD is one of the leading causes of kidney failure requiring dialysis.
"	renal dialysis	MAXO:0000601	renal dialysis		"{""preferred_term"": ""renal dialysis"", ""term"": {""id"": ""MAXO:0000601"", ""label"": ""renal dialysis""}}"																											
5690	6236	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	treatments	3	Kidney Transplantation	"Kidney transplantation is the preferred treatment for end-stage renal disease in PKD. Native nephrectomy may be required if kidneys are too large.
"	treatment_term	treatment_term	$	Kidney Transplantation	"Kidney transplantation is the preferred treatment for end-stage renal disease in PKD. Native nephrectomy may be required if kidneys are too large.
"	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
5715	6280	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	0	Therapeutic Phlebotomy	Therapeutic phlebotomy to maintain hematocrit below 45% is the cornerstone of treatment for all PV patients. Reduces thrombotic risk by lowering blood viscosity.	treatment_term	treatment_term	$	Therapeutic Phlebotomy	Therapeutic phlebotomy to maintain hematocrit below 45% is the cornerstone of treatment for all PV patients. Reduces thrombotic risk by lowering blood viscosity.	therapeutic procedure	MAXO:0000002	therapeutic procedure		"{""preferred_term"": ""therapeutic procedure"", ""term"": {""id"": ""MAXO:0000002"", ""label"": ""therapeutic procedure""}}"																											
5716	6281	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	1	Low-Dose Aspirin	Low-dose aspirin (81-100 mg daily) is recommended for all PV patients without contraindications to reduce thrombotic risk. Reduces arterial and possibly venous thrombosis.	treatment_term	treatment_term	$	Low-Dose Aspirin	Low-dose aspirin (81-100 mg daily) is recommended for all PV patients without contraindications to reduce thrombotic risk. Reduces arterial and possibly venous thrombosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5717	6282	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	2	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	treatment_term	treatment_term	$	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}"				hydroxyurea	CHEBI:44423																						
5718	6282	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	2	Hydroxyurea	First-line cytoreductive therapy for high-risk PV patients (age >60 years or prior thrombosis). Reduces all three cell lines and decreases thrombotic events.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"																											
5719	6283	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	3	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	treatment_term	treatment_term	$	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}]}"				ruxolitinib	CHEBI:66919																						
5720	6283	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	3	Ruxolitinib	JAK1/JAK2 inhibitor approved for PV inadequately controlled by hydroxyurea. Provides excellent control of hematocrit, reduces spleen size, and markedly improves symptom burden including pruritus and fatigue.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"																											
5721	6284	266	Polycythemia Vera	Polycythemia_Vera.yaml	treatments	4	Interferon-alpha	Alternative to hydroxyurea, particularly for younger patients and during pregnancy. May induce molecular remissions with reduction in JAK2 V617F allele burden.	treatment_term	treatment_term	$	Interferon-alpha	Alternative to hydroxyurea, particularly for younger patients and during pregnancy. May induce molecular remissions with reduction in JAK2 V617F allele burden.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5749	6317	268	Pouchitis	Pouchitis.yaml	treatments	0	Antibiotic Therapy	"First-line treatment with antibiotics such as ciprofloxacin and metronidazole to reduce bacterial overgrowth and restore microbial balance. Response rates are typically 80-90% for acute pouchitis.
"	treatment_term	treatment_term	$	Antibiotic Therapy	"First-line treatment with antibiotics such as ciprofloxacin and metronidazole to reduce bacterial overgrowth and restore microbial balance. Response rates are typically 80-90% for acute pouchitis.
"	antibacterial agent therapy	MAXO:0000061	antibacterial agent therapy		"{""preferred_term"": ""antibacterial agent therapy"", ""term"": {""id"": ""MAXO:0000061"", ""label"": ""antibacterial agent therapy""}}"																											
5750	6318	268	Pouchitis	Pouchitis.yaml	treatments	1	Probiotic Therapy	"VSL#3 (now marketed as Visbiome), a high-potency probiotic mixture containing 8 bacterial strains, has demonstrated efficacy in preventing recurrent pouchitis and maintaining remission.
"	treatment_term	treatment_term	$	Probiotic Therapy	"VSL#3 (now marketed as Visbiome), a high-potency probiotic mixture containing 8 bacterial strains, has demonstrated efficacy in preventing recurrent pouchitis and maintaining remission.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5751	6319	268	Pouchitis	Pouchitis.yaml	treatments	2	Anti-inflammatory Medications	"Topical or oral 5-aminosalicylic acid (5-ASA) compounds, topical corticosteroids, or corticosteroid enemas for management of chronic or refractory pouchitis.
"	treatment_term	treatment_term	$	Anti-inflammatory Medications	"Topical or oral 5-aminosalicylic acid (5-ASA) compounds, topical corticosteroids, or corticosteroid enemas for management of chronic or refractory pouchitis.
"	anti-inflammatory agent therapy	MAXO:0000169	anti-inflammatory agent therapy		"{""preferred_term"": ""anti-inflammatory agent therapy"", ""term"": {""id"": ""MAXO:0000169"", ""label"": ""anti-inflammatory agent therapy""}}"																											
5752	6320	268	Pouchitis	Pouchitis.yaml	treatments	3	Immunosuppressive Therapy	"For chronic refractory pouchitis, biologic agents (anti-TNF therapy such as infliximab or adalimumab) or immunomodulators (azathioprine, 6-mercaptopurine) may be necessary.
"	treatment_term	treatment_term	$	Immunosuppressive Therapy	"For chronic refractory pouchitis, biologic agents (anti-TNF therapy such as infliximab or adalimumab) or immunomodulators (azathioprine, 6-mercaptopurine) may be necessary.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5795	6373	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	0	Airway Clearance Techniques	Methods to help clear mucus from the lungs, such as chest physical therapy.	treatment_term	treatment_term	$	Airway Clearance Techniques	Methods to help clear mucus from the lungs, such as chest physical therapy.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
5796	6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	Antibiotic Therapy	Long-term or prophylactic antibiotics to control respiratory infections.	target_phenotypes[0]	target_phenotypes	target_phenotypes			Recurrent Respiratory Infections	HP:0002205	Recurrent respiratory infections		"{""preferred_term"": ""Recurrent Respiratory Infections"", ""term"": {""id"": ""HP:0002205"", ""label"": ""Recurrent respiratory infections""}}"																											
5797	6374	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	1	Antibiotic Therapy	Long-term or prophylactic antibiotics to control respiratory infections.	treatment_term	treatment_term	$	Antibiotic Therapy	Long-term or prophylactic antibiotics to control respiratory infections.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5798	6375	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	2	Bronchodilators	Medications to help open airways and ease breathing.	treatment_term	treatment_term	$	Bronchodilators	Medications to help open airways and ease breathing.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5799	6376	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	3	Nasal Steroids	Used to treat nasal polyps and chronic sinusitis.	treatment_term	treatment_term	$	Nasal Steroids	Used to treat nasal polyps and chronic sinusitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5800	6377	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	4	Hearing Aids	Assistive devices for hearing loss management.	treatment_term	treatment_term	$	Hearing Aids	Assistive devices for hearing loss management.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5801	6378	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	treatments	5	Genetic Counseling	Provides information and support for affected individuals and families.	treatment_term	treatment_term	$	Genetic Counseling	Provides information and support for affected individuals and families.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
5805	6384	271	Primary Lateral Sclerosis	Primary_Lateral_Sclerosis.yaml	treatments	0	Supportive Care	Symptomatic management and supportive interventions.	treatment_term	treatment_term	$	Supportive Care	Symptomatic management and supportive interventions.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
5821	6404	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	0	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	treatment_term	treatment_term	$	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}]}"				ruxolitinib	CHEBI:66919																						
5822	6404	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	0	Ruxolitinib	JAK1/JAK2 inhibitor approved for intermediate-2 and high-risk PMF. Provides marked reduction in spleen size and constitutional symptoms but does not significantly alter disease course or prevent leukemic transformation.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ruxolitinib	CHEBI:66919	ruxolitinib		"{""preferred_term"": ""ruxolitinib"", ""term"": {""id"": ""CHEBI:66919"", ""label"": ""ruxolitinib""}}"																											
5823	6405	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	1	Fedratinib	JAK2 inhibitor approved for intermediate-2 and high-risk PMF, including patients previously treated with ruxolitinib. Selective JAK2 inhibition with similar efficacy profile.	treatment_term	treatment_term	$	Fedratinib	JAK2 inhibitor approved for intermediate-2 and high-risk PMF, including patients previously treated with ruxolitinib. Selective JAK2 inhibition with similar efficacy profile.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5824	6406	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	2	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for PMF. Considered for younger patients with high-risk disease. Significant transplant-related morbidity and mortality must be weighed against disease risk.	treatment_term	treatment_term	$	Allogeneic Stem Cell Transplantation	Only potentially curative treatment for PMF. Considered for younger patients with high-risk disease. Significant transplant-related morbidity and mortality must be weighed against disease risk.	hematopoietic stem cell transplantation	MAXO:0000747	hematopoietic stem cell transplantation		"{""preferred_term"": ""hematopoietic stem cell transplantation"", ""term"": {""id"": ""MAXO:0000747"", ""label"": ""hematopoietic stem cell transplantation""}}"																											
5825	6407	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	3	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	treatment_term	treatment_term	$	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}]}"				hydroxyurea	CHEBI:44423																						
5826	6407	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	3	Hydroxyurea	Cytoreductive therapy for symptomatic splenomegaly or thrombocytosis. Provides modest benefit but does not address constitutional symptoms as effectively as JAK inhibitors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			hydroxyurea	CHEBI:44423	hydroxyurea		"{""preferred_term"": ""hydroxyurea"", ""term"": {""id"": ""CHEBI:44423"", ""label"": ""hydroxyurea""}}"																											
5827	6408	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	4	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	treatment_term	treatment_term	$	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}]}"				anagrelide	CHEBI:142290																						
5828	6408	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	treatments	4	Anagrelide	Platelet-lowering agent used for thrombocytosis when present. Selective megakaryocyte inhibitor.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			anagrelide	CHEBI:142290	anagrelide		"{""preferred_term"": ""anagrelide"", ""term"": {""id"": ""CHEBI:142290"", ""label"": ""anagrelide""}}"																											
5885	6461	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	0	Chemotherapy	Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone).	treatment_term	treatment_term	$	Chemotherapy	Systemic treatment aimed at eradicating lymphoma cells, often using CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone).	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5886	6462	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	1	Radiation Therapy	Targeted radiation to the tonsil and surrounding structures to control local disease.	treatment_term	treatment_term	$	Radiation Therapy	Targeted radiation to the tonsil and surrounding structures to control local disease.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
5887	6463	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	2	Targeted Therapy	Use of drugs like rituximab for B-cell lymphomas.	treatment_term	treatment_term	$	Targeted Therapy	Use of drugs like rituximab for B-cell lymphomas.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5888	6464	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	treatments	3	Stem Cell Transplant	Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function.	treatment_term	treatment_term	$	Stem Cell Transplant	Considered in certain cases where high-dose chemotherapy is followed by infusion of healthy stem cells to restore bone marrow function.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
5924	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term	treatment_term	$	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""miransertib"", ""term"": {""id"": ""NCIT:C99172"", ""label"": ""Miransertib""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Miransertib	NCIT:C99172	NCIT:C2259			
5925	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
5926	6512	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	0	AKT inhibitor (miransertib/ARQ 092)	Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			miransertib	NCIT:C99172	Miransertib		"{""preferred_term"": ""miransertib"", ""term"": {""id"": ""NCIT:C99172"", ""label"": ""Miransertib""}}"																											
5927	6513	276	Proteus syndrome	Proteus_syndrome.yaml	treatments	1	Surgical intervention	Surgical debulking or corrective procedures used to manage focal overgrowth and deformity.	treatment_term	treatment_term	$	Surgical intervention	Surgical debulking or corrective procedures used to manage focal overgrowth and deformity.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
5947	6559	279	Psoriatic Arthritis	Psoriatic_Arthritis.yaml	treatments	0	Targeted Cytokine Biologic Therapy	Biologic agents targeting IL-23/IL-17 and TNF pathways to reduce inflammation and control disease activity.	treatment_term	treatment_term	$	Targeted Cytokine Biologic Therapy	Biologic agents targeting IL-23/IL-17 and TNF pathways to reduce inflammation and control disease activity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5986	6592	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	0	Phosphodiesterase-5 Inhibitors	Medications like sildenafil and tadalafil that relax blood vessels in the lungs	treatment_term	treatment_term	$	Phosphodiesterase-5 Inhibitors	Medications like sildenafil and tadalafil that relax blood vessels in the lungs	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5987	6593	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	1	Endothelin Receptor Antagonists	Medications that block the effects of endothelin and help decrease blood pressure in the lungs	treatment_term	treatment_term	$	Endothelin Receptor Antagonists	Medications that block the effects of endothelin and help decrease blood pressure in the lungs	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5988	6594	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	2	Prostacyclin Analogues	Medications that mimic the effects of prostacyclin, dilating pulmonary and systemic arterial vascular beds	treatment_term	treatment_term	$	Prostacyclin Analogues	Medications that mimic the effects of prostacyclin, dilating pulmonary and systemic arterial vascular beds	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
5989	6595	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	3	Oxygen Therapy	Used to reduce symptoms in patients with hypoxemia	treatment_term	treatment_term	$	Oxygen Therapy	Used to reduce symptoms in patients with hypoxemia	artificial respiration	MAXO:0000503	artificial respiration		"{""preferred_term"": ""artificial respiration"", ""term"": {""id"": ""MAXO:0000503"", ""label"": ""artificial respiration""}}"																											
5990	6596	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	treatments	4	Anticoagulation	Used particularly in chronic thromboembolic pulmonary hypertension to prevent clotting complications	treatment_term	treatment_term	$	Anticoagulation	Used particularly in chronic thromboembolic pulmonary hypertension to prevent clotting complications	cardiovascular agent therapy	MAXO:0000181	cardiovascular agent therapy		"{""preferred_term"": ""cardiovascular agent therapy"", ""term"": {""id"": ""MAXO:0000181"", ""label"": ""cardiovascular agent therapy""}}"																											
6000	6610	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	0	Thyroidectomy	Total thyroidectomy with lymph node dissection is the primary treatment. Most RET fusion-positive PTCs have excellent outcomes with surgery alone.	treatment_term	treatment_term	$	Thyroidectomy	Total thyroidectomy with lymph node dissection is the primary treatment. Most RET fusion-positive PTCs have excellent outcomes with surgery alone.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6001	6611	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	1	Radioiodine Therapy	Adjuvant radioactive iodine therapy is used for intermediate and high-risk disease. RET fusion-positive tumors generally maintain radioiodine avidity better than BRAF-mutant tumors.	treatment_term	treatment_term	$	Radioiodine Therapy	Adjuvant radioactive iodine therapy is used for intermediate and high-risk disease. RET fusion-positive tumors generally maintain radioiodine avidity better than BRAF-mutant tumors.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6002	6612	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	2	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive thyroid cancer that is radioiodine-refractory. Demonstrates high response rates with durable disease control.	treatment_term	treatment_term	$	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive thyroid cancer that is radioiodine-refractory. Demonstrates high response rates with durable disease control.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6003	6613	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	3	Pralsetinib	Another selective RET inhibitor with activity in RET fusion-positive thyroid cancer. Similar efficacy profile to selpercatinib.	treatment_term	treatment_term	$	Pralsetinib	Another selective RET inhibitor with activity in RET fusion-positive thyroid cancer. Similar efficacy profile to selpercatinib.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6004	6614	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	4	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	treatment_term	treatment_term	$	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}]}"				lenvatinib	CHEBI:85994																						
6005	6614	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	treatments	4	Lenvatinib or Sorafenib	Multi-kinase inhibitors approved for radioiodine-refractory differentiated thyroid cancer. May be used but selective RET inhibitors are preferred for RET fusion-positive tumors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			lenvatinib	CHEBI:85994	lenvatinib		"{""preferred_term"": ""lenvatinib"", ""term"": {""id"": ""CHEBI:85994"", ""label"": ""lenvatinib""}}"																											
6017	6630	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	0	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive NSCLC based on LIBRETTO-001 trial. Excellent CNS penetration with demonstrated intracranial activity. Well-tolerated with manageable side effects (hypertension, LFT elevation).	treatment_term	treatment_term	$	Selpercatinib	Highly selective RET inhibitor approved for RET fusion-positive NSCLC based on LIBRETTO-001 trial. Excellent CNS penetration with demonstrated intracranial activity. Well-tolerated with manageable side effects (hypertension, LFT elevation).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6018	6631	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	1	Pralsetinib	Selective RET inhibitor approved for RET fusion-positive NSCLC based on ARROW trial. Active in treatment-naive and previously treated patients. Side effects include hypertension and pneumonitis.	treatment_term	treatment_term	$	Pralsetinib	Selective RET inhibitor approved for RET fusion-positive NSCLC based on ARROW trial. Active in treatment-naive and previously treated patients. Side effects include hypertension and pneumonitis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6019	6632	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	2	Cabozantinib	Multi-kinase inhibitor (RET/VEGFR/MET) with RET activity. Less selective than selpercatinib/pralsetinib, used historically before selective inhibitors were available. More toxicity due to VEGFR inhibition.	treatment_term	treatment_term	$	Cabozantinib	Multi-kinase inhibitor (RET/VEGFR/MET) with RET activity. Less selective than selpercatinib/pralsetinib, used historically before selective inhibitors were available. More toxicity due to VEGFR inhibition.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6020	6633	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	3	Immunotherapy	Checkpoint inhibitors may be used for RET-positive NSCLC at progression, though driver mutation-positive tumors often have lower response rates to immunotherapy.	treatment_term	treatment_term	$	Immunotherapy	Checkpoint inhibitors may be used for RET-positive NSCLC at progression, though driver mutation-positive tumors often have lower response rates to immunotherapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6021	6634	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on RET inhibitors or historically before RET inhibitors were available.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on RET inhibitors or historically before RET inhibitors were available.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6034	6650	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	0	Crizotinib	First ROS1 inhibitor approved for ROS1-rearranged NSCLC. Originally developed as ALK/MET inhibitor, cross-reactive with ROS1 due to kinase domain homology. Limited CNS penetration is a clinical limitation.	treatment_term	treatment_term	$	Crizotinib	First ROS1 inhibitor approved for ROS1-rearranged NSCLC. Originally developed as ALK/MET inhibitor, cross-reactive with ROS1 due to kinase domain homology. Limited CNS penetration is a clinical limitation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6035	6651	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	1	Entrectinib	ROS1/TRK/ALK inhibitor with excellent CNS penetration. Approved for ROS1-positive NSCLC including patients with CNS metastases. Also active against NTRK fusions.	treatment_term	treatment_term	$	Entrectinib	ROS1/TRK/ALK inhibitor with excellent CNS penetration. Approved for ROS1-positive NSCLC including patients with CNS metastases. Also active against NTRK fusions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6036	6652	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	2	Lorlatinib	Third-generation ALK/ROS1 inhibitor with activity against many resistance mutations including G2032R. Excellent CNS penetration. Used after progression on prior ROS1 inhibitors.	treatment_term	treatment_term	$	Lorlatinib	Third-generation ALK/ROS1 inhibitor with activity against many resistance mutations including G2032R. Excellent CNS penetration. Used after progression on prior ROS1 inhibitors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6037	6653	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	3	Repotrectinib	Next-generation ROS1/TRK inhibitor designed to overcome G2032R solvent front mutation. Compact macrocyclic structure allows binding despite steric hindrance from resistance mutations.	treatment_term	treatment_term	$	Repotrectinib	Next-generation ROS1/TRK inhibitor designed to overcome G2032R solvent front mutation. Compact macrocyclic structure allows binding despite steric hindrance from resistance mutations.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6038	6654	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	treatments	4	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ROS1 inhibitors or in combination with immunotherapy.	treatment_term	treatment_term	$	Chemotherapy	Platinum-based chemotherapy (pemetrexed-based) used at progression on ROS1 inhibitors or in combination with immunotherapy.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6041	6660	284	Rabies	Rabies.yaml	treatments	0	Rabies post-exposure vaccination	Post-exposure prophylaxis includes rabies vaccination.	treatment_term	treatment_term	$	Rabies post-exposure vaccination	Post-exposure prophylaxis includes rabies vaccination.	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
6042	6661	284	Rabies	Rabies.yaml	treatments	1	Rabies immunoglobulin administration	Rabies immune globulin is used in post-exposure prophylaxis.	treatment_term	treatment_term	$	Rabies immunoglobulin administration	Rabies immune globulin is used in post-exposure prophylaxis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6056	6699	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	0	Controlled refeeding and caloric advancement	Gradual reintroduction of calories with careful monitoring to avoid rapid metabolic shifts.	treatment_term	treatment_term	$	Controlled refeeding and caloric advancement	Gradual reintroduction of calories with careful monitoring to avoid rapid metabolic shifts.	nutrition intervention	MAXO:0000009	nutrition intervention		"{""preferred_term"": ""nutrition intervention"", ""term"": {""id"": ""MAXO:0000009"", ""label"": ""nutrition intervention""}}"																											
6057	6700	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	1	Electrolyte supplementation and monitoring	Repletion of phosphate, potassium, and magnesium with close monitoring of serum electrolytes during refeeding.	treatment_term	treatment_term	$	Electrolyte supplementation and monitoring	Repletion of phosphate, potassium, and magnesium with close monitoring of serum electrolytes during refeeding.	nutritional supplementation	MAXO:0000106	nutritional supplementation		"{""preferred_term"": ""nutritional supplementation"", ""term"": {""id"": ""MAXO:0000106"", ""label"": ""nutritional supplementation""}}"																											
6058	6701	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	2	Thiamine (vitamin B1) supplementation	Thiamine supplementation prior to and during refeeding to prevent deficiency and related complications.	treatment_term	treatment_term	$	Thiamine (vitamin B1) supplementation	Thiamine supplementation prior to and during refeeding to prevent deficiency and related complications.	vitamin B1 supplementation	MAXO:0010019	vitamin B1 supplementation		"{""preferred_term"": ""vitamin B1 supplementation"", ""term"": {""id"": ""MAXO:0010019"", ""label"": ""vitamin B1 supplementation""}}"																											
6059	6702	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	treatments	3	Micronutrient supplementation during refeeding	Micronutrient supplementation during refeeding helps prevent deficiencies and refeeding syndrome.	treatment_term	treatment_term	$	Micronutrient supplementation during refeeding	Micronutrient supplementation during refeeding helps prevent deficiencies and refeeding syndrome.	micronutrient supplementation	MAXO:0001262	micronutrient supplementation		"{""preferred_term"": ""micronutrient supplementation"", ""term"": {""id"": ""MAXO:0001262"", ""label"": ""micronutrient supplementation""}}"																											
6065	6708	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	0	Radical Nephrectomy	Surgical removal of the kidney for localized renal cell carcinoma.	treatment_term	treatment_term	$	Radical Nephrectomy	Surgical removal of the kidney for localized renal cell carcinoma.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6066	6709	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	1	Targeted Systemic Therapy	Molecularly targeted agents used to treat advanced renal cell carcinoma.	treatment_term	treatment_term	$	Targeted Systemic Therapy	Molecularly targeted agents used to treat advanced renal cell carcinoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6067	6710	286	Renal Cell Carcinoma	Renal_Cell_Carcinoma.yaml	treatments	2	Belzutifan	HIF-2 inhibitor approved for treating renal cell carcinoma.	treatment_term	treatment_term	$	Belzutifan	HIF-2 inhibitor approved for treating renal cell carcinoma.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6081	6724	287	Retinoblastoma	Retinoblastoma.yaml	treatments	0	Focal Therapy (Laser/Cryotherapy)	Small tumors may be treated with focal ablation including laser photocoagulation or cryotherapy. These treatments spare vision and avoid systemic toxicity.	treatment_term	treatment_term	$	Focal Therapy (Laser/Cryotherapy)	Small tumors may be treated with focal ablation including laser photocoagulation or cryotherapy. These treatments spare vision and avoid systemic toxicity.	laser ablation therapy	MAXO:0000453	laser ablation therapy		"{""preferred_term"": ""laser ablation therapy"", ""term"": {""id"": ""MAXO:0000453"", ""label"": ""laser ablation therapy""}}"																											
6082	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term	treatment_term	$	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""carboplatin"", ""term"": {""id"": ""CHEBI:31355"", ""label"": ""carboplatin""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}, {""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}, {""preferred_term"": ""melphalan"", ""term"": {""id"": ""CHEBI:28876"", ""label"": ""melphalan""}}]}"				carboplatin; vincristine; etoposide; melphalan	CHEBI:31355; CHEBI:27375; CHEBI:4911; CHEBI:28876																						
6083	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			carboplatin	CHEBI:31355	carboplatin		"{""preferred_term"": ""carboplatin"", ""term"": {""id"": ""CHEBI:31355"", ""label"": ""carboplatin""}}"																											
6084	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:27375	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:27375"", ""label"": ""vincristine""}}"																											
6085	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			etoposide	CHEBI:4911	etoposide		"{""preferred_term"": ""etoposide"", ""term"": {""id"": ""CHEBI:4911"", ""label"": ""etoposide""}}"																											
6086	6725	287	Retinoblastoma	Retinoblastoma.yaml	treatments	1	Chemotherapy	Systemic chemotherapy with carboplatin, vincristine, and etoposide (CEV) reduces tumor size enabling focal consolidation. Intra-arterial chemotherapy delivers melphalan directly to the ophthalmic artery for localized effect.	treatment_term.therapeutic_agent[3]	treatment_term	treatment_term.therapeutic_agent			melphalan	CHEBI:28876	melphalan		"{""preferred_term"": ""melphalan"", ""term"": {""id"": ""CHEBI:28876"", ""label"": ""melphalan""}}"																											
6087	6726	287	Retinoblastoma	Retinoblastoma.yaml	treatments	2	Enucleation	Surgical removal of the eye is indicated for advanced intraocular disease, particularly when vision cannot be preserved. Provides excellent local control and prevents extraocular spread.	treatment_term	treatment_term	$	Enucleation	Surgical removal of the eye is indicated for advanced intraocular disease, particularly when vision cannot be preserved. Provides excellent local control and prevents extraocular spread.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6088	6727	287	Retinoblastoma	Retinoblastoma.yaml	treatments	3	External Beam Radiation	Historically used for retinoblastoma but now avoided when possible due to significantly increased risk of secondary malignancies in RB1 germline mutation carriers, particularly osteosarcoma in the radiation field.	treatment_term	treatment_term	$	External Beam Radiation	Historically used for retinoblastoma but now avoided when possible due to significantly increased risk of secondary malignancies in RB1 germline mutation carriers, particularly osteosarcoma in the radiation field.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6103	6737	288	Retrograde Cricopharyngeus Dysfunction	Retrograde_Cricopharyngeus_Dysfunction.yaml	treatments	0	Botulinum Toxin Injection	Injection of botulinum toxin type A into the cricopharyngeus muscle to induce temporary relaxation. This is both diagnostic and therapeutic, with high success rates in restoring the ability to belch.	treatment_term	treatment_term	$	Botulinum Toxin Injection	Injection of botulinum toxin type A into the cricopharyngeus muscle to induce temporary relaxation. This is both diagnostic and therapeutic, with high success rates in restoring the ability to belch.	botulinum toxin type A therapy	MAXO:0009016	botulinum toxin type A therapy		"{""preferred_term"": ""botulinum toxin type A therapy"", ""term"": {""id"": ""MAXO:0009016"", ""label"": ""botulinum toxin type A therapy""}}"																											
6156	6802	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	0	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Reduce pain and inflammation.	treatment_term	treatment_term	$	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Reduce pain and inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6157	6803	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	1	Disease-Modifying Antirheumatic Drugs (DMARDs)	Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).	treatment_term	treatment_term	$	Disease-Modifying Antirheumatic Drugs (DMARDs)	Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6158	6804	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	2	Biologics	Target specific components of the immune system (e.g., TNF- inhibitors, IL-6 inhibitors).	treatment_term	treatment_term	$	Biologics	Target specific components of the immune system (e.g., TNF- inhibitors, IL-6 inhibitors).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6159	6805	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	3	Glucocorticoids	Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.	treatment_term	treatment_term	$	Glucocorticoids	Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6160	6806	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	treatments	4	Physical Therapy	Maintains joint mobility and strengthens surrounding muscles.	treatment_term	treatment_term	$	Physical Therapy	Maintains joint mobility and strengthens surrounding muscles.	physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
6167	6822	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	0	Immunoglobulin Replacement Therapy	Regular infusions to prevent infections.	treatment_term	treatment_term	$	Immunoglobulin Replacement Therapy	Regular infusions to prevent infections.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6168	6823	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	1	Antibiotic Prophylaxis	Preventative antibiotic treatment to reduce infection risk.	treatment_term	treatment_term	$	Antibiotic Prophylaxis	Preventative antibiotic treatment to reduce infection risk.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6169	6824	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	2	Growth Hormone Therapy	May be used to address growth retardation.	treatment_term	treatment_term	$	Growth Hormone Therapy	May be used to address growth retardation.	hormone modifying therapy	MAXO:0000283	hormone modifying therapy		"{""preferred_term"": ""hormone modifying therapy"", ""term"": {""id"": ""MAXO:0000283"", ""label"": ""hormone modifying therapy""}}"																											
6170	6825	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	3	Supportive Educational Programs	Tailored to address intellectual disability and developmental delays.	treatment_term	treatment_term	$	Supportive Educational Programs	Tailored to address intellectual disability and developmental delays.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
6171	6826	291	Roifman-syndrome	Roifman-syndrome.yaml	treatments	4	Surgical Interventions	For severe skeletal or craniofacial abnormalities.	treatment_term	treatment_term	$	Surgical Interventions	For severe skeletal or craniofacial abnormalities.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6188	6842	292	SADDAN	SADDAN.yaml	treatments	0	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	treatment_term	treatment_term	$	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""growth hormone"", ""term"": {""id"": ""CHEBI:37845"", ""label"": ""growth hormone""}}]}"				growth hormone	CHEBI:37845																						
6189	6842	292	SADDAN	SADDAN.yaml	treatments	0	Growth hormone therapy	Growth hormone therapy for marked short stature in SADDAN.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			growth hormone	CHEBI:37845	growth hormone		"{""preferred_term"": ""growth hormone"", ""term"": {""id"": ""CHEBI:37845"", ""label"": ""growth hormone""}}"																											
6236	6894	294	Sarcoidosis	Sarcoidosis.yaml	treatments	0	Corticosteroid Therapy	"First-line treatment for symptomatic sarcoidosis. Prednisone typically initiated at 20-40mg daily with gradual taper over months. Effective for most organ manifestations.
"	treatment_term	treatment_term	$	Corticosteroid Therapy	"First-line treatment for symptomatic sarcoidosis. Prednisone typically initiated at 20-40mg daily with gradual taper over months. Effective for most organ manifestations.
"	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
6237	6895	294	Sarcoidosis	Sarcoidosis.yaml	treatments	1	Methotrexate	"Most commonly used steroid-sparing agent for chronic sarcoidosis. Allows reduction of corticosteroid dose while maintaining disease control.
"	treatment_term	treatment_term	$	Methotrexate	"Most commonly used steroid-sparing agent for chronic sarcoidosis. Allows reduction of corticosteroid dose while maintaining disease control.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6238	6896	294	Sarcoidosis	Sarcoidosis.yaml	treatments	2	Anti-TNF Therapy	"Infliximab or adalimumab for refractory disease, particularly effective in neurosarcoidosis, lupus pernio, and cardiac sarcoidosis.
"	treatment_term	treatment_term	$	Anti-TNF Therapy	"Infliximab or adalimumab for refractory disease, particularly effective in neurosarcoidosis, lupus pernio, and cardiac sarcoidosis.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6242	6902	295	Scabies	Scabies.yaml	treatments	0	Permethrin cream or ivermectin	Mass treatment can use permethrin cream or ivermectin.	treatment_term	treatment_term	$	Permethrin cream or ivermectin	Mass treatment can use permethrin cream or ivermectin.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6249	6911	296	Schistosomiasis	Schistosomiasis.yaml	treatments	0	Praziquantel mass drug administration	Periodic praziquantel treatment to suppress morbidity in endemic regions.	treatment_term	treatment_term	$	Praziquantel mass drug administration	Periodic praziquantel treatment to suppress morbidity in endemic regions.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6278	6945	297	Schizophrenia	Schizophrenia.yaml	treatments	0	Antipsychotic Medications	Medications such as risperidone, olanzapine, and clozapine to manage symptoms.	treatment_term	treatment_term	$	Antipsychotic Medications	Medications such as risperidone, olanzapine, and clozapine to manage symptoms.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6279	6946	297	Schizophrenia	Schizophrenia.yaml	treatments	1	Cognitive Behavioral Therapy (CBT)	Therapy aimed at changing maladaptive thought patterns and behaviors.	treatment_term	treatment_term	$	Cognitive Behavioral Therapy (CBT)	Therapy aimed at changing maladaptive thought patterns and behaviors.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
6280	6947	297	Schizophrenia	Schizophrenia.yaml	treatments	2	Social Skills Training	Programs to enhance social interactions and functioning.	treatment_term	treatment_term	$	Social Skills Training	Programs to enhance social interactions and functioning.	behavioral counseling	MAXO:0000077	behavioral counseling		"{""preferred_term"": ""behavioral counseling"", ""term"": {""id"": ""MAXO:0000077"", ""label"": ""behavioral counseling""}}"																											
6281	6948	297	Schizophrenia	Schizophrenia.yaml	treatments	3	Supportive Therapy	Ongoing support to help manage daily life and stress.	treatment_term	treatment_term	$	Supportive Therapy	Ongoing support to help manage daily life and stress.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6282	6949	297	Schizophrenia	Schizophrenia.yaml	treatments	4	Vocational Rehabilitation	Help with gaining and maintaining employment.	treatment_term	treatment_term	$	Vocational Rehabilitation	Help with gaining and maintaining employment.	occupational therapy	MAXO:0001351	occupational therapy		"{""preferred_term"": ""occupational therapy"", ""term"": {""id"": ""MAXO:0001351"", ""label"": ""occupational therapy""}}"																											
6316	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	treatment_term	treatment_term	$	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6317	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Partial anomalous pulmonary venous return	HP:0010773	Partial anomalous pulmonary venous return		"{""preferred_term"": ""Partial anomalous pulmonary venous return"", ""term"": {""id"": ""HP:0010773"", ""label"": ""Partial anomalous pulmonary venous return""}}"																											
6318	6980	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	0	Surgical repair	"Surgical correction involves reimplantation or baffling of the anomalous pulmonary vein to the left atrium. Various techniques include direct reimplantation, creation of an intracardiac baffle, or newer multipatch techniques. Indicated for significant left-to-right shunting (Qp:Qs > 1.5-2.0), recurrent infections, or pulmonary hypertension. Postoperative pulmonary vein obstruction is a significant complication, occurring in up to 45-50% of cases with traditional techniques.
"	target_phenotypes[1]	target_phenotypes	target_phenotypes			Congestive heart failure	HP:0001635	Congestive heart failure		"{""preferred_term"": ""Congestive heart failure"", ""term"": {""id"": ""HP:0001635"", ""label"": ""Congestive heart failure""}}"																											
6319	6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	Catheter-based intervention	"Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.
"	treatment_term	treatment_term	$	Catheter-based intervention	"Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.
"	catheterization	MAXO:0001389	catheterization		"{""preferred_term"": ""catheterization"", ""term"": {""id"": ""MAXO:0001389"", ""label"": ""catheterization""}}"																											
6320	6981	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	1	Catheter-based intervention	"Transcatheter interventions include coil or plug embolization of anomalous systemic arteries (aortopulmonary collaterals) and occlusion of associated intracardiac defects. Catheter-based embolization of collateral arteries can reduce pulmonary overcirculation as a standalone procedure or as an adjunct to surgery.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Pulmonary arterial hypertension	HP:0002092	Pulmonary arterial hypertension		"{""preferred_term"": ""Pulmonary arterial hypertension"", ""term"": {""id"": ""HP:0002092"", ""label"": ""Pulmonary arterial hypertension""}}"																											
6321	6982	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	2	Conservative management	"Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.
"	treatment_term	treatment_term	$	Conservative management	"Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6322	6982	298	Scimitar Syndrome	Scimitar_Syndrome.yaml	treatments	2	Conservative management	"Observation and medical management for asymptomatic patients with small shunts and no pulmonary hypertension. Regular follow-up with echocardiography to monitor for progressive right heart dilation or pulmonary hypertension. Medical management is effective for mild to moderate cases.
"	target_phenotypes[0]	target_phenotypes	target_phenotypes			Partial anomalous pulmonary venous return	HP:0010773	Partial anomalous pulmonary venous return		"{""preferred_term"": ""Partial anomalous pulmonary venous return"", ""term"": {""id"": ""HP:0010773"", ""label"": ""Partial anomalous pulmonary venous return""}}"																											
6329	6993	299	Scurvy	Scurvy.yaml	treatments	0	Vitamin C Supplementation	"Oral vitamin C supplementation (100-300 mg daily) rapidly reverses symptoms. Clinical improvement typically begins within 24-48 hours. The condition can be adequately treated and prevented via vitamin C supplementation.
"	treatment_term	treatment_term	$	Vitamin C Supplementation	"Oral vitamin C supplementation (100-300 mg daily) rapidly reverses symptoms. Clinical improvement typically begins within 24-48 hours. The condition can be adequately treated and prevented via vitamin C supplementation.
"	vitamin C supplementation	MAXO:0000109	vitamin C supplementation		"{""preferred_term"": ""vitamin C supplementation"", ""term"": {""id"": ""MAXO:0000109"", ""label"": ""vitamin C supplementation""}}"																											
6335	7002	301	Semantic Dementia	Semantic_Dementia.yaml	treatments	0	Speech and Language Therapy	Communication support provided by specialist speech and language therapists.	treatment_term	treatment_term	$	Speech and Language Therapy	Communication support provided by specialist speech and language therapists.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6352	7019	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	1	Surgical Canal Plugging	Surgical occlusion of the dehiscent superior semicircular canal via middle cranial fossa or transmastoid approach to eliminate the third window effect. Canal plugging achieves long-term control more often than resurfacing.	treatment_term	treatment_term	$	Surgical Canal Plugging	Surgical occlusion of the dehiscent superior semicircular canal via middle cranial fossa or transmastoid approach to eliminate the third window effect. Canal plugging achieves long-term control more often than resurfacing.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6353	7020	302	Semicircular Canal Dehiscence Syndrome	Semicircular_Canal_Dehiscence_Syndrome.yaml	treatments	2	Surgical Resurfacing	Surgical repair by placing bone graft or other material over the dehiscence to restore normal inner ear mechanics without occluding the canal lumen.	treatment_term	treatment_term	$	Surgical Resurfacing	Surgical repair by placing bone graft or other material over the dehiscence to restore normal inner ear mechanics without occluding the canal lumen.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6370	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term	treatment_term	$	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	coenzyme Q10 supplementation	MAXO:0010012	coenzyme Q10 supplementation		"{""preferred_term"": ""coenzyme Q10 supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""coenzyme Q10"", ""term"": {""id"": ""NCIT:C916"", ""label"": ""Coenzyme Q10""}}}], ""term"": {""id"": ""MAXO:0010012"", ""label"": ""coenzyme Q10 supplementation""}}"																						Coenzyme Q10	NCIT:C916	NCIT:C2259			
6371	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6372	7043	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	0	Coenzyme Q10 supplementation	Coenzyme Q10 used as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			coenzyme Q10	NCIT:C916	Coenzyme Q10		"{""preferred_term"": ""coenzyme Q10"", ""term"": {""id"": ""NCIT:C916"", ""label"": ""Coenzyme Q10""}}"																											
6373	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term	treatment_term	$	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	carnitine supplementation	MAXO:0010006	carnitine supplementation		"{""preferred_term"": ""carnitine supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levocarnitine"", ""term"": {""id"": ""NCIT:C26657"", ""label"": ""Levocarnitine""}}}], ""term"": {""id"": ""MAXO:0010006"", ""label"": ""carnitine supplementation""}}"																						Levocarnitine	NCIT:C26657	NCIT:C2259			
6374	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6375	7044	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	1	Carnitine supplementation	L-carnitine provided as part of mitochondrial supportive therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			levocarnitine	NCIT:C26657	Levocarnitine		"{""preferred_term"": ""levocarnitine"", ""term"": {""id"": ""NCIT:C26657"", ""label"": ""Levocarnitine""}}"																											
6376	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term	treatment_term	$	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	B vitamin supplementation	MAXO:0000761	B vitamin supplementation		"{""preferred_term"": ""B vitamin supplementation"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""thiamine"", ""term"": {""id"": ""NCIT:C874"", ""label"": ""Thiamine""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""riboflavin"", ""term"": {""id"": ""NCIT:C808"", ""label"": ""Riboflavin""}}}], ""term"": {""id"": ""MAXO:0000761"", ""label"": ""B vitamin supplementation""}}"																						Thiamine; Riboflavin	NCIT:C874; NCIT:C808	NCIT:C2259			
6377	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6378	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			thiamine	NCIT:C874	Thiamine		"{""preferred_term"": ""thiamine"", ""term"": {""id"": ""NCIT:C874"", ""label"": ""Thiamine""}}"																											
6379	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6380	7045	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	2	B vitamin supplementation	Vitamin B complex supplementation as part of supportive therapy.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			riboflavin	NCIT:C808	Riboflavin		"{""preferred_term"": ""riboflavin"", ""term"": {""id"": ""NCIT:C808"", ""label"": ""Riboflavin""}}"																											
6381	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term	treatment_term	$	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	ACE inhibitor therapy	MAXO:0000652	ACE inhibitor therapy		"{""preferred_term"": ""ACE inhibitor therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""captopril"", ""term"": {""id"": ""NCIT:C340"", ""label"": ""Captopril""}}}], ""term"": {""id"": ""MAXO:0000652"", ""label"": ""ACE inhibitor therapy""}}"																						Captopril	NCIT:C340	NCIT:C2259			
6382	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6383	7046	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	3	ACE inhibitor therapy	ACE inhibitor therapy used for heart failure management.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			captopril	NCIT:C340	Captopril		"{""preferred_term"": ""captopril"", ""term"": {""id"": ""NCIT:C340"", ""label"": ""Captopril""}}"																											
6384	7047	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	4	Cardiac transplantation	Heart transplantation for severe cardiomyopathy in Sengers syndrome.	treatment_term	treatment_term	$	Cardiac transplantation	Heart transplantation for severe cardiomyopathy in Sengers syndrome.	cardiac transplantation	MAXO:0010032	cardiac transplantation		"{""preferred_term"": ""cardiac transplantation"", ""term"": {""id"": ""MAXO:0010032"", ""label"": ""cardiac transplantation""}}"																											
6385	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term	treatment_term	$	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	diuretic agent therapy	MAXO:0000165	diuretic agent therapy		"{""preferred_term"": ""diuretic agent therapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""furosemide"", ""term"": {""id"": ""NCIT:C515"", ""label"": ""Furosemide""}}}, {""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}}], ""term"": {""id"": ""MAXO:0000165"", ""label"": ""diuretic agent therapy""}}"																						Furosemide; Spironolactone	NCIT:C515; NCIT:C840	NCIT:C2259			
6386	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6387	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			furosemide	NCIT:C515	Furosemide		"{""preferred_term"": ""furosemide"", ""term"": {""id"": ""NCIT:C515"", ""label"": ""Furosemide""}}"																											
6388	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[1].predicate	treatment_term	treatment_term.qualifiers[1]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6389	7048	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	5	Diuretic therapy	Diuretics used for heart failure management in Sengers syndrome.	treatment_term.qualifiers[1].value	treatment_term	treatment_term.qualifiers[1]			spironolactone	NCIT:C840	Spironolactone		"{""preferred_term"": ""spironolactone"", ""term"": {""id"": ""NCIT:C840"", ""label"": ""Spironolactone""}}"																											
6390	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term	treatment_term	$	Levosimendan infusion	Levosimendan infusions used for heart failure support.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""levosimendan"", ""term"": {""id"": ""NCIT:C174653"", ""label"": ""Levosimendan""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Levosimendan	NCIT:C174653	NCIT:C2259			
6391	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6392	7049	303	Sengers syndrome	Sengers_syndrome.yaml	treatments	6	Levosimendan infusion	Levosimendan infusions used for heart failure support.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			levosimendan	NCIT:C174653	Levosimendan		"{""preferred_term"": ""levosimendan"", ""term"": {""id"": ""NCIT:C174653"", ""label"": ""Levosimendan""}}"																											
6433	7079	304	Shigellosis	Shigellosis.yaml	treatments	0	Antibiotic therapy	"Fluoroquinolones (ciprofloxacin) or azithromycin are first-line treatments for shigellosis. These antibiotics reduce duration of symptoms and bacterial shedding.
"	treatment_term	treatment_term	$	Antibiotic therapy	"Fluoroquinolones (ciprofloxacin) or azithromycin are first-line treatments for shigellosis. These antibiotics reduce duration of symptoms and bacterial shedding.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6434	7080	304	Shigellosis	Shigellosis.yaml	treatments	1	Oral rehydration therapy	"Oral rehydration solution (ORS) with electrolytes to replace fluid and electrolyte losses.
"	treatment_term	treatment_term	$	Oral rehydration therapy	"Oral rehydration solution (ORS) with electrolytes to replace fluid and electrolyte losses.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6435	7081	304	Shigellosis	Shigellosis.yaml	treatments	2	Fluid and electrolyte replacement	"Intravenous fluid replacement in severe cases with significant dehydration.
"	treatment_term	treatment_term	$	Fluid and electrolyte replacement	"Intravenous fluid replacement in severe cases with significant dehydration.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6455	7127	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	0	Functional Endoscopic Sinus Surgery	Endoscopic uncinectomy and maxillary antrostomy to restore sinus ventilation and equalize pressure. This addresses the underlying cause by relieving ostial obstruction.	treatment_term	treatment_term	$	Functional Endoscopic Sinus Surgery	Endoscopic uncinectomy and maxillary antrostomy to restore sinus ventilation and equalize pressure. This addresses the underlying cause by relieving ostial obstruction.	nasal endoscopy	MAXO:0035089	nasal endoscopy		"{""preferred_term"": ""nasal endoscopy"", ""term"": {""id"": ""MAXO:0035089"", ""label"": ""nasal endoscopy""}}"																											
6456	7128	306	Silent Sinus Syndrome	Silent_Sinus_Syndrome.yaml	treatments	1	Orbital Floor Reconstruction	Surgical repair of the orbital floor using implants or grafts to correct enophthalmos when spontaneous resolution does not occur after sinus surgery. May be performed simultaneously with or staged after FESS.	treatment_term	treatment_term	$	Orbital Floor Reconstruction	Surgical repair of the orbital floor using implants or grafts to correct enophthalmos when spontaneous resolution does not occur after sinus surgery. May be performed simultaneously with or staged after FESS.	surgical plastic reconstruction of face	MAXO:0001292	surgical plastic reconstruction of face		"{""preferred_term"": ""surgical plastic reconstruction of face"", ""term"": {""id"": ""MAXO:0001292"", ""label"": ""surgical plastic reconstruction of face""}}"																											
6485	7175	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	0	Platinum-Etoposide Chemotherapy	Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage.	treatment_term	treatment_term	$	Platinum-Etoposide Chemotherapy	Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6486	7176	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	1	Atezolizumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage.	treatment_term	treatment_term	$	Atezolizumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6487	7177	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	2	Durvalumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen.	treatment_term	treatment_term	$	Durvalumab (with Chemotherapy)	PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6488	7178	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	3	Thoracic Radiation	Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients.	treatment_term	treatment_term	$	Thoracic Radiation	Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6489	7179	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	4	Prophylactic Cranial Irradiation	Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI.	treatment_term	treatment_term	$	Prophylactic Cranial Irradiation	Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6490	7180	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	5	Lurbinectedin	Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors.	treatment_term	treatment_term	$	Lurbinectedin	Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6491	7181	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	treatments	6	Topotecan	Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived.	treatment_term	treatment_term	$	Topotecan	Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6501	7188	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	0	Antibiotic therapy	Rifaximin or other antibiotics to reduce bacterial overgrowth.	treatment_term	treatment_term	$	Antibiotic therapy	Rifaximin or other antibiotics to reduce bacterial overgrowth.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6502	7189	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	1	Dietary modification	Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation.	treatment_term	treatment_term	$	Dietary modification	Low-fermentable carbohydrate diets to reduce substrate for bacterial fermentation.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
6503	7190	309	Small Intestinal Bacterial Overgrowth	Small_Intestinal_Bacterial_Overgrowth.yaml	treatments	2	Prokinetic agents	Medications to improve intestinal motility and reduce stasis.	treatment_term	treatment_term	$	Prokinetic agents	Medications to improve intestinal motility and reduce stasis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6508	7197	310	Snakebite envenoming	Snakebite_Envenoming.yaml	treatments	0	Antivenom administration	Intravenous antivenom is the only specific therapy to counteract envenoming.	treatment_term	treatment_term	$	Antivenom administration	Intravenous antivenom is the only specific therapy to counteract envenoming.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6515	7206	311	Soil-transmitted helminthiases	Soil_Transmitted_Helminthiases.yaml	treatments	0	Albendazole or mebendazole therapy	Benzimidazole anthelmintics used for treatment and preventive deworming.	treatment_term	treatment_term	$	Albendazole or mebendazole therapy	Benzimidazole anthelmintics used for treatment and preventive deworming.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6543	7240	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	0	Orthopedic Management	"Management of scoliosis (bracing, surgery as needed), limb deformities, and hip dysplasia.
"	treatment_term	treatment_term	$	Orthopedic Management	"Management of scoliosis (bracing, surgery as needed), limb deformities, and hip dysplasia.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6544	7243	313	Spondyloepimetaphyseal Dysplasia Strudwick Type	Spondyloepimetaphyseal_Dysplasia_Strudwick_Type.yaml	treatments	3	Cleft Palate Repair	"Surgical repair if cleft palate present.
"	treatment_term	treatment_term	$	Cleft Palate Repair	"Surgical repair if cleft palate present.
"	Cleft repair surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6562	7259	314	Spondyloepiphyseal Dysplasia Congenita	Spondyloepiphyseal_Dysplasia_Congenita.yaml	treatments	0	Orthopedic Management	"Management of spinal instability, hip dysplasia, and limb deformities. Cervical spine evaluation for odontoid hypoplasia is essential before anesthesia or contact activities.
"	treatment_term	treatment_term	$	Orthopedic Management	"Management of spinal instability, hip dysplasia, and limb deformities. Cervical spine evaluation for odontoid hypoplasia is essential before anesthesia or contact activities.
"	Orthopedic surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Orthopedic surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6575	7274	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	0	Prophylactic Retinal Treatment	"Prophylactic cryotherapy or laser photocoagulation to reduce retinal detachment risk. Regular ophthalmologic surveillance essential.
"	treatment_term	treatment_term	$	Prophylactic Retinal Treatment	"Prophylactic cryotherapy or laser photocoagulation to reduce retinal detachment risk. Regular ophthalmologic surveillance essential.
"	Ophthalmologic procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Ophthalmologic procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6576	7276	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	2	Joint Protection	"Physical therapy, joint protection strategies, and management of early-onset osteoarthritis.
"	treatment_term	treatment_term	$	Joint Protection	"Physical therapy, joint protection strategies, and management of early-onset osteoarthritis.
"	Physical therapy	MAXO:0000011	physical therapy		"{""preferred_term"": ""Physical therapy"", ""term"": {""id"": ""MAXO:0000011"", ""label"": ""physical therapy""}}"																											
6577	7277	315	Stickler Syndrome Type 1	Stickler_Syndrome_Type_1.yaml	treatments	3	Cleft Repair	"Surgical repair for cleft palate; management of Pierre Robin sequence if present.
"	treatment_term	treatment_term	$	Cleft Repair	"Surgical repair for cleft palate; management of Pierre Robin sequence if present.
"	Cleft repair surgery	MAXO:0000004	surgical procedure		"{""preferred_term"": ""Cleft repair surgery"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6591	7296	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	0	Benzodiazepines	First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily.	treatment_term	treatment_term	$	Benzodiazepines	First-line symptomatic therapy. GABA-A receptor agonists that enhance GABAergic inhibition to reduce stiffness and spasms. Diazepam is most commonly used, starting at 5-10mg twice daily.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6592	7297	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	1	Baclofen	GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases.	treatment_term	treatment_term	$	Baclofen	GABA-B receptor agonist used for spasticity control. Often used when benzodiazepines are insufficient or poorly tolerated. Can be given orally or intrathecally for refractory cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6593	7298	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	2	Intravenous Immunoglobulin	Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients.	treatment_term	treatment_term	$	Intravenous Immunoglobulin	Immunomodulatory therapy that significantly reduces stiffness scores and improves mobility. Administered as 2g/kg divided over 2-5 days with monthly maintenance of 1g/kg. First-line immunotherapy effective in up to 75% of patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6594	7299	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	treatments	3	Rituximab	Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months.	treatment_term	treatment_term	$	Rituximab	Anti-CD20 monoclonal antibody that depletes B cells. Used as second-line immunotherapy when IVIg fails. Targets peripheral B-cell sources of autoantibodies. Dosing is empirical, typically 1-2g every 6-12 months.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6603	7314	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	0	Surgical Resection	Wide surgical resection with negative margins is the primary treatment for localized disease. Limb-sparing surgery is preferred when oncologically feasible.	treatment_term	treatment_term	$	Surgical Resection	Wide surgical resection with negative margins is the primary treatment for localized disease. Limb-sparing surgery is preferred when oncologically feasible.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6604	7315	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	1	Radiation Therapy	Adjuvant radiation improves local control, particularly for tumors larger than 5 cm, high grade, or with close/positive margins. May be given preoperatively or postoperatively.	treatment_term	treatment_term	$	Radiation Therapy	Adjuvant radiation improves local control, particularly for tumors larger than 5 cm, high grade, or with close/positive margins. May be given preoperatively or postoperatively.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
6605	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term	treatment_term	$	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}"				ifosfamide; doxorubicin	CHEBI:5864; CHEBI:28748																						
6606	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			ifosfamide	CHEBI:5864	ifosfamide		"{""preferred_term"": ""ifosfamide"", ""term"": {""id"": ""CHEBI:5864"", ""label"": ""ifosfamide""}}"																											
6607	7316	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	treatments	2	Chemotherapy	Role of adjuvant chemotherapy is debated. Ifosfamide-based regimens are most commonly used in high-risk disease or metastatic setting. Doxorubicin is also active in synovial sarcoma.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
6656	7367	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	0	Type I Interferon Receptor Antagonist	Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.	treatment_term	treatment_term	$	Type I Interferon Receptor Antagonist	Anifrolumab targets the type I interferon receptor (IFNAR1) to block IFN signaling. Efficacy is enriched in patients with high IFN gene signatures, enabling mechanism-based patient stratification.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6657	7368	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	1	B Cell Depletion Therapy	Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.	treatment_term	treatment_term	$	B Cell Depletion Therapy	Anti-CD20 monoclonal antibodies (rituximab) and anti-CD19 CAR-T cell therapy target B cells, which are central to SLE pathogenesis through autoantibody production and antigen presentation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6658	7369	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	2	BAFF Pathway Inhibition	Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.	treatment_term	treatment_term	$	BAFF Pathway Inhibition	Belimumab targets B cell activating factor (BAFF/TNFSF13B) to reduce B cell survival and activation, fitting the B cell tolerance failure paradigm.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6659	7370	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	3	Immunosuppressive Therapy	Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.	treatment_term	treatment_term	$	Immunosuppressive Therapy	Corticosteroids, hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide are used to suppress immune system activity and reduce inflammation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6660	7371	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	treatments	4	Supportive Care	Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.	treatment_term	treatment_term	$	Supportive Care	Management of specific organ manifestations including nephritis, neuropsychiatric symptoms, and cytopenias. Includes antihypertensives, anticoagulation, and renal replacement therapy as needed.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6692	7409	320	TARP syndrome	TARP_syndrome.yaml	treatments	0	Cardiac surgery	Surgical repair of atrial septal defects and other congenital heart defects to correct hemodynamics and prevent complications	treatment_term	treatment_term	$	Cardiac surgery	Surgical repair of atrial septal defects and other congenital heart defects to correct hemodynamics and prevent complications	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6693	7410	320	TARP syndrome	TARP_syndrome.yaml	treatments	1	Palatal cleft repair	Surgical correction of cleft palate to restore normal feeding and speech development	treatment_term	treatment_term	$	Palatal cleft repair	Surgical correction of cleft palate to restore normal feeding and speech development	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6694	7411	320	TARP syndrome	TARP_syndrome.yaml	treatments	2	Orthopedic surgery	Surgical management of talipes and other skeletal deformities	treatment_term	treatment_term	$	Orthopedic surgery	Surgical management of talipes and other skeletal deformities	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6695	7413	320	TARP syndrome	TARP_syndrome.yaml	treatments	4	Multidisciplinary supportive care	Coordinated care from cardiology, orthopedics, otolaryngology, and genetics for comprehensive management	treatment_term	treatment_term	$	Multidisciplinary supportive care	Coordinated care from cardiology, orthopedics, otolaryngology, and genetics for comprehensive management	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6698	7417	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	0	Antiparasitic therapy	Antiparasitic drugs are used to kill brain parasites in neurocysticercosis.	treatment_term	treatment_term	$	Antiparasitic therapy	Antiparasitic drugs are used to kill brain parasites in neurocysticercosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6699	7418	321	Taeniasis/cysticercosis	Taeniasis_Cysticercosis.yaml	treatments	1	Surgical management	Surgical interventions may be used in selected cases.	treatment_term	treatment_term	$	Surgical management	Surgical interventions may be used in selected cases.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6713	7436	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	0	Supportive Care	Symptomatic management including seizure control, nutrition support, respiratory care.	treatment_term	treatment_term	$	Supportive Care	Symptomatic management including seizure control, nutrition support, respiratory care.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6714	7437	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	1	Genetic Counseling	Carrier screening especially in high-risk populations.	treatment_term	treatment_term	$	Genetic Counseling	Carrier screening especially in high-risk populations.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
6715	7438	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	2	Substrate Reduction Therapy	Investigational approaches to reduce GM2 synthesis.	treatment_term	treatment_term	$	Substrate Reduction Therapy	Investigational approaches to reduce GM2 synthesis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6716	7439	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	treatments	3	Gene Therapy	Experimental AAV-based gene therapy in clinical trials.	treatment_term	treatment_term	$	Gene Therapy	Experimental AAV-based gene therapy in clinical trials.	gene therapy	MAXO:0001001	gene therapy		"{""preferred_term"": ""gene therapy"", ""term"": {""id"": ""MAXO:0001001"", ""label"": ""gene therapy""}}"																											
6737	7454	323	Tetanus	Tetanus.yaml	treatments	0	Tetanus Immunoglobulin (TIG)	"Human tetanus immunoglobulin provides passive immunity by neutralizing circulating toxin. Should be administered as early as possible.
"	treatment_term	treatment_term	$	Tetanus Immunoglobulin (TIG)	"Human tetanus immunoglobulin provides passive immunity by neutralizing circulating toxin. Should be administered as early as possible.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6738	7455	323	Tetanus	Tetanus.yaml	treatments	1	Wound Debridement	"Surgical cleaning and removal of necrotic tissue eliminates the anaerobic environment that supports C. tetani growth and toxin production.
"	treatment_term	treatment_term	$	Wound Debridement	"Surgical cleaning and removal of necrotic tissue eliminates the anaerobic environment that supports C. tetani growth and toxin production.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
6739	7456	323	Tetanus	Tetanus.yaml	treatments	2	Antibiotic Therapy	"Metronidazole is the preferred antibiotic to eliminate C. tetani from the wound and prevent further toxin production. Penicillin is an alternative.
"	treatment_term	treatment_term	$	Antibiotic Therapy	"Metronidazole is the preferred antibiotic to eliminate C. tetani from the wound and prevent further toxin production. Penicillin is an alternative.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6740	7457	323	Tetanus	Tetanus.yaml	treatments	3	Muscle Relaxants and Sedation	"Benzodiazepines (diazepam) are first-line for controlling spasms. Severe cases may require neuromuscular blocking agents and mechanical ventilation.
"	treatment_term	treatment_term	$	Muscle Relaxants and Sedation	"Benzodiazepines (diazepam) are first-line for controlling spasms. Severe cases may require neuromuscular blocking agents and mechanical ventilation.
"	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6741	7458	323	Tetanus	Tetanus.yaml	treatments	4	Supportive Care	"ICU care including mechanical ventilation, nutritional support, and management of autonomic instability with beta-blockers or magnesium sulfate.
"	treatment_term	treatment_term	$	Supportive Care	"ICU care including mechanical ventilation, nutritional support, and management of autonomic instability with beta-blockers or magnesium sulfate.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6742	7459	323	Tetanus	Tetanus.yaml	treatments	5	Active Immunization	"Tetanus toxoid vaccine should be administered during recovery as natural infection does not confer immunity.
"	treatment_term	treatment_term	$	Active Immunization	"Tetanus toxoid vaccine should be administered during recovery as natural infection does not confer immunity.
"	vaccination	MAXO:0001017	vaccination		"{""preferred_term"": ""vaccination"", ""term"": {""id"": ""MAXO:0001017"", ""label"": ""vaccination""}}"																											
6759	7472	324	Thanatophoric Dysplasia Type 1	Thanatophoric_Dysplasia_Type_1.yaml	treatments	0	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Intensive respiratory support may prolong survival in rare cases, but long-term survival is exceptional. Palliative care is typically provided.
"	treatment_term	treatment_term	$	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Intensive respiratory support may prolong survival in rare cases, but long-term survival is exceptional. Palliative care is typically provided.
"	Supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6775	7485	325	Thanatophoric Dysplasia Type 2	Thanatophoric_Dysplasia_Type_2.yaml	treatments	0	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require intensive respiratory support.
"	treatment_term	treatment_term	$	Supportive care	"Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require intensive respiratory support.
"	Supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""Supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6778	7489	326	Trachoma	Trachoma.yaml	treatments	0	Antibiotic mass drug administration (SAFE strategy)	Antibiotic mass drug administration reduces infection prevalence and transmission.	treatment_term	treatment_term	$	Antibiotic mass drug administration (SAFE strategy)	Antibiotic mass drug administration reduces infection prevalence and transmission.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6796	7509	327	Transient Neonatal Pustular Melanosis	Transient_Neonatal_Pustular_Melanosis.yaml	treatments	0	None Required	Condition is self-limiting and resolves without treatment.	treatment_term	treatment_term	$	None Required	Condition is self-limiting and resolves without treatment.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6812	7522	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	0	Corticosteroid Therapy	High-dose steroids as standard acute therapy.	treatment_term	treatment_term	$	Corticosteroid Therapy	High-dose steroids as standard acute therapy.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
6813	7523	328	Transverse Myelitis	Transverse_Myelitis.yaml	treatments	1	Plasma Exchange	Plasma exchange for more severe transverse myelitis.	treatment_term	treatment_term	$	Plasma Exchange	Plasma exchange for more severe transverse myelitis.	plasma exchange				"{""preferred_term"": ""plasma exchange""}"																											
6823	7534	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	0	Oral rehydration therapy	Fluid and electrolyte replacement is the cornerstone of treatment.	treatment_term	treatment_term	$	Oral rehydration therapy	Fluid and electrolyte replacement is the cornerstone of treatment.	fluid replacement therapy	MAXO:0000618	fluid replacement therapy		"{""preferred_term"": ""fluid replacement therapy"", ""term"": {""id"": ""MAXO:0000618"", ""label"": ""fluid replacement therapy""}}"																											
6824	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term	treatment_term	$	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""loperamide hydrochloride"", ""term"": {""id"": ""NCIT:C62046"", ""label"": ""Loperamide Hydrochloride""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Loperamide Hydrochloride	NCIT:C62046	NCIT:C2259			
6825	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6826	7535	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	1	Loperamide	Antimotility agent for symptomatic relief in non-invasive cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			loperamide hydrochloride	NCIT:C62046	Loperamide Hydrochloride		"{""preferred_term"": ""loperamide hydrochloride"", ""term"": {""id"": ""NCIT:C62046"", ""label"": ""Loperamide Hydrochloride""}}"																											
6827	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term	treatment_term	$	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""ciprofloxacin"", ""term"": {""id"": ""NCIT:C376"", ""label"": ""Ciprofloxacin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Ciprofloxacin	NCIT:C376	NCIT:C2259			
6828	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6829	7536	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	2	Fluoroquinolone antibiotics	Empiric antibiotic therapy for moderate to severe cases.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			ciprofloxacin	NCIT:C376	Ciprofloxacin		"{""preferred_term"": ""ciprofloxacin"", ""term"": {""id"": ""NCIT:C376"", ""label"": ""Ciprofloxacin""}}"																											
6830	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term	treatment_term	$	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						rifaximin	NCIT:C95262	NCIT:C2259			
6831	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6832	7537	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	3	Rifaximin	Nonabsorbable antibiotic option for traveler's diarrhea due to noninvasive E. coli.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			rifaximin	NCIT:C95262	rifaximin		"{""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}"																											
6833	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	treatment_term	treatment_term	$	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""bismuth subsalicylate"", ""term"": {""id"": ""NCIT:C333"", ""label"": ""Bismuth Subsalicylate""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Bismuth Subsalicylate	NCIT:C333	NCIT:C2259			
6834	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6835	7538	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	4	Bismuth subsalicylate	Bismuth-based agent for symptom control and prophylaxis of travelers diarrhea.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			bismuth subsalicylate	NCIT:C333	Bismuth Subsalicylate		"{""preferred_term"": ""bismuth subsalicylate"", ""term"": {""id"": ""NCIT:C333"", ""label"": ""Bismuth Subsalicylate""}}"																											
6836	7539	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	5	Probiotic prophylaxis	Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.	treatment_term	treatment_term	$	Probiotic prophylaxis	Specific probiotic strains can reduce risk of traveler's diarrhea when taken before and during travel.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6837	7540	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	6	Education on safe food and water practices	Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.	treatment_term	treatment_term	$	Education on safe food and water practices	Supportive counseling on safe food and water practices reduces risk and unnecessary antibiotic use during travel.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6838	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term	treatment_term	$	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						rifaximin	NCIT:C95262	NCIT:C2259			
6839	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
6840	7541	329	Traveler's Diarrhea	Travelers_Diarrhea.yaml	treatments	7	Rifaximin prophylaxis	Prophylactic rifaximin to reduce incidence of travelers diarrhea in high-risk itineraries with noninvasive E. coli exposure.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			rifaximin	NCIT:C95262	rifaximin		"{""preferred_term"": ""rifaximin"", ""term"": {""id"": ""NCIT:C95262"", ""label"": ""rifaximin""}}"																											
6850	7559	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	0	Neoadjuvant Chemotherapy	Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes.	treatment_term	treatment_term	$	Neoadjuvant Chemotherapy	Standard treatment includes anthracycline and taxane-based regimens given before surgery. Pathologic complete response (pCR) rates are higher in TNBC than other subtypes and strongly predict long-term outcomes.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6851	7560	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	1	Pembrolizumab Plus Chemotherapy	PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status.	treatment_term	treatment_term	$	Pembrolizumab Plus Chemotherapy	PD-1 inhibitor pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC. KEYNOTE-522 established pembrolizumab in the neoadjuvant/adjuvant setting regardless of PD-L1 status.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6852	7561	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	2	PARP Inhibitors	Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks.	treatment_term	treatment_term	$	PARP Inhibitors	Olaparib and talazoparib are approved for germline BRCA-mutated metastatic TNBC. They exploit synthetic lethality in HRD-positive tumors unable to repair DNA double-strand breaks.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6853	7562	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	3	Sacituzumab Govitecan	Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial.	treatment_term	treatment_term	$	Sacituzumab Govitecan	Antibody-drug conjugate targeting Trop-2 with an SN-38 payload. Approved for previously treated metastatic TNBC with significant survival benefit demonstrated in ASCENT trial.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6854	7563	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	treatments	4	Platinum Chemotherapy	Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.	treatment_term	treatment_term	$	Platinum Chemotherapy	Carboplatin improves pCR rates in neoadjuvant therapy, particularly in BRCA-mutated or HRD-positive TNBC. Used in combination with taxanes.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}}"																											
6884	7596	331	Tuberculosis	Tuberculosis.yaml	treatments	0	Isoniazid	First-line antibiotic for TB treatment.	treatment_term	treatment_term	$	Isoniazid	First-line antibiotic for TB treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6885	7597	331	Tuberculosis	Tuberculosis.yaml	treatments	1	Rifampicin	Bactericidal antibiotic used for TB treatment.	treatment_term	treatment_term	$	Rifampicin	Bactericidal antibiotic used for TB treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6886	7598	331	Tuberculosis	Tuberculosis.yaml	treatments	2	Ethambutol	Bacteriostatic antibiotic used for TB treatment.	treatment_term	treatment_term	$	Ethambutol	Bacteriostatic antibiotic used for TB treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6887	7599	331	Tuberculosis	Tuberculosis.yaml	treatments	3	Directly Observed Therapy (DOT)	Health worker observes and records patients taking their medication to ensure adherence.	treatment_term	treatment_term	$	Directly Observed Therapy (DOT)	Health worker observes and records patients taking their medication to ensure adherence.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6888	7600	331	Tuberculosis	Tuberculosis.yaml	treatments	4	Latent TB Treatment	Isoniazid or rifapentine used to prevent latent TB from becoming active.	treatment_term	treatment_term	$	Latent TB Treatment	Isoniazid or rifapentine used to prevent latent TB from becoming active.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6889	7601	331	Tuberculosis	Tuberculosis.yaml	treatments	5	Host-Directed Therapy	Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.	treatment_term	treatment_term	$	Host-Directed Therapy	Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
6928	7633	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	0	Metformin	First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity.	treatment_term	treatment_term	$	Metformin	First-line oral medication that reduces hepatic glucose production and improves insulin sensitivity.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6929	7634	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	1	Lifestyle Modification	Diet and exercise interventions to reduce weight and improve metabolic health.	treatment_term	treatment_term	$	Lifestyle Modification	Diet and exercise interventions to reduce weight and improve metabolic health.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
6930	7635	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	2	GLP-1 Receptor Agonists	Injectable medications that enhance insulin secretion and promote weight loss.	treatment_term	treatment_term	$	GLP-1 Receptor Agonists	Injectable medications that enhance insulin secretion and promote weight loss.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6931	7636	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	3	SGLT2 Inhibitors	Oral medications that increase urinary glucose excretion.	treatment_term	treatment_term	$	SGLT2 Inhibitors	Oral medications that increase urinary glucose excretion.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6932	7637	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	4	Insulin Therapy	Required when beta cell function declines significantly.	treatment_term	treatment_term	$	Insulin Therapy	Required when beta cell function declines significantly.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6933	7638	332	Type 2 Diabetes Mellitus	Type_2_Diabetes_Mellitus.yaml	treatments	5	GLP-1/GIP Dual Agonists	Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss.	treatment_term	treatment_term	$	GLP-1/GIP Dual Agonists	Tirzepatide and similar agents that activate both GLP-1 and GIP receptors for enhanced glycemic control and weight loss.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
6981	7683	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	0	Insulin Therapy	Essential treatment to replace the missing insulin and regulate blood glucose levels.	treatment_term	treatment_term	$	Insulin Therapy	Essential treatment to replace the missing insulin and regulate blood glucose levels.	insulin treatment	MAXO:0000259	insulin treatment		"{""preferred_term"": ""insulin treatment"", ""term"": {""id"": ""MAXO:0000259"", ""label"": ""insulin treatment""}}"																											
6982	7685	333	Type I Diabetes	Type_I_Diabetes.yaml	treatments	2	Lifestyle Modifications	Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.	treatment_term	treatment_term	$	Lifestyle Modifications	Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
7014	7746	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	0	Tebentafusp	Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01 on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells. First systemic therapy to improve overall survival in metastatic uveal melanoma. Requires HLA-A*02:01 positive status (approximately 50% of patients).	treatment_term	treatment_term	$	Tebentafusp	Bispecific T-cell engager (TCE) that binds gp100 peptide presented by HLA-A*02:01 on tumor cells and CD3 on T cells, redirecting T cells to kill melanoma cells. First systemic therapy to improve overall survival in metastatic uveal melanoma. Requires HLA-A*02:01 positive status (approximately 50% of patients).	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7015	7747	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	1	Plaque Brachytherapy	Radiation therapy using radioactive plaque sutured to the sclera overlying the tumor. First-line local therapy for many uveal melanomas, achieving excellent local control while preserving the eye in most cases.	treatment_term	treatment_term	$	Plaque Brachytherapy	Radiation therapy using radioactive plaque sutured to the sclera overlying the tumor. First-line local therapy for many uveal melanomas, achieving excellent local control while preserving the eye in most cases.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
7016	7748	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	2	Enucleation	Surgical removal of the eye. Indicated for large tumors, those with optic nerve involvement, or when vision cannot be preserved. Provides excellent local control but does not prevent metastatic disease.	treatment_term	treatment_term	$	Enucleation	Surgical removal of the eye. Indicated for large tumors, those with optic nerve involvement, or when vision cannot be preserved. Provides excellent local control but does not prevent metastatic disease.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7017	7749	336	Uveal Melanoma	Uveal_Melanoma.yaml	treatments	3	Immune Checkpoint Inhibitors	Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma compared to cutaneous melanoma, with response rates of approximately 5-10%. The immunologically cold tumor microenvironment may contribute to this resistance.	treatment_term	treatment_term	$	Immune Checkpoint Inhibitors	Anti-PD-1 and anti-CTLA-4 antibodies have limited efficacy in uveal melanoma compared to cutaneous melanoma, with response rates of approximately 5-10%. The immunologically cold tumor microenvironment may contribute to this resistance.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7026	7762	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	0	Lamotrigine	Anticonvulsant that may reduce symptoms in some patients by reducing cortical hyperexcitability. Provides partial relief in approximately 20% of patients.	treatment_term	treatment_term	$	Lamotrigine	Anticonvulsant that may reduce symptoms in some patients by reducing cortical hyperexcitability. Provides partial relief in approximately 20% of patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7027	7765	337	Visual Snow Syndrome	Visual_Snow_Syndrome.yaml	treatments	3	Benzodiazepines	May provide symptom relief in some patients, though long-term use carries risks.	treatment_term	treatment_term	$	Benzodiazepines	May provide symptom relief in some patients, though long-term use carries risks.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7047	7798	338	Vitiligo	Vitiligo.yaml	treatments	0	Topical Corticosteroid	Common first-line treatment to reduce inflammation and potentially stimulate repigmentation.	treatment_term	treatment_term	$	Topical Corticosteroid	Common first-line treatment to reduce inflammation and potentially stimulate repigmentation.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7048	7799	338	Vitiligo	Vitiligo.yaml	treatments	1	JAK Inhibitor Therapy	Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy.	treatment_term	treatment_term	$	JAK Inhibitor Therapy	Targeting the IFN-gamma-JAK/STAT signaling pathway with JAK inhibitors (e.g., topical ruxolitinib) represents a leading therapeutic strategy. Often combined with narrowband UVB phototherapy to enhance repigmentation efficacy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7049	7800	338	Vitiligo	Vitiligo.yaml	treatments	2	Phototherapy	UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production.	treatment_term	treatment_term	$	Phototherapy	UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
7050	7801	338	Vitiligo	Vitiligo.yaml	treatments	3	Skin Graft	can be used for stable vitiligo.	treatment_term	treatment_term	$	Skin Graft	can be used for stable vitiligo.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7051	7802	338	Vitiligo	Vitiligo.yaml	treatments	4	Melanocyte Transplantation	can be used for stable vitiligo.	treatment_term	treatment_term	$	Melanocyte Transplantation	can be used for stable vitiligo.	organ transplantation	MAXO:0010039	organ transplantation		"{""preferred_term"": ""organ transplantation"", ""term"": {""id"": ""MAXO:0010039"", ""label"": ""organ transplantation""}}"																											
7052	7803	338	Vitiligo	Vitiligo.yaml	treatments	5	Monobenzone Cream	Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo.	treatment_term	treatment_term	$	Monobenzone Cream	Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7067	7824	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	0	Surveillance Protocol	Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur.	treatment_term	treatment_term	$	Surveillance Protocol	Comprehensive surveillance beginning in childhood includes annual ophthalmologic examination (from age 1), annual plasma metanephrines (from age 5), annual abdominal ultrasound (from age 8), and MRI brain/spine every 2 years (from age 11). Earlier imaging if symptoms occur.	cancer screening	MAXO:0000126	cancer screening		"{""preferred_term"": ""cancer screening"", ""term"": {""id"": ""MAXO:0000126"", ""label"": ""cancer screening""}}"																											
7068	7825	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	1	Nephron-Sparing Surgery	Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation.	treatment_term	treatment_term	$	Nephron-Sparing Surgery	Partial nephrectomy is the preferred approach for renal tumors to preserve renal function given the high likelihood of bilateral/multifocal disease. Surgery is typically recommended when tumors reach 3 cm to balance cancer risk with nephron preservation.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7069	7826	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	2	Belzutifan	HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types.	treatment_term	treatment_term	$	Belzutifan	HIF-2alpha inhibitor FDA-approved for VHL-associated RCC, hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery. First targeted therapy directly addressing the molecular defect in VHL disease. Objective response rates of 49% in RCC and 30-77% across tumor types.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7070	7827	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	treatments	3	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options.	treatment_term	treatment_term	$	Genetic Counseling	Genetic counseling and testing for at-risk family members. Children of affected parents have 50% risk. Predictive testing allows targeted surveillance in mutation carriers and can reassure non-carriers. Prenatal and preimplantation genetic testing are options.	genetic counseling	MAXO:0000079	genetic counseling		"{""preferred_term"": ""genetic counseling"", ""term"": {""id"": ""MAXO:0000079"", ""label"": ""genetic counseling""}}"																											
7093	7848	340	Whipple Disease	Whipple_Disease.yaml	treatments	0	Ceftriaxone induction followed by trimethoprim/sulfamethoxazole	Two-week intravenous ceftriaxone induction followed by oral TMP-SMX maintenance to eradicate infection and prevent relapse.	treatment_term	treatment_term	$	Ceftriaxone induction followed by trimethoprim/sulfamethoxazole	Two-week intravenous ceftriaxone induction followed by oral TMP-SMX maintenance to eradicate infection and prevent relapse.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7094	7849	340	Whipple Disease	Whipple_Disease.yaml	treatments	1	Doxycycline plus hydroxychloroquine regimen	Oral doxycycline and hydroxychloroquine for one year, followed by lifelong doxycycline for relapse prevention.	treatment_term	treatment_term	$	Doxycycline plus hydroxychloroquine regimen	Oral doxycycline and hydroxychloroquine for one year, followed by lifelong doxycycline for relapse prevention.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7106	7868	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	0	Surgical Resection	Nephrectomy is the primary treatment for unilateral Wilms tumor. In North America, upfront nephrectomy provides staging information. In Europe, preoperative chemotherapy is often given first.	treatment_term	treatment_term	$	Surgical Resection	Nephrectomy is the primary treatment for unilateral Wilms tumor. In North America, upfront nephrectomy provides staging information. In Europe, preoperative chemotherapy is often given first.	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
7107	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term	treatment_term	$	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	chemotherapy	MAXO:0000647	chemotherapy		"{""preferred_term"": ""chemotherapy"", ""term"": {""id"": ""MAXO:0000647"", ""label"": ""chemotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}, {""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}, {""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}]}"				actinomycin D; vincristine; doxorubicin	CHEBI:27666; CHEBI:28445; CHEBI:28748																						
7108	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			actinomycin D	CHEBI:27666	actinomycin D		"{""preferred_term"": ""actinomycin D"", ""term"": {""id"": ""CHEBI:27666"", ""label"": ""actinomycin D""}}"																											
7109	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term.therapeutic_agent[1]	treatment_term	treatment_term.therapeutic_agent			vincristine	CHEBI:28445	vincristine		"{""preferred_term"": ""vincristine"", ""term"": {""id"": ""CHEBI:28445"", ""label"": ""vincristine""}}"																											
7110	7869	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	1	Chemotherapy	Actinomycin D and vincristine form the backbone of treatment for favorable histology tumors. Doxorubicin and other agents are added for higher-stage or anaplastic tumors.	treatment_term.therapeutic_agent[2]	treatment_term	treatment_term.therapeutic_agent			doxorubicin	CHEBI:28748	doxorubicin		"{""preferred_term"": ""doxorubicin"", ""term"": {""id"": ""CHEBI:28748"", ""label"": ""doxorubicin""}}"																											
7111	7870	341	Wilms Tumor	Wilms_Tumor.yaml	treatments	2	Radiation Therapy	Flank radiation is used for stage III tumors and higher. Whole abdominal radiation is used for tumor rupture or diffuse peritoneal contamination.	treatment_term	treatment_term	$	Radiation Therapy	Flank radiation is used for stage III tumors and higher. Whole abdominal radiation is used for tumor rupture or diffuse peritoneal contamination.	radiation therapy	MAXO:0000014	radiation therapy		"{""preferred_term"": ""radiation therapy"", ""term"": {""id"": ""MAXO:0000014"", ""label"": ""radiation therapy""}}"																											
7145	7900	342	Wilson Disease	Wilsons_Disease.yaml	treatments	0	D-Penicillamine	Copper chelator, first-line therapy, promotes urinary copper excretion.	treatment_term	treatment_term	$	D-Penicillamine	Copper chelator, first-line therapy, promotes urinary copper excretion.	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy		"{""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}}"																											
7146	7901	342	Wilson Disease	Wilsons_Disease.yaml	treatments	1	Trientine	Alternative copper chelator, better tolerated than penicillamine.	treatment_term	treatment_term	$	Trientine	Alternative copper chelator, better tolerated than penicillamine.	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy		"{""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}}"																											
7147	7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	treatment_term	treatment_term	$	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}, ""therapeutic_agent"": [{""preferred_term"": ""zinc acetate"", ""term"": {""id"": ""CHEBI:62984"", ""label"": ""zinc acetate""}}]}"				zinc acetate	CHEBI:62984																						
7148	7902	342	Wilson Disease	Wilsons_Disease.yaml	treatments	2	Zinc Acetate	Blocks intestinal copper absorption, maintenance therapy.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			zinc acetate	CHEBI:62984	zinc acetate		"{""preferred_term"": ""zinc acetate"", ""term"": {""id"": ""CHEBI:62984"", ""label"": ""zinc acetate""}}"																											
7149	7903	342	Wilson Disease	Wilsons_Disease.yaml	treatments	3	Low Copper Diet	Avoid liver, shellfish, chocolate, nuts, mushrooms.	treatment_term	treatment_term	$	Low Copper Diet	Avoid liver, shellfish, chocolate, nuts, mushrooms.	dietary intervention	MAXO:0000088	dietary intervention		"{""preferred_term"": ""dietary intervention"", ""term"": {""id"": ""MAXO:0000088"", ""label"": ""dietary intervention""}}"																											
7150	7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	treatment_term	treatment_term	$	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	copper chelator agent therapy	MAXO:0001224	copper chelator agent therapy		"{""preferred_term"": ""copper chelator agent therapy"", ""term"": {""id"": ""MAXO:0001224"", ""label"": ""copper chelator agent therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""tetrathiomolybdate"", ""term"": {""id"": ""CHEBI:30703"", ""label"": ""tetrathiomolybdate(2-)""}}]}"				tetrathiomolybdate(2-)	CHEBI:30703																						
7151	7904	342	Wilson Disease	Wilsons_Disease.yaml	treatments	4	Tetrathiomolybdate	Emerging copper chelator that rapidly complexes free copper, reducing bioavailable copper.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			tetrathiomolybdate	CHEBI:30703	tetrathiomolybdate(2-)		"{""preferred_term"": ""tetrathiomolybdate"", ""term"": {""id"": ""CHEBI:30703"", ""label"": ""tetrathiomolybdate(2-)""}}"																											
7152	7905	342	Wilson Disease	Wilsons_Disease.yaml	treatments	5	Liver Transplantation	Curative for hepatic Wilson disease, reverses copper metabolism defect.	treatment_term	treatment_term	$	Liver Transplantation	Curative for hepatic Wilson disease, reverses copper metabolism defect.	liver transplantation	MAXO:0001175	liver transplantation		"{""preferred_term"": ""liver transplantation"", ""term"": {""id"": ""MAXO:0001175"", ""label"": ""liver transplantation""}}"																											
7167	7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	treatment_term	treatment_term	$	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	NSAID therapy	MAXO:0000221	NSAID therapy		"{""preferred_term"": ""NSAID therapy"", ""term"": {""id"": ""MAXO:0000221"", ""label"": ""NSAID therapy""}, ""therapeutic_agent"": [{""preferred_term"": ""naproxen"", ""term"": {""id"": ""NCIT:C680"", ""label"": ""Naproxen""}}]}"				Naproxen	NCIT:C680																						
7168	7924	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	0	Nonsteroidal anti-inflammatory drugs	NSAIDs can reduce fever and inflammatory symptoms.	treatment_term.therapeutic_agent[0]	treatment_term	treatment_term.therapeutic_agent			naproxen	NCIT:C680	Naproxen		"{""preferred_term"": ""naproxen"", ""term"": {""id"": ""NCIT:C680"", ""label"": ""Naproxen""}}"																											
7169	7925	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	1	Corticosteroids	Systemic corticosteroids (e.g., prednisolone) used as part of combination regimens to control inflammation.	treatment_term	treatment_term	$	Corticosteroids	Systemic corticosteroids (e.g., prednisolone) used as part of combination regimens to control inflammation.	corticosteroid agent therapy	MAXO:0000640	corticosteroid agent therapy		"{""preferred_term"": ""corticosteroid agent therapy"", ""term"": {""id"": ""MAXO:0000640"", ""label"": ""corticosteroid agent therapy""}}"																											
7170	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term	treatment_term	$	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""dapsone"", ""term"": {""id"": ""NCIT:C415"", ""label"": ""Dapsone""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Dapsone	NCIT:C415	NCIT:C2259			
7171	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
7172	7926	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	2	Dapsone	Dapsone was used alongside NSAIDs and corticosteroids in a reported case.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			dapsone	NCIT:C415	Dapsone		"{""preferred_term"": ""dapsone"", ""term"": {""id"": ""NCIT:C415"", ""label"": ""Dapsone""}}"																											
7173	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term	treatment_term	$	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""qualifiers"": [{""predicate"": {""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}, ""value"": {""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}}], ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																						Azathioprine	NCIT:C290	NCIT:C2259			
7174	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term.qualifiers[0].predicate	treatment_term	treatment_term.qualifiers[0]			therapeutic agent	NCIT:C2259	Therapeutic Agent		"{""preferred_term"": ""therapeutic agent"", ""term"": {""id"": ""NCIT:C2259"", ""label"": ""Therapeutic Agent""}}"																											
7175	7927	343	Wissler syndrome	Wissler_syndrome.yaml	treatments	3	Azathioprine	Immunosuppressive therapy used in combination with corticosteroids.	treatment_term.qualifiers[0].value	treatment_term	treatment_term.qualifiers[0]			azathioprine	NCIT:C290	Azathioprine		"{""preferred_term"": ""azathioprine"", ""term"": {""id"": ""NCIT:C290"", ""label"": ""Azathioprine""}}"																											
7191	7947	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	0	Seizure Management with Levetiracetam	Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients.	treatment_term	treatment_term	$	Seizure Management with Levetiracetam	Levetiracetam has shown efficacy in controlling seizures in Wolf-Hirschhorn syndrome patients.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7192	7948	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	1	Seizure Management with Valproic Acid	Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome.	treatment_term	treatment_term	$	Seizure Management with Valproic Acid	Valproic acid is commonly used for epilepsy management in Wolf-Hirschhorn syndrome.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7193	7949	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	2	Growth Hormone Therapy	Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency.	treatment_term	treatment_term	$	Growth Hormone Therapy	Recombinant human growth hormone therapy for patients with concurrent growth hormone deficiency.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7194	7950	344	Wolf-Hirschhorn_Syndrome	Wolf-Hirschhorn_Syndrome.yaml	treatments	3	Early Aggressive Seizure Management	Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis.	treatment_term	treatment_term	$	Early Aggressive Seizure Management	Early aggressive management using multiple antiseizure medications may be critical to improve neurological prognosis.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7197	7954	345	Yaws	Yaws.yaml	treatments	0	Azithromycin therapy	Oral azithromycin is preferred for treatment.	treatment_term	treatment_term	$	Azithromycin therapy	Oral azithromycin is preferred for treatment.	pharmacotherapy	MAXO:0000058	pharmacotherapy		"{""preferred_term"": ""pharmacotherapy"", ""term"": {""id"": ""MAXO:0000058"", ""label"": ""pharmacotherapy""}}"																											
7209	7965	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	treatments	0	Supportive care	"Multidisciplinary management including physical therapy, occupational therapy, speech therapy, and management of seizures when present.
"	treatment_term	treatment_term	$	Supportive care	"Multidisciplinary management including physical therapy, occupational therapy, speech therapy, and management of seizures when present.
"	supportive care	MAXO:0000950	supportive care		"{""preferred_term"": ""supportive care"", ""term"": {""id"": ""MAXO:0000950"", ""label"": ""supportive care""}}"																											
7210	7966	346	You-Hoover-Fong Syndrome	You-Hoover-Fong_Syndrome.yaml	treatments	1	Cataract surgery	"Surgical removal of congenital cataracts can improve visual responses and social interactions.
"	treatment_term	treatment_term	$	Cataract surgery	"Surgical removal of congenital cataracts can improve visual responses and social interactions.
"	surgical procedure	MAXO:0000004	surgical procedure		"{""preferred_term"": ""surgical procedure"", ""term"": {""id"": ""MAXO:0000004"", ""label"": ""surgical procedure""}}"																											
